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YHTEENVETO 
Uusien proteiinien kehittäminen biokemiallisiin ja lääketieteellisiin sovellutuksiin 
on kehittynyt nopeasti viime vuosina. Nykyteknologia mahdollistaa esimerkiksi sel-
laisten proteiinirakenteiden valmistamisen, joita ei esiinny luonnossa, sekä proteii-
nien laaja-alaisen muokkaamiseen bioteknologisiin sovellutuksiin paremmin sopi-
viksi.  Moderneilla tekniikoilla voidaan parantaa proteiinin affiniteettia ja spesifi-
syyttä sekä jopa lisätä proteiineille uusia toimintoja. Lisäksi proteiinien tuottotasoja 
voidaan kasvattaa esimerkiksi lisäämällä proteiinien kestävyyttä tai liukoisuutta. 
Tutkimusmenetelmien kehittyessä ominaisuuksiltaan muokattujen proteiinien tarve 
kasvaa kokoajan. Erityisen mielenkiinnonkohteena ovat molekyylit, jotka kykenevät 
tarkkaan ja spesifiin molekyylitunnistukseen. Tunnistusmolekyylien valmistamisen 
lisäksi proteiinien muokkaus tarjoaa arvokasta tietoa proteiinien vuorovaikutuksista 
sekä proteiinin rakenteen ja toiminnan yhteydestä. 
Tämän väitöskirjatutkimuksen tavoitteena oli kehittää uusia muokattuja avi-
diinimolekyylejä avidiini-biotiiniteknologiaan ja samalla saada lisää tietoa avidiinin 
ligandin sitomisominaisuuksista. Tutkimuksessa avidiinin kolmiulotteinen rakenne 
määritettiin korkealla resoluutiolla, jolloin havaittiin avidiinin tynnyrirakenteen be-
ta-säikeiden 3 ja 4 välissä olevan silmukan tärkeys ligandin sitomisessa. Analyyseis-
sä, joissa määritettiin avidiinin kykyä sitoutua atsoväreihin, avidiini ja avidiinin kal-
tainen proteiini 4 (AVR4) osoittivat toisistaan poikkeavaa ligandin sitomiskykyä. 
Eroja tutkittiin molekyylimallinnuksen avulla käyttäen ns. molekyylien telakoitu-
mista. Mallinnus osoitti kolmiulotteisen rakenteen tavoin beta-säikeiden 3 ja 4 välis-
sä olevan silmukan tärkeyden ligandin sitomisessa. 
Väitöskirjatutkimuksessa avidiinin rakennetta muokattiin laajalti, jotta saataisiin 
sopivampia molekyylejä diagnostisiin ja biokemiallisiin sovellutuksiin. Alunperin 
kehitetyn kaksoisketjuavidiinin käytettävyyttä parannettiin kehittämällä kimeerinen 
kaksoisketjuavidiini avidiinin sirkulaarisesta permutantista ja AVR4:n sirkulaarises-
ta permutantista. Kimeerisellä fuusioproteiinilla havaittiin parantuneet proteiinin 
tuottotasot sekä lämmönkestävyys verrattuna alkuperäiseen kaksoisketjuavidiiniin. 
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Lisäksi proteiinia koodaavan DNA-ketjun monistaminen PCR-menetelmällä oli te-
hokkaampaa kimeerisen fuusiogeenin avulla. Tämä mahdollistaa mm. satunnaismu-
tageneesimenetelmän käytön molekyylin edelleen kehittämisessä.  
Sirkulaaristen permutaatioiden lisäksi tutkimuksessa modifioitiin myös avidiini-
proteiinin ligandin sitomiseen osallistuvaa silmukka-aluetta kohdennetun satun-
naismutageneesin avulla. Tavoitteena oli tuottaa avidiini, jolla on heikentynyt sito-
miskyky avidiinin luonnolliseen ligandiin biotiiniin ja toisaalta korkea sitomisaffini-
teetti uuteen pienmolekyyliin. Valmistettujen avidiinigeenikirjastojen seulontaan 
käytettiin faagidisplay-menetelmää. Seulontamenetelmää varten avidiiniproteiinia 
ilmennettiin M13-bakteriofaagin pinnalla p3-pintaproteiinin fuusiona. Seulonnan 
tuloksena löydettiin lämmönkestäviä avidiinimutantteja, joilla on mikromolaarinen 
affiniteetti steroidihormoni testosteroniin. Lisäksi valikoidun avidiinimutantin affi-
niteettia biotiinin saatiin heikennettyä kohdennetulla mutageneesillä niin, että prote-
iini sitoi mieluumin steroideja kuin biotiinia. 
Tutkimuksessa edistettiin avidiini-biotiini-teknologiaa kehittämällä myös bioak-
tiivisia kalvoja. Sovelluksessa yhdistettiin aikaisemmin kehitetyn lämmönkestävän 
kimeerisen avidiinin ominaisuudet selluloosa-asetaattikalvojen helppokäyttöisyy-
teen. Kalvot päällystettiin kimeerisellä avidiinilla ja kalvojen bioaktiivisuutta seu-
rattiin tritium-biotiinilla. Kalvojen bioaktiivisuus säilyi lähes muuttumattomana 
kolmen kuukauden pituisen kokeen aikana, vaikka kalvot säilytettiin huoneen-
lämpötilassa. Kehitettyjä kalvoja voitaisiin käyttää perustana useissa sovelluksissa, 
esimerkiksi diagnostisten pikatestien kehityksessä. 
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ABSTRACT  
In recent years, the development of novel scaffolds from non-immunoglobulin pro-
teins have been an area of great intrest, and a powerful new technology has been 
born. Today, it is possible to design structures never seen before in nature and to 
generate proteins with improved suitability for biomedical and biochemical applica-
tions. With modern techniques, the affinity and specificity of target proteins can be 
enhanced, and novel functions or activities can even be added to modified proteins. 
Additionally, proteins with more stable structures or higher solubility have been 
created, thus increasing the expression of recombinant proteins. Ongoing research 
may answer the increasing need for molecules capable of more sensitive and spe-
cific recognition in biotechnology applications. Further research will provide valu-
able knowledge about molecular recognition and protein structure-function relation-
ships. 
The aim of this study was to develop novel molecules for avidin-based technolo-
gies and, at the same time, to acquire more information about the ligand-binding 
properties of avidin. A high-resolution 3D -structure of avidin was determined, and 
it revealed an important role for the loop between beta-strands 3 and 4 in ligand 
binding. Analyses of the binding of avidin and avidin-related protein 4 (AVR4) to 
azo dyes showed clearly different binding modes for each protein. Therefore, mo-
lecular docking was used to analyze the difference in binding. This experiment also 
highlighted the importance of the loop between beta-strands 3 and 4 in ligand-
binding. 
In this study, the avidin protein was extensively modified to be more suitable for 
diagnostic and biochemical applications. The utility of the original dual-chain avidin 
protein was improved by constructing chimeric dual-chain avidin proteins consisting 
of a fusion of circularly permutated wild-type (wt) avidin and circularly permuted 
AVR4. The chimeric tandem fusion showed enhanced protein expression and ther-
mal stability compared to the original dual-chain avidin. Moreover, PCR amplifica-
11 
tion was more straightforward for the chimeric protein. Interestingly, binding analy-
ses of the chimeric tandem fusion showed heterogeneous biotin-binding.   
In addition to circular permutation, the loop areas in the ligand-binding site of wt 
avidin were modified in this study. The loop area was subjected to targeted random 
mutagenesis, and genes carrying the desired mutations were selected from a library 
by the phage display method. For selection, avidin was displayed on the M13 phage 
as a fusion with the coat protein p3. As a result, thermostable avidin variants with 
micromolar affinity for the steroid hormone testosterone were obtained. In terms of 
ligand binding, the steroid-binding avidin preferred steroids to its natural ligand, bi-
otin. 
To further advance the possibile applications of avidin-biotin -technology, avi-
din-coated cellulose acetate-films were developed. Films covered with thermostable 
chimeric avidin and stored at room temperature remained biologically active during 
three-month test period. These films could be used as a universal base for various 
applications, including in diagnostic platforms.  
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INTRODUCTION 
Proteins can be found everywhere, and they are essential for many biological proc-
esses. Inside the cell, proteins work together with other biological macromolecules, 
such as polysaccharides and nucleic acids. Proteins vary considerably in their struc-
tures and functions. Many proteins are enzymes that catalyze biochemical reactions, 
whereas proteins such as actin and myosin have mechanical functions. Proteins ca-
pable of molecular recognition are essential for cell signaling and for the immune 
response.  
Generally, the best known class of recognition molecules is antibodies, also 
known as immunoglobulins (Igs). Antibodies are Y-shaped molecules that partici-
pate in the immune response by identifying and neutralizing foreign intruders. A 
molecule recognized by antibodies is referred to as an antigen. Traditionally, anti-
bodies have been involved in many biomedical applications because of their charac-
teristic ability to recognize and bind other molecules. Antibodies are a true success 
story; today more than 20 different antibodies have been approved for therapy in 
Europe and in the USA (Gebauer, Skerra 2009). There are many reasons for this 
success. One important reason is the ability to generate antibodies that target a wide 
range of molecules, often with picomolar affinities.  
However, due to the complex structure of antibodies, the engineering of proteins 
outside the Ig family began two decades ago, and nowadays, the development of 
novel proteins has grown into a powerful technology. With developed technologies, 
it is possible to design structures never seen before in nature and catalyze reactions 
for which no natural enzyme exists (Smith, Hecht 2011). Additionally, the isolation 
of sequences that have no biological ancestors but nonetheless enable the growth of 
living cells is possible (Smith, Hecht 2011). These advances led to the production of 
proteins more suitable for biomedical and biochemical applications. The affinity and 
specificity of several proteins toward their ligands have been enhanced, and novel 
functions or activities have been generated. Proteins have also been tailored to pro-
duce more stable molecules or to improve solubility, which helps to increase pro-
13 
duction levels. For therapeutic purposes, the half-lives of protein molecules have 
been extended, and the immunogenicity of many molecules has been decreased 
(Kurtzman et al. 2001; Leader, Baca & Golan 2008).  
Generally, proteins that recognize other molecules with high specificity can be 
used for diagnostic applications in vivo and in medical applications, such as targeted 
therapeutic drug treatment. Recombinant proteins are highly specific and may pro-
vide effective treatment without the need for gene delivery. Protein-based therapeu-
tics have less potential to interfere with normal biological processes and are there-
fore often well tolerated (Leader, Baca & Golan 2008). Besides therapeutic uses, 
proteins with tailored affinities can be included in several applications, such as bio-
separation, detection and proteomic analysis (Gronwall, Stahl 2009). Currently, 
some of the most promising non-Ig scaffolds are Staphylococcal protein A, 
lipocalins, a fibronectin domain, an ankyrin consensus repeat domain, and thiore-
doxin (Skerra 2007).  
At present, recombinant human proteins, including monoclonal antibodies, inter-
ferons, vaccines, hormones and modified enzymes make up the majority of FDA-
approved biotechnology-based medicines (Leader, Baca & Golan 2008). Personal-
ized approaches for the treatment of disease are becoming more common all the 
time. These approaches require more specific properties from the recognition mole-
cules involved. Non-Ig scaffolds with specific recognition properties will provide 
considerable alternatives to novel approaches. In addition to generating novel mole-
cules, protein engineering gives us valuable knowledge about molecular recognition 
and protein structure-function relationships.  
This review of the literature will focus on the generation of proteins with novel 
affinities. One of the best examples of such proteins is antibodies due to their con-
siderable influence and importance for the development of methods and applications 
in the field. Beyond antibodies, the most successful non-Ig-based recognition mole-
cules are also discussed. Additionally, the strategies for gene library construction 
and methods for selection are described. In the experimental section, the protein en-
gineering methods used to modify the chicken avidin protein to be more suitable for 
life-science applications are detailed. 
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2. REVIEW OF THE LITERATURE 
2.1 Antibodies are naturally evolved affinity proteins 
 
Antibodies, also known as immunoglobulins (Igs), are a central part of the humoral 
immune system. The immune system protects the body against foreign intruders, 
such as bacteria, viruses, fungi and parasites. Upon activation of immune system, 
antibodies are produced by the B lymphocytes. Antibodies are also known to par-
ticipate in allergic reactions and autoimmune diseases.  
Unmodified polyclonal antibodies were the first molecules accepted for therapeu-
tic use, and today, antibodies are the most successful biomolecules utilized in bio-
technological and medical applications. Mouse hybridomas (Kohler, Milstein 1975) 
were the first reliable source of monoclonal antibodies developed for a number of 
therapeutic applications. B cell hybridoma technology offers a reproducible supply 
of an antibody with a high specificity (Nelson et al. 2000), but unfortunately, if 
treatment is repeated, mouse-derived molecules provoke an anti-mouse response in 
humans. Therefore, different strategies have been developed to redirect, mask or 
avoid human immune surveillance. For instance, chimeric antibodies in which the 
variable regions of the mouse antibody are fused to the constant regions of the hu-
man antibody have been generated (Boulianne, Hozumi & Shulman 1984; Morrison 
et al. 1984). In humanized antibodies, only the complementarity-determining re-
gions (CDRs) of the variable regions are of non-human origin. Throughout the 
years, technologies have evolved, and fully synthetic human antibodies having high 
affinities for antigens such as DNA, peptides, and proteins have also been generated 
(Knappik et al. 2000, Lonberg 2008). Most recently, innovative structural designs 
have improved in	  vivo	  pharmacokinetics, expanded immune repertoires and permit-
ted screening using refractory targets and complex proteome arrays. These in vitro 
evolution strategies have improved the affinity, specificity and expression levels of 
antibodies (Hudson, Souriau 2003). Engineered antibodies that are easily and inex-
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pensively produced are widely used because of their capacity to detect multiple epi-
topes (Nelson et al. 2000). 
2.1.1 Antibody structure  
Generally speaking, antibodies are Y-shaped glycoprotein molecules that belong to 
the immunoglobulin superfamily (Schroeder, Cavacini 2010). However, antibodies 
can differ in structure; for example, the extent of glycosylation varies. Antibodies 
can be divided into five isotypes (Table 1): IgA, IgD, IgE, IgG, and IgM.  
Table 1. Properties of immunoglobulin isotypes and subclasses. The table 
adapted adapted and modified from Schroeder and Cavacini (2010). Only 
the IgG isotype can cross the placenta and reach the fetus. 
Serum (%) Structure Placental crossing Other functions 
IgG 75 Monomer + For all IgGs: 
IgG1  Monomer + Secondary response 
IgG2  Monomer + Neutralization of toxins  
and 
IgG3  Monomer + viruses 
IgG4  Monomer +  
IgM 10 Pentamer - Primary response 
IgA 15 Monomer, dimer - Mucosal response 
IgA1  Monomer, dimer -  
IgA2  Monomer, dimer -  
IgD <0.5 Monomer - Homeostasis 
IgE <0.01 Monomer - Allergy 
 
IgG is the central antibody that recognizes and neutralizes pathogens. IgG also 
crosses the placenta to provide passive immunity to the fetus. IgGs can be split to 
four subclasses: IgG1, IgG2, IgG3, and IgG4 (Schroeder, Cavacini 2010). Like IgG, 
IgM also serves to help eliminate pathogens, but IgM also has the ability to facilitate 
the removal of apoptotic cells (Ehrenstein, Notley 2010). IgA can be found in mu-
cosal areas, such as the gut, respiratory tract, and urogenital tract (Underdown, 
Schiff 1986). IgAs can be split to two subclasses: IgA1 and IgA2 (Schroeder, 
Cavacini 2010). IgD fine-tunes humoral responses and modulates B cell selection 
and homeostasis (Geisberger, Lamers & Achatz 2006). IgE acts during allergenic 
reaction and also protects against parasitic worms.  
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Antibodies are built from two identical heavy chains (50 to 70 kDa) and two 
identical light chains (23 kDa each) (Figure 1). The heavy and light chains are held 
together by disulphide bonds and by non-covalent interactions, but intra-chain disul-
fide bonds can also be found from the antibody structure. There are two gene fami-
lies, κ and λ, for light chains, and each light chain consists of one variable (VL) do-
main and one constant (CL) domain. The heavy chain includes one variable (VH) 
domain and three constant (CH) domains. Each variable or constant domain is, on 
average, 12,000 to 13,000 Da in size and consists of 110 to 130 amino acids 
(Schroeder, Cavacini 2010). 
In the center of the antibody molecule, there is a the hinge region that provides 
flexibility to the molecule. Upon protease treatment, the antibody molecule can be 
digested into smaller parts. The Fab fragment contains one VL domain and one VH 
domain with one CL and one CH domain. The Fc fragment of the antibody includes 
four CH domains and specifies effector functions. The glycans associated with the 
Fc domain are known to affect the function of antibody (Schroeder, Cavacini 2010).  
 
 
Figure 1. The structure of an IgG molecule. In the figure light chains are presented with 
red color and heavy chains in blue color. Disulphide-bridges are displayed as a 
yellow line in the figure. Figure from: http://www.biochem.arizona.edu/classes/ 
bioc471/pages/Lecture10/Lecture10.html (9.6.2011).  
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2.1.1.1 The antigen recognition site of an antibody 
The structural mechanism by which antibodies recognize their antigens is well stud-
ied and rather understood. Molecular recognition and ligand-binding occurs in the 
CDR, which is located at the very top of the antibody molecule. Six CDRs (CDR-
V1 to V3 and CDR-H1 to H3) are located in the variable regions (Chothia et al. 
1989). These loops are highly diverse in terms of amino acid composition and are in 
direct contact with the antigen. However, the key determinants of specificity in anti-
gen binding are the CDR 3 loops, especially VH, which contacts the antigen tightly 
(Xu, Davis 2000).   
The overall composition of a functional CDR is biased in favor of certain amino 
acid residues. Sidhu et al. studied antigen binding by generating randomized CDRs 
with codons encoding only four amino acids (tyrosine, alanine, aspartate, and se-
rine) (Fellouse, Wiesmann & Sidhu 2004). They discovered that antigen recognition 
was mediated primarily by tyrosine residues, whereas alanine and serine residues 
have no contact with the antigen. Alanine and serine residues induced conforma-
tional flexibility of the binding site. Sidhu et al. also postulated that the overabun-
dance of tyrosine in natural antigen-binding sites is a consequence of its large 
chemically active side chain, which is particularly well -suited for making contacts 
with an antigen (Fellouse, Wiesmann & Sidhu 2004; Fellouse et al. 2005). Surpris-
ingly, highly specific antibodies could be built using an interface consisting only of 
two amino acids, tyrosine and serine (Fellouse et al. 2005). This result is consistent 
with the discovery that the most specific antibodies are rich in tyrosine in CDR-H3 
part of the antibody (Birtalan et al. 2008). However, the duration of co-evolution 
affects the protein moieties that contribute to ligand binding by an antibody. For in-
stance, tyrosine, tryptophan and arginine mediate ligand binding at co-evolved inter-
faces, whereas small amino acids such as glycine, serine, alanine and threonine are 
favored in the naïve loop of antibodies (Zemlin et al. 2003).  
Generally, tryptophan and arginine amino acid residues are scarce in the naïve 
molecular recognition sites of antibodies. However, Sidhu and co-workers noticed 
that the arginine residue becomes more abundant when an antibody has undergone 
affinity maturation, and glycine residues have favorable effects on antigen recogni-
tion in high-affinity antibodies when present in the CDR-H3 domain (Birtalan et al. 
2008). Conformational flexibility, not just the specific interaction to an antigen, is of 
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great importance during antigen recognition by the CDR loop. The amino acid resi-
dues of glycine, tyrosine and serine have been shown to be frequently present in an-
tibody hot spots and are also frequently mutated during somatic hypermutation 
(Clark et al. 2006).  
2.1.1.2 Vast diversity generated by somatic hypermutation 
The immune system is capable of triggering efficient responses against almost every 
foreign intruder. More than 109 different B lymphocyte clones circulate through the 
body, providing an enormous diversity of antibodies. The immediate response to-
ward an intruder usually involves low affinity, but the affinity for the antigen in-
creases as the response progresses (Neuberger, Milstein 1995).  
In humans the genetic mechanism behind the generation of high-affinity binding 
of numerous antigens is the random recombination of an inherited set of gene seg-
ments followed by hypermutation. During hypermutation, genes encoding variable 
regions are modified, and these genes are translated into thousands of different anti-
bodies. Somatic hypermutation creates point -mutations in IgG V(D)J gene seg-
ments (Krebs, Goldstein & Kilpatrick 2011). These mutations are targeted to certain 
positions, called ‘hotspots,’ where amino acid modifications can efficiently lead to 
affinity maturation (Neuberger, Milstein 1995). However, there are also other possi-
bilities for acquiring genetic diversity such as gene conversion, which is frequently 
utilized in the immune response of chickens (Reynaud et al. 1987). The molecular 
mechanisms behind the antibody diversity generation have also been adapted for the 
creation of binding proteins in vitro (Skerra 2003), as will be discussed later. 
2.1.2 Engineered antibodies 
Antibodies have been extensively engineered to reduce the size of the molecule or to 
create multivalent binding proteins. For many applications, only the functional anti-
gen-binding region of an antibody is needed. Compared to intact antibodies, smaller 
fragments have beneficial characteristics, such as better pharmacokinetics and tissue 
penetration.  
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Small antibody molecules can be produced by proteolytic cleavage. Depending 
on the enzyme, cleavage will result in a single Fab2 fragment or two Fab fragments 
(Figure 2). Similarly, Fv fragments may also be acquired, but microbial expression 
of single-chain Fv molecules (scFv, Figure 2) is currently favored (Hudson, Souriau 
2003). However, Fab and scFv molecules are monovalent and often have fast off 
rates and poor retention times for their targets (Hudson, Souriau 2003). To over-
come these limitations, small antibody molecules have been engineered into di-
meric, trimeric or tetrameric conjugates (Figure 2). Multivalent recombinant anti-
bodies provide high binding avidity with optimal size (60-120 kDa) and are capable 
of rapid tumor penetration without rapid renal clearance (Todorovska et al. 2001). 
In many applications, recombinant antibodies have been fused with various sub-
stances, such as radionuclides, toxins, enzymes and viruses (Hudson, Souriau 2003). 
Lipids and PEGs have also been coupled to antibodies to improve the stability of the 
molecule.  
 
Figure 2. Schematic representation of an intact antibody (IgG) together with Fab and Fv 
fragments and single variable (V) (colored ovals; dots represent antigen-binding 
sites) and constant (C) domains (uncolored ovals). Figure reprinted by permis-
sion from Macmillan Publisher Ltd: [Nature Medicine] Hudson and Souriau 
(2003). 
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Bispecific antibodies (bsAbs) contain two different binding specificities fused to-
gether (Segal, Weiner & Weiner 2001). In the simplest case, the specificities are di-
rected toward the same target, increasing the avidity, but bispecific antibodies are 
also used to crosslink two different antigens. In a recent study, Glaser and co-
workers produced stable IgG-like bispecific antibodies that targeted and cross-
linked two TNF family receptors (TNF-related apoptosis-inducing ligand receptor 2 
and lymphotoxin beta receptor) (Michaelson et al. 2009). Other experiments showed 
that therapeutic treatment with the developed bispecific antibody resulted in a reduc-
tion in tumor volume that was similar or greater than that induced by treatment with 
a combination of parental antibodies. These so-called “two-in-one” antibodies have 
also been generated from the well-known therapeutic antibody Herceptin. This 
molecule binds human epidermal growth factor receptor 2 (HER2) and was engi-
neered to simultaneously bind vascular endothelial growth factor (VEGF) (Bostrom 
et al. 2009). By combining different specificities and multivalent antibodies, it is 
possible to create multispecific antibody molecules (Todorovska et al. 2001). 
 
2.1.2.1 Therapeutic antibodies 
Monoclonal antibodies are the best-selling class of biologics in the US market, 
reaching 16.9 billion dollars in sales in 2009 (Aggarwal 2010). Additionally, the av-
erage growth in sales has been 10% during the past few years. At the moment, the 
US Food and Drug Administration (FDA) has registered 31 monoclonal antibodies 
for marketing (Aggarwal 2010) (Table 2). Antibody therapies for cancer and in-
flammatory disorders have been the most successful products.  
For cancer treatments, there are more monoclonal antibodies against circulating 
cancer cells than against solid tumors (Table 2). This bias is due to greater accessi-
bility of circulating cells for the antibody. Antibodies fused with radioactive sub-
stances are widely used in applications such as cancer imaging and therapy. The 
balance between long dissociation rates at the target site and slow blood clearance is 
important because accumulation in the liver together with high radiation exposure 
for other tissues present severe side effects of the treatment.  
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Table 2. Therapeutic antibodies approved by the US Food and Drug Administra-
tion (FDA). The table is adapted from Hudson and Souriau (2003) and 
from http://www.immunologylink.com/FDA-APP-Abs.html (19.8.2011). 
Product namea Specificity Product type Indication Year 
Orthoclone OKT3 CD3 Mouse Transplant rejection 1986 
ReoPro gpIIb/gpIIa Chimeric Fab Cardiovascular disease 1994 
Rituxan CD20 Chimeric Non-Hodgkin lymphoma 1997 
Zenapax CD25 Humanized Transplant rejection 1997 
Remicade TNF-α Chimeric Crohn’s disease, rheumatoid arthritis 1998- 
1999 
Simulect CD25 Chimeric Transplant rejection 1998 
Synagis RSV Humanized Respiratory syncytial virus 1998 
Herceptin Her-2 Humanized Metastatic breast cancer 1998 
Mylotarg CD33 Humanized Acute myeloid 
 leukemia 
2000 
Campath DC52 Humanized Chronic lymphocytic leukemia 2001 
Zevalin CD20 Mouse Non-Hodgkin lymphoma 2002 
Humira TNF-α Human Inflammatory diseases 2002 
Bexxar DC20 Murine Non-Hodgkin lymphoma 2003 
Xolair IgE Humanized Severe allergic asthma 2003 
Raptiva CD11 Humanized Autoimmune disease 2003 
Avastin VEGF Humanized Metastatic colorectal cancer,  
non-small cell lung cancer,   
metastatic breast cancer 
2004 
Tysabri α4 subunit  
of α4β1 
Humanized Multiple sclerosis,  
Crohn’s disease 
2004 
Erbitux EGFR Chimeric Colorectal cancer,  
head and neck cancer 
2004 
Vectibix EGFR Human Metastatic colorectal carcinoma 2006 
Lucentis VEGF-A Humanized Fab Wet macular degeneration 2006 
Soliris CD59 Humanized Paroxysmal nocturnal hemoglobinuria 2007 
Cimzia TNF-α Humanized Fab Crohn’s disease, 
rheumatoid arthritis 
2008 
Simponi TNF-α Human Rheumatoid and psoriatic arthritis,  
active ankylosing spondylitis 
2009 
Ilaris IL1b Human Inflammatory disease 2009 
Stelara IL-12/23 Human Inflammatory disease 2009 
Arzerra CD20 Human Chronic lymphocytic leukemia 2009 
Actemra Anti-IL-6R Humanized Autoimmune disease 2010 
Benlysta BLyS Human Autoimmune disease 2011 
Yervoy CTLA-4 Human Melanoma 2011 
a Product names are registered trademarks. 
 
Classically, therapeutic monoclonal antibodies have been used in combination with 
chemotherapeutic drugs to treat cancer because in many cases monoclonal antibod-
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ies treatment is not effective enough on its own. Many strategies have also been in-
vestigated to improve the efficiency of therapeutic antibodies, including enhance-
ment of intrinsic Fc-linked effector functions by glycoengineering and the use of 
bispecific antibodies, polyclonal antibodies, and conjugates (Figure 3, Beck et al. 
2010a).  
 
Figure 3. Antibody design to improve the pharmacological properties and therapeutic re-
sponse. Figure reprinted by permission from Macmillan Publisher Ltd: [Nature 
Reviews Immunology] Beck et al. (2010b). 
The key strategy of a new generation of antibody drug conjugates is to combine the 
cytotoxicity of natural or synthetic agents with monoclonal antibodies conjugated by 
optimized linkers (Beck et al. 2010a). However, the clinical success of these im-
muno-conjugates to date has been limited compared to unmodified antibodies be-
cause the development of antibody drug conjugates takes longer and is much more 
complex. The successful development of antibody conjugates depends on the opti-
mization of antibody selection, linker stability, cytotoxic drug potency, and the 
mode of conjugation (Junutula et al. 2010). Gemtuzumab ozogamicin (Mylotarg) is 
a clinically approved antibody conjugated to calicheamicin that is used for the 
treatment of acute myeloid leukemia (see Table 2) (Hamann et al. 2002). This 
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therapeutic antibody targets and eliminates the CD33 receptor, which is highly ex-
pressed on cancer cells. Another successful example of a drug-conjugated antibody 
is trastuzumab emtansine (previously called T-DM1), which shows greater activity 
than the nonconjugated HER2-targeting antibody trastuzumab during HER2-
positive breast cancer therapy  (Lewis et al. 2008, Junutula et al. 2010) 
The tumor-associated antigens that are over-expressed in B-cells, T-cells, carci-
noma cells, endothelial, or stroma cells have been widely investigated (Beck et al. 
2010a). Reducing the blood supply to tumors has been another efficient alternative 
treatment for cancer. Taken together, antibody therapeutics has been extensively 
studied during recent years, and third-generation antibodies having multiple simul-
taneous activities as discussed above, have entered clinical trials.  
2.1.3 Challenges inherent to antibody usage  
Despite the success of antibody molecules as therapeutic agents or as recognition 
molecules in diagnostic applications, there are considerable limitations to antibody 
usage. For instance, in in terms of drug targeting, conventional antibodies appear to 
have structural features that are less desirable including their rather large size and a 
composition based on two different protein chains (Skerra 2003). Large molecule 
size limits tissue penetration, and the presence of two different polypeptide chain 
structures can lead to unstable domain association. Complex structures also compli-
cate the cloning steps that are required for recombinant expression and manipulation 
of the antigen-binding site of antibody. The stability of the antibody molecule can 
also be a limiting factor in some applications. Additionally, some antibody mole-
cules tend to aggregate especially when fused to other molecules (Binz, Amstutz & 
Pluckthun 2005). 
Despite the immense amount of different specific binding molecules that the an-
tibody repertoire includes, some molecules are still not recognized by the immune 
system. Molecules with cavities or clefts, such as prions, have been refractory to 
conventional antibodies (Hudson, Souriau 2003). Interestingly, single V-like anti-
body domains with cavity-penetrating CDR -loops have been discovered in came-
lids (camels and llamas) (Desmyter et al. 2001) and in sharks (Nuttall et al. 2001). 
By tailoring these proteins (Vincke et al. 2009) or mimicking their structure in 
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in human antibodies, improved characteristics could be achieved to access immu-
nosilent sites.  
One severe drawback to antibody usage in human therapies is the ability to trig-
ger a human anti-mouse antibody (HAMA) or human anti-rat antibody (HARA) re-
sponse (Getts et al. 2010). Fully human antibodies have been utilized in many appli-
cations to overcome this drawback, but even these antibodies have been shown to 
induce marked immune responses (Getts et al. 2010, Harding et al. 2010). Surpris-
ingly, in some cases, a humanized murine antibody may provide a therapeutic ad-
vantage when compared to fully human antibodies. Therefore, it is essential to iden-
tify and design predictive models to select appropriate therapeutic forms in the fu-
ture (Getts et al. 2010). 
The aspects that limit the industrial use of antibodies are the high cost of produc-
tion and intellectual property issues. For example, the large-scale production of gly-
cosylated full-sized antibodies requires time-consuming and expensive eukaryotic 
expression (Skerra 2007). To solve this problem recombinant non-glycosylated Fab 
and scFv fragments are efficiently expressed in bacterial expression systems with 
purification tags (e.g.,c-Myc, Histidine, FLAG). Affordable antibody treatments 
have been developed by increasing the productivity and using less costly down-
stream processing (Beck et al. 2010b). However, it must be taken into account that 
the intellectual property situation surrounding antibodies is quite complex and there-
fore, it can be difficult to protect research results (Skerra 2007).  
As with other protein drug therapies, antibody cancer therapy may also lose its 
therapeutic efficacy due to acquired resistance to the antibody. Primary resistance 
toward therapeutic antibodies may also arise. For example, both of these drawbacks 
have been reported for the therapeutic use of the well-known antibody trastuzumab 
to treat HER2-positive breast cancer (Nahta et al. 2006; Kruser, Wheeler 2010). 
2.2 Non-immunoglobulin affinity proteins provide a 
valuable alternative to antibodies 
The development of life science technologies has made it possible to generate engi-
neered non-immunoglobulin affinity proteins comparable to conventional antibodies 
in terms of specificity and affinity. Recently, protein engineering of non-
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immunoglobulin affinity proteins has been extensively studied, and a number of re-
views describing engineered scaffolds can be found elsewhere (Gebauer, Skerra 
2009; Gronwall, Stahl 2009; Skerra 2007; Binz, Amstutz & Pluckthun 2005; Ny-
gren, Skerra 2004; Hey et al. 2005; Hosse, Rothe & Power 2006). Approximately 50 
different non-Ig protein scaffolds have been successfully modified (Gronwall, Stahl 
2009). Examples of modified scaffolds and the protein engineering and selection 
methods use to generate them are listed in Table 3.  
Engineered proteins vary in structure and in function, but the choice of the scaf-
fold is mostly dependent on the indented use. If affinity proteins are to be used as an 
alternative to antibodies, they should lack the inherent limitations of antibodies. The 
ideal scaffold has a robust, stable architecture, as it must provide the capability to 
fold as a functional protein despite extensive reshaping, even in cases of amino acid 
replacements or insertions and deletions (Skerra 2003). The ideal scaffold should 
also be composed of a single polypeptide chain. Additionally, a low degree of post-
translational modification is also advantageous (Gronwall, Stahl 2009; Skerra 2003). 
If the intended use of the engineered protein is therapeutic, the protein must also 
have appropriate pharmaceutical properties, such as a long serum half-life, and it 
should remain homogenous despite large-scale manufacturing or long-term storage.  
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Table 3. Examples of affinity proteins tailored from immunoglobulins and from alternative scaffolds.
Name Scaffold Randomization Selection method Antigen/ Target Affinity (Kd) Reference 
Antibody Fab CDR-L3, -H1, -H2: Y,S  
CDR-H3: Y,S,G/Y,S,R/Y,S,G,R 
Phage display Insulin, VEGF  
and HER 
0.3 – 188 nM Birtalan et al. (2008) 
Antibody scFv CDR1, CDR2, CDR3 Ribosome display Bovine insulin 82 pM Hanes et al. (2000) 
Antibody Fab CDR-L3 
CDR-H3 
Phage display Testosterone 0.3 nM Hemminki et al. (1998a) 
Hemminki et al. (1998b) 
Adnectin Fibronectin 3 loops mRNA display  TNF-α 20 pM Xu et al. (2002) 
Affibody Protein A 13 amino acids on 2 α-helices Phage display ErbB2 22 pM Orlova et al. (2006) 
Anticalin  Lipocalin  
(BBP) 
4 loops (16 amino acids) Phage display Digoxigenin, 
digoxin, 
fluorescein  
30 nM 
800 pM 
1 nM 
Beste et al. (1999) 
Schlehuber, Beste & 
Skerra (2000) 
 Lipocalin 
(Lcn2) 
4 loops (20 amino acids) 
by error-prone PCR 
Phage display CLTA-4 240 pM Schonfeld et al. (2009) 
DARPin Ankyrin repeat 7 amino acids on a β-turn and  
1 α-helix of every repeat 
Ribosome display Maltose binding protein, 
JNK2, 
p38 
4.4-2.1 nM Binz et al. (2004) 
Kunitz domain APP1 1 to 2 loops Phage display Human plasma kallikrein 1.2 nM Dennis and Lazarus 
(1994)  
Williams and Baird 
(2003) 
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There are already a number of different biotechnological and medical applications 
available in which novel affinity scaffolds have been utilized (Figure 4). Engineered 
affinity proteins have been used as capture agents in affinity matrices when large 
amounts of protein are needed. The use of such proteins has been advantageous be-
cause they can be efficiently produced in prokaryotic expression systems and inex-
pensively purified. Protein A-derived affibodies have been successfully used as cap-
ture agents (Nygren 2008). These multipurpose molecules will be discussed in more 
detail in Section 2.2.2.  
 
Figure 4. Possible applications of novel affinity scaffolds in biotechnology and medical ap-
plications. Reprinted from Gronwall and Stahl (2009) with permission from El-
sevier.  
Novel affinity molecules can also be used as detection reagents in traditional anti-
body-based procedures such as ELISAs, flow cytometry and immunohistochemis-
try. Modified affinity proteins such as affibodies (Hogbom et al. 2003) and 
DARPins (Binz et al. 2004) have been used for co-crystallization to determine the 
structures of proteins that are otherwise not possible to crystallize. Engineered pro-
teins are highly promising as imaging agents for in vivo diagnostics (Gronwall, Stahl 
2009). They can be used to identify or localize pathological conditions, as high af-
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finity and specificity are essential requirements for proteins used for imaging. Small 
size and rapid body clearance are of great importance for imaging molecules.  
Engineered proteins are also used as pharmaceuticals for biotherapeutic applica-
tions, and today, the majority of biopharmaceuticals are so called “protein-drugs” 
(Walsh 2005). Protein-drugs can interfere with or block functions, target molecules 
or organisms, or even stimulate a signaling pathway. Additionally, these proteins 
can serve as delivery vehicles.  
2.2.1 Anticalins are artificial affinity proteins tailored from 
lipocalin structures 
Anticalins are artificial binding proteins tailored from the plastic structures of 
lipocalins (Skerra 2008). Lipocalins are members of a protein family that includes 
several hundred different proteins, of which many are well characterized and have 
determined 3D -structures (Skerra 2008). Anticalins can bind small hydrophobic 
molecules and specific cell-surface receptors as well as form complexes with other 
soluble macromolecules (Flower, North & Sansom 2000). Lipocalins are used for 
the transportation or storage of organic compounds, especially vitamins, steroids, 
and lipids (Skerra 2008).  
Lipocalins serve as an excellent scaffold for protein engineering; they have a 
small and simple molecular architecture (being 160 to 180 amino acid residues in 
length), and they are often thermostable. The lipocalin fold is a β-barrel structure 
with eight antiparallel β-sheets. The ligand binding site is composed of an internal 
cavity and an external loop scaffold (Flower 1996). The absence of post-
translational modifications is also advantageous for a modified protein scaffold. The 
robust structure of lipocalins tolerates structural modifications and mutations quite 
well. Additionally, the ligand-binding sites of lipocalins resemble the CDRs of anti-
bodies; therefore, this site has considerable potential for molecular engineering and 
recognition technology. 
Novel affinity proteins derived from the lipocalin fold have been successfully se-
lected using small hapten-like compounds and large protein antigens. Additionally, 
lipocalins have been extensively modified, and even forms where two lipocalins 
have been fused together to form duocalin have been generated (Schlehuber, Skerra 
2001). Because the diversity of the different lipocalins cannot be acquired by so-
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matic gene recombination and hypermutation, as in the case of antibodies, novel 
methods of combinatorial biochemistry have been developed and applied to engi-
neer lipocalins as novel affinity proteins. For instance, the lipocalin from Pieris 
brassicae, bilin-binding protein (BBP), has been successfully engineered to recog-
nize novel ligands (Beste et al. 1999), such as fluorescein (Gotz et al. 2002) and di-
goxigenin (Schlehuber, Beste & Skerra 2000). Importantly, this modification leads 
to affinities comparable to those of antibodies (fluorescein KD ~ 1 nM; digoxigenin 
KD = 30 nM). Possible applications for a fluorescein-binding anticalin may include 
use as a reagent for the specific quenching of background signals in biophysics stud-
ies. A dioxigenin-binding anticalin was subjected to affinity maturation by a combi-
natorial approach of loop-walking randomization and rational protein design. This 
successful strategy led to the capture of a high-affinity digoxin binding protein with 
a KD value 800 pM (digoxin is a natural glycosylated derivative of digoxigenin) 
(Schlehuber, Skerra 2002). This novel molecule may be applicable as a therapeutic 
agent for the treatment of digitalis intoxication. 
Human anticalin libraries have been created and selected against a variety of dis-
ease-related protein antigens. For example, an antagonist with an inhibitory effect 
on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) receptor was found using a neu-
trophil lipocalin library. This protein may be used as a drug in the immunotherapy 
of cancer (Skerra 2008). An anticalin recognizing vascular endothelial growth factor 
(VEGF) was also foud; this molecule exhibits favorable binding when compared to 
currently approved VEGF antagonists (Skerra 2008). Human lipocalins can be used 
as carrier molecules or scavengers for pharmaceutically active compounds because 
they are soluble in plasma and also in other body fluids in quite high concentrations 
(up to 1 mg/mL) (Skerra 2008). 
One challenge for the use of lipocalins is their rapid clearance by renal filtration. 
This clearance is disadvantage in many therapeutic applications. To extend the se-
rum half-life, anticalins can be fused with serum albumin or with an albumin-
binding domain (Skerra 2008). Alternatively, the addition of polyethylene glycol 
(PEG) to the anticalin molecule has been used for the same purpose. The properties 
and possible application of anticalins have been widely reviewed elsewhere (Beste 
et al. 1999; Schlehuber, Beste & Skerra 2000; Skerra 2008; Schlehuber, Skerra 
2002; Skerra 2001).  
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Pieris AG is a biotechnology company employing Anticalin® technology to de-
velop more efficacious and convenient protein therapeutics (http://www.pieris-
ag.com/index.php (18.6.2011)). The company was founded in 2001 by Dr. Arne 
Skerra and Claus Schalper.  
2.2.2 Affibodies are affinity proteins derived from Staphylococcal 
protein A 
Affibodies are the ultimate example of artificial binding molecules. These affinity 
proteins have been selected toward a large number of targets and used in several ap-
plications, such as bioseparation, diagnostics, functional inhibition, viral targeting, 
and in vivo tumor imaging and therapy (Nygren 2008). Staphylococcal protein A-
derived affinity molecules are ideal scaffolds for protein engineering (Figure 5). Af-
fibodies are small (6 kDa), cysteine-free molecules with a structure containing a 
three-helix bundle domain. They are easy to produce in soluble and proteolytically 
stable forms, and their robust structure is highly tolerant of modifications and fusion 
to other protein or peptides.   
 
 
Figure 5. Comparison of the structures of monoclonal antibody and affibody molecule. Af-
fibody (6 kDa) is significantly smaller and simpler in structure than monoclonal 
antibody (150 kDa). Figure adapted from http://www.affibody.com/en/Product-
Portfolio/Technology/Affibody-Molecules---Technology/ (18.6.2011). 
Originally, protein A molecules were employed in the purification and detection of 
antibodies. However, due to a specific interaction with antibodies, protein A was 
subjected to mutagenesis to change its ligand recognition to target other molecules. 
A gene library based on protein A, in which 13 amino acids from helices 1 and 2 
were randomly mutated was created and tested for novel binding proteins via phage 
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display selection (Nord et al. 1997). Since then, specific affibody molecules have 
been generated toward various ligands including human epidermal growth factor 
receptor 2 (HER2) (Wikman et al. 2004), HIV-1 envelope glycoprotein gp120 
(Wikman et al. 2006), and interleukin-2 receptor α (Gronwall et al. 2008). Re-
markably, generated binders provide affinities comparable to those obtained for na-
ïve libraries of antibody fragments.  
In addition to selection for novel binding properties, affibodies have been fused 
to several different molecules. For example, antibody-like fusion constructs have 
been generated and successfully expressed in E. coli, where the Fab-arms were re-
placed with affibodies (Ronnmark et al. 2002). These artificial antibodies may rep-
resent alternatives for antibodies in diagnostic or therapeutic applications. Addition-
ally, affibodies have been fused to various labels for detection in techniques like 
flow cytometry, immunofluorescence and immunohistochemistry. Technetium-
labeled HER2-targeting affibodies have been used for radionuclide tumor targeting 
in vitro and in vivo (Orlova et al. 2006). Affibody molecules have been used also to 
re-direct viral vectors to cancer cellsas part of gene therapy (Henning et al. 2002). 
This technique was taken further, and an adenovirus vector was engineered to rec-
ognize two different ligands, HER2 and Taq polymerase, for use in gene transfer 
assays (Myhre et al. 2009). Furthermore, there are commercially available applica-
tions based on affibody technology, such as a DNA polymerase-binding affibody 
that creates hot-start PCR conditions when added to the reaction (Phusion Hot Start 
High-fidelity DNA Polymerase, Finnzymes, Thermo Fisher Scientific).  
The Swedish biotech company called Affibody (http://www.affibody.com/en/ 
(18.6.2011)), launched in 1998, focuses on developing biopharmaceuticals based on 
Affibody® molecules.  
2.2.3 The avidin scaffold has potential as a novel affinity protein  
Avidin is a tetrameric protein found in the chicken egg white, and it is originally 
known for its capacity to bind biotin with a high-affinity (Eakin, Snell & Williams 
1941). Like lipocalins, avidins have beta-barrel structures, and both belong to the 
calycin superfamily (Flower 1993). Due to its extreme stability and its ultra-tight 
ligand binding (Kd for biotin ~10-15 M (Green 1975)), avidin provides an attractive 
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scaffold for protein engineering. Avidin proteins have been extensively modified 
during recent years (Laitinen et al. 2006) and utilized in many biotechnology appli-
cations (Laitinen et al. 2007). 
The structure of avidin is well–known, and the 3D -structure has been determined 
(Livnah et al. 1993b, Pugliese et al. 1993, Repo et al. 2006), enabling the use of so-
phisticated mutagenesis methods. Avidin consists of four identical subunits, and 
each subunit consists of 128 amino acid residues (DeLange, Huang 1971). The 
avidin protein is basic, unlike its bacterial analog streptavidin, which is neutral. It is 
important to remember that avidin is a glycoprotein and has one intramonomeric 
disulfide bridge when considering its use for protein engineering.  However, despite 
its post-translational modifications, avidin can be expressed efficiently in E. coli 
(Hytönen et al. 2004).  
We have used avidin as a scaffold for protein engineering and modified the bind-
ing properties of avidin by targeted random mutagenesis. An avidin form (sbAvd-2) 
that binds steroids instead of its natural ligand was generated (Riihimaki et al. 
2011). In the study, the loop area of the ligand binding site was randomized, and the 
phage display method (Smith 1985) was used for selection. We have also created 
other avidin mutants that bind small molecules that are considerably different from 
biotin (Hiltunen S. et al., unpublished results). 
The structure of avidin has been modified extensively during the past few years. 
For instance, two circularly permutated avidin subunits have been fused together to 
form dual-chain avidin (Nordlund et al. 2004, Nordlund et al. 2005). To improve 
properties of dual chain avidin, a chimeric dual-chain avidin with enhanced thermal 
stability and expression in E. coli was generated (Riihimaki et al. 2011). 
2.3 Generation of novel affinity proteins by affinity se-
lection from gene libraries 
Recognition molecules are required for various life-science applications. Protein 
engineering of alternative protein scaffolds addresses this challenge by complement-
ing traditional antibody-based biotechnology applications. Currently, novel affinity 
proteins with desired characteristics can be acquired by combinatorial protein engi-
neering and library selection (Gronwall, Stahl 2009; Binz, Amstutz & Pluckthun 
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2005). The solubility, stability, resistance to aggregation, and expression level of the 
protein can also be notably improved with these techniques (Binz, Amstutz & 
Pluckthun 2005). The challenge, however, is to predict the changes needed to alter 
the protein function but still retain its structure. Fortunately, in many cases, an af-
finity protein can be changed significantly without changing the basics of the pro-
tein-ligand interface (Reichmann et al. 2007). 
As discussed in Section 2.1.1.2 to acquire the vast diversity of naturally occur-
ring antibodies, mammals use somatic hypermutation and selection (Figure 6B). 
This cyclic process is mimicked in the methods of protein engineering to produce 
high-affinity proteins (Skerra 2003). So far, the most successful methods for mod-
ifing proteins rely on several cycles of mutation, display, selection and gene 
amplification (Hudson, Souriau 2003) (Figure 6A). These cycles of mutation and 
selection can be carried out both in vivo and in vitro. 
 
Figure 6. Selection methods rely on the several cycles of mutation, display, selection and 
gene amplification. Phage display (C) and ribosome display methods (D) are de-
scribed more closely in Sections 2.3.2.1 and 2.3.2.2 respectively. Figure re-
printed by permission from Macmillan Publisher Ltd: [Nature Medicine] Hudson 
and Souriau (2003). 
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2.3.1 Mutagenesis strategies for affinity protein modification 
Because tailored proteins vary in their structures and functions, and the require-
ments for affinity proteins are diverse, there are a variety of different ways to modi-
fy the genes encoding such proteins. If the 3D -structure of a protein has been 
solved, rational design (Figure 7H), in which mutations can be targeted to known 
spots or regions of the gene, can be applified. This technique requires specific 
knowledge about the ligand-protein interaction. Detailed information about the 
characteristics of the amino acid residues that are the building blocks of proteins is 
also needed. Alanine scanning, in which each corresponding amino acid is changed 
to alanine, is often used to detect the effects of certain amino acid residues on the 
function of a protein (DeLano 2002).  
With extensive knowledge of the ligand-binding site, an affinity protein with 
high affinity and specificity can be created. The shape complementarity between 
protein and ligand is primarily generated by aromatic side chains and specific inter-
actions with suitably placed hydrogen-bond donors and acceptors (Skerra 2008). 
Computational methods are advancing rapidly, and as a result, computationally de-
signed novel proteins with improved protein stability and functionality have been 
reported (Saven 2011). Hellinga et al. presented a computational method whit they 
constructed soluble receptors with high affinity and specificity for different ligands 
(Looger et al. 2003).  
In some rational engineering approaches, a pre-existing binding domain has been 
grafted onto a recombinant protein (Figure 7G). For example, Desmadril et al. trans-
ferred the CDR3 of the VHH chain of the camel anti-lysozyme antibody to the 
structure of the small antibody-like protein neocarzinostatin (Nicaise et al. 2004). 
The resulting molecule was stable and specifically bound lysozyme.  
However, the rational design of an affinity protein can be challenging because 
different proteins have diverse solutions to accomplish the requirements of specific-
ity and affinity binding. Therefore, in many cases, combinatorial engineering is used 
instead of rational mutagenesis. In combinatorial mutagenesis the sequences of spe-
cific positions can be diversified by randomized codons. To modify or change the 
affinity of the protein, the randomization is generally targeted to the ligand-binding 
site, for instance to loop areas (Figure 7A) or to the ligand cavity (Figure 7D). These 
strategies are discussed in more detail in Section 2.3.1.1. 
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Figure 7. Mutagenesis strategies frequently used in affinity protein engineering. Figure 
reprinted by permission from Macmillan Publisher Ltd: [Nature Biotechnology] 
Binz, Amstutz & Pluckthun (2005). 
Combinatorial strategies include random peptide insertion (Figure 7E) and error-
prone PCR methods (Figure 7F). In a study by Brent et al., the random peptide in-
sertion strategy was used, and 20-residue peptide aptamers were transferred into the 
loop area of E. coli thioredoxin (Colas et al. 1996). Affinity selection of the aptam-
ers resulted in a molecule that bound cyclin-dependent kinase 2. When the structure 
of a protein is unknown, the error-prone PCR method (Cadwell, Joyce 1992) may be 
a good choice for a mutagenesis strategy. In this method, random point mutations 
are introduced throughout the sequence due to the decreased fidelity of the DNA 
polymerase used in the PCR reaction. For instance, PDZ domains have been modi-
fied to specifically bind novel ligands using this method (Schneider et al. 1999). 
One commonly used strategy is combining mutagenesis methods. Skerra et al. 
generated a molecule recognizing the T-cell core receptor CLTA-4 with subnano-
molar activity from human lipocalin Lcn 2 using a combination of targeted muta-
genesis and error-prone PCR (Schonfeld et al. 2009). In that study the loop area of 
lipocalin (20 amino acid residues) was randomized, and a library of 2×1010 individ-
ual molecules was created. To increase the affinity and specificity, molecules were 
affinity-matured by in vitro evolution using an error-prone PCR. As a result, Skerra 
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and colleagues captured an engineered lipocalin with an affinity (240 pM) approxi-
mately 10-fold better than the affinity of a humanized CTLA-4-specific antibody 
that is under clinical investigation (Phan et al. 2003).  
Finally, in vitro homologous recombination is a good alternative to engineer pro-
teins when the function or the structure of the protein is not well-known. For exam-
ple, enzymes are difficult to engineer using rational mutagenesis, but the functions 
of enzymes have been improved successfully with homologous recombination in 
vitro (Minshull, Stemmer 1999).  
2.3.1.1 Oligonucleotide-directed mutagenesis 
A selective random mutagenesis strategy based on randomized codons is frequently 
used when creating affinity protein gene libraries. In the development of novel af-
finity scaffolds, strategies in which mutagenesis is targeted to a loop area (Beste et 
al. 1999; Schonfeld et al. 2009; Dennis, Lazarus 1994), flat surfaces (Nord et al. 
1997), combinations of loops and helices (Binz et al. 2004), or cavities (Beste et al. 
1999) have been reported (Binz, Amstutz & Pluckthun 2005).   
Library design requires extensive planning because proteins may contain thou-
sands of amino acid residues, and they may fold into various conformations. This 
property results in a large configurational space (Saven 2011) as well as in a large 
sequence space. Thus, it is challenging to design affinity proteins with well-folded 
structures and proper functions because the function of a protein is dependent on a 
well-ordered structure. In general, randomly generated sequences often fail to fold 
into proper conformations (Hecht et al. 2004).  
Szostak et al. hypothesized that functional proteins are sufficiently common 
(roughly 1 in 1011) that they can be discovered from the protein sequence space 
(Keefe, Szostak 2001). To address this hypothesis, they generated an enormous li-
brary of 6×1012 individual proteins containing contiguous stretches of 80 random 
amino acids and successfully selected functional ATP-binding proteins from the li-
brary. 
Due to practical considerations, in many cases, six to eight amino acid residues at 
maximum can be totally randomized in a library (Clackson, Wells 1994). In the case 
of eight amino acids, there would be 208 different types of proteins in the library 
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because there are 20 naturally occurring amino acids. The library size can be de-
creased considerably using degenerate codons (Table 4). One codon commonly used 
in library design is NNK (Barbas et al. 2001, Cwirla et al. 1990), in which N is any 
nucleotide and K is either guanine or thymine. This codon allows for all 20 amino 
acids to be present. This set includes one stop codon instead of three possible stop 
codons. In addition, the number of codons is decreased from 64 to 32, which makes 
it easier to cover the sequence space. 
Table 4. A set of degenerate codons used frequently in library design. The table is 
taken from Tonikian et al. (2007). 
Sequence symbols: A (adenine), C (cytosine), G (guanine), T (thymine)  
Wobble IUPAC-IUB symbols: N (A/C/G/T), K (G/T), W (A/T), V (A/C/G), R (A/G), S (C/G), D (A/G/T) 
 
To enhance the discovery of functional proteins from the sequence space, features of 
rational design must be used to focus sequence diversity into regions that are most 
likely to yield proper structures (Hecht et al. 2004). Amino acid residues have spe-
cific roles based on their different structures. For instance, cysteine residues increase 
stability in small proteins by forming disulfide bridges, whereas proline residues, 
abundant in α-helical domains, are known to induce kinks in the protein structure. 
The forces that guide a protein to its folded form are largely based on the non-
covalent interactions among of amino acid side chains, such as van der Waals, hy-
drophobic, electrostatic, and hydrogen-bonding interactions. 
Limiting the sequence space of the library in favor of those amino acids that are 
most likely to contribute to affinity and/or specificity is beneficial, especially when 
aiming to alter or change the affinity of a protein (Birtalan et al. 2008). Some amino 
acids are over represented in ligand-recognition sites. For example, in a study of 50 
Codon Description Amino acids Stop 
codons 
Unique 
codons 
NNK All 20 amino acids All 20 TAG 32 
NNC 15 amino acids A,C,D,F,G,H,I,L,N,P,R,S,T,V,Y None 16 
NWW Charged, hydrophobic D,E,F,H,I,K,L,N,Q,V,Y TAA 16 
RVK Charged, hydrophilic A,D,E,G,H,K,N,R,S,T None 12 
DVT Hydrophilic A,C,D,G,N,S,T,Y None 9 
NVT Charged, hydrophilic C,D,G,H,N,P,R,S,T,Y None 12 
NNT Mixed A,D,G,H,I,L,N,P,R,S,T,V,F,I,L,V None 16 
VVC Hydrophobic A,D,G,H,N,P,R,S,T None 9 
NTT Hydrophobic F,I,L,V None 4 
RST Small side chains A,G,S,T None 4 
TDK Hydrophobic C,F,L,W,Y TAG 6 
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different proteins (including streptavidin), glycine, serine, arginine and tyrosine 
were the most abundant residues found 4 Å from the ligand (Villar, Kauvar 1994). 
As mentioned in Section 2.1.1.1, serine and tyrosine were found to also be highly 
abundant in the ligand-binding sites of antibodies. Amino acid residues such as gly-
cine, serine, arginine and tyrosine are often found in β-turn regions, where they have 
considerable influence on the characteristics of the ligand-recognition site. Due to 
the different structures of amino acid residues, interactions with the ligand are based 
on distinct mechanisms; serine and tyrosine form hydrogen bonds, positively 
charged arginine residues form salt bridges, and aromatic tryptophan moieties create 
hydrophobic interactions (π-π stacking) with the ligand. Minimalistic libraries that 
include only two amino acid residues in the ligand-binding site have been generated: 
Sidhu et al. obtained functional and high-affinity (KD=60 nM) antibodies from a 
minimalistic library in which the amino acid residues of an antigen-binding site 
were changed to tyrosine or serine (Fellouse et al. 2005). 
In an interesting study by Hecht et al., a binary patterning strategy was used in 
the design of de novo four-helix bundle proteins (Kamtekar et al. 1993). In this 
strategy, hydrophobic and hydrophilic residues were explicitly selected and placed, 
as shown in figure 8. This library design was found to be very efficient, as half of 
the library members showed an affinity for heme (Rojas et al. 1997). 
 
 
Figure 8. Strategy of four-helix bundle library using binary patterning. Nonpolar amino 
acids are placed in the ligand-binding cavity, whereas polar amino acids are lo-
cated in the surface area. By extensive planning of codon usage, the sequence 
space of library can be limited and as a result the selection will be more efficient. 
Reprinted from Smith and Hecht (2011) with permission from Elsevier. 
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2.3.1.2 Homologous recombination in vitro 
Homologous recombination in vitro is an effective mutagenesis method, that mimics 
sexual recombination in the evolution of new traits. During recombination, parental 
genes are combined together to create novel characteristics. This strategy generates 
enormous libraries; therefore, the major challenge is to identify the functional muta-
tions from the background of neutral mutations (Giver, Arnold 1998). However, the 
method presents mutants throughout the entire target sequence which is not possible 
with many other strategies. 
In 1994, Stemmer developed a DNA shuffling method (Stemmer 1994a, Stem-
mer 1994b) that enabled the in vitro formation of recombinant genes from parental 
genes. In this method, the parental genes were randomly fragmented by the DNase I 
–enzyme, and the purified fragments were then extended by repeated cycles of over-
lap extension into full-length genes.  
Throughout the years, other methods such as random-priming in vitro recombina-
tion (RPR) (Shao et al. 1998) or staggered expression process (StEP) (Zhao et al. 
1998) have also been developed. These methods are based on the de novo synthesis 
of template products and therefore require a much smaller amount of template. The 
DNase I fragmentation step is no longer needed.  
2.3.1.3 Challenges in library design and construction 
Introduced mutations are not always predictable. A distinctive drop in binding af-
finity can arise if destabilizing events such as the loss of van der Waals contacts, 
electrostatic pairings or buried nonpolar surfaces occurs. Protein aggregation or 
complete unfolding will also lead to a distinctive drop in binding affinity (DeLano 
2002).  
Library design can easily lead to biases. As discussed in Section 2.3.1.2, codons 
can be selected to limit the library size through the use of codons that allow for the 
insertion of only certain amino acid residues. This selection will cause controlled 
bias in the library. Unfortunately, gene libraries may be biased in unfavorable ways. 
The degenerate codon motif NNK (Table 4) is frequently used codon in random mu-
tagenesis. However, the use of the NNK codon results in a large bias toward amino 
acids having more than one possible codon. There is also a significant influence on 
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ence on the part of the expression host selected for library generation because dif-
ferent organisms prefer certain codons over others (Sharp et al. 1988). In the error-
prone PCR method, the genetic material is biased toward AT→GC transitions and 
AT→TA transversions. This effect results in a strong bias toward dAMP and dTMP 
substitutions, making these nucleotides more likely to be mutated (Vanhercke et al. 
2005). 
During transformation of the plasmids into bacterial cells, plasmids containing 
short inserts or no insert can allow for the overgrowth of bacterial clones containing 
them (Barbas et al. 2001). Furthermore, these clones can be overrepresented during 
library amplification, generating an unfavorable bias. If stop codons are allowed in 
the mutagenesis strategy, this choice can result in inserts that are too short to be ex-
pressed as functional domains, again giving a competitive growth advantage to bac-
teria harboring these clones. However, stop codons can be avoided using degenerate 
codon motifs (Table 4).   
A sufficient library size is essential for the successful screening of novel binding 
proteins. At a minimum, the functional library size should exceed the sequence 
space of the library. In a functional library, only correctly assembled clones without 
any frameshift, stop codon or deletion will contribute to diversity (Knappik et al. 
2000). Of note, this number is usually well below the reported diversity obtained by 
counting the number of transformants.  
2.3.2 Selection systems 
Selection systems are needed to screen gene libraries for proteins with novel, de-
sired properties. A number of different selection methods have been developed, be-
cause the selection conditions may vary significantly from one protein to another, as 
the selection depends on the nature of the tailored protein. For instance, phage dis-
play is a powerful method for peptides and small, simple proteins, but if an affinity 
protein is complex in structure and includes disulfide bridges, the protein may not 
be folded correctly during the phage assembly process inside a bacterial cell. In such 
cases, another selection system, e.g., eukaryotic yeast display, would be more effi-
cient. Selection systems can be divided into three categories: cell-dependent sys-
tems, cell-free systems, and non-display systems relying on the protein interaction 
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between an affinity protein and its target to allow for survival or generate fluores-
cence (Gronwall, Stahl 2009).  
In cell-dependent systems, the affinity proteins are displayed on the surface of 
phage or cells. The most frequently used method is phage display (Smith 1985), in 
which an affinity protein is displayed on a bacteriophage, but due to the develop-
ment of flow cytometry techniques, bacterial display (Daugherty 2007) has also be-
come more popular. Libraries with sizes up to 1013 can be created with cell-
dependent methods. However, the use of these systems is limited by the need for 
DNA transformation and by the limits of in vitro transcription and translation 
(Gronwall, Stahl 2009).  
When larger gene library sizes are desired, methods that utilize in vivo transcrip-
tion and translation should be used to avoid these limitations. Cell-free systems such 
as the ribosome display (Mattheakis, Bhatt & Dower 1994) and mRNA display 
(Weng et al. 2002) enable the creation of enormous libraries, and these methods are 
more amenable to automation. The mutagenesis step can be performed during selec-
tion. Strategies such as homologous recombination in vitro produce enormous gene 
libraries (Giver, Arnold 1998), and cell-free systems are appropriate choices to 
screen such libraries. 
2.3.2.1 Phage display 
 
Phage display is based on bacteriophages, viruses that infect bacteria, and was in-
itially created for the affinity selection of protein fragments. The method was first 
described by Smith in 1985, and since that time, the method has been used success-
fully to generate several different affinity peptides and proteins (Clackson, Wells 
1994; Winter et al. 1994; Hoogenboom et al. 1998; Hoogenboom, Chames 2000; 
Uchiyama et al. 2005). In this method, viruses are used to link protein recognition to 
DNA replication by displaying the protein on the surface of the phage that carries 
the corresponding gene in its genome. Large gene libraries can be cloned into phag-
es, thus creating a powerful tool to analyze and select proteins with desired proper-
ties. Based on the properties of the displayed protein, an individual phage can be 
captured and amplified through the infection of bacteria. The new generation of 
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phages is then used for another selection round. The principle of this method is 
shown in figure 9.  
 
 
Figure 9. The principle of phage display and affinity maturation. A diverse phage library is 
incubated with the target molecules (1) that are immobilized for example on a 
solid surface. Washing steps remove the non-specifically bound phages (2) and 
the binders are then released typically by using a pH shock (3). Binders are then 
amplified by infection and multiplication in E. coli (4) to generate a new genera-
tion of highly enriched phages with binding sites specific for the antigen. This cy-
cle is repeated two to four times until desired binders dominate the population 
(5). To affinity-mature selected binders, their genes are isolated from the display 
vector (6) and diversity is introduced by mutagenesis (7). After mutagenesis 
genes are sub-cloned (8) and phage particles of the new repertoire produced (9), 
to be used in re-selection procedure (1–4) with increasing stringency. Figure re-
printed from Hoogenboom and Chames (2000) with permission from Elsevier. 
Different types of phages, such as lambda (Huse et al. 1989), have been used for 
the phage display method, the Ff class of filamentous phages (f1, fd, and M13) be-
ing the most extensively studied (Barbas et al. 2001). Ff -viruses use the F conjuga-
tive pilus as a receptor, and therefore they are specific for E. coli carrying the F 
plasmid. Importantly, infection by the Ff phage is well tolerated by the host, causing 
only a 50 % longer generation time than that of uninfected bacteria.  
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During assembly, circular single-stranded DNA is packaged within the protein 
capsid cylinder of the bacterial envelope. The protein capsid cylinder consists of 11 
different proteins (Figure 10). The length of the cylinder is dependent on the length 
of the DNA, leading to little constraint on the size of the DNA packaged (Barbas et 
al. 2001).  
 
 
Figure 10. Structure of scFv displaying filamentous phage. Figure is from Smith et al. 
(2005). 
Many phage coat proteins have been used as fusion partners in this method, but 
the most frequently utilized coat proteins, p8 and p3, are discussed here. The major 
coat protein p8 is the most abundant of the capsid proteins. There are approximately 
2700 molecules of p8 in one virion (Barbas et al. 2001). Casareni and colleagues 
have studied the effect of fusing peptides to p8 on phage propagation, and they 
found that phage viability is affected by the length of the corresponding peptide and 
that peptide sequence plays a minor “tuning” role (Iannolo et al. 1995). At maxi-
mum, 6 to 8 amino acid residues can be added for functional display when peptides 
are fused to p8 (Iannolo et al. 1995). The reason for this limit is unknown, but the 
assembly of the phages may be interfered with by the fusion partner. In addition, 
inserts may disturb the rate of successful targeting and translocation of the chimeric 
p8 into the membrane (Barbas et al. 2001). Larger peptides or even proteins can be 
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displayed in a hybrid virion where 80 % of p8 proteins are wild type, and the re-
maining 20 % are fused p8 molecules (Greenwood, Willis & Perham 1991). The 
choice of p8 as a fusion partner instead of p3 can be based on two things: i) in some 
experiments, it is advantageous to have multiplicity in the binding sites along the 
phage surface, and (ii) the p8 fusion will not interfere with phage infectivity (Kang 
et al. 1991).  
The most utilized capsid protein for the display of proteins is p3. Because there 
are only approximately five molecules of p3 per phage molecule, the chimeric p3 
proteins containing large inserts are tolerated and packaged well into phage (Barbas 
et al. 2001). Wt p3 includes three domains that are separated by glycine-rich regions 
(Deng, Malik & Perham 1999). Domain 1 (amino acids 1-66) is required during in-
fection for translocation of the phage DNA into the bacterial cytoplasm and for in-
sertion of the coat proteins in to the membrane. Domain 2 (amino acids 86-216) is 
utilized when the phage binds to the F pilus during the initial phage of the infection. 
Domain 3 (amino acids 257-377) is essential for forming a stable phage particle by 
anchoring p3 to the tip of the virion. Because of the central role of the p3 protein in 
the phage infection process, the insertion of a large insert may lead to non-infective 
phages (Smith 1985). For monovalent display of larger proteins, hybrid phage-based 
method can be used. In these methods, a fusion of a novel protein to p3 is expressed 
from a phagemid, and wt p3 is encoded by a helper phage. Proteins may be intro-
duced into the c-terminal part of p3 from which domains 1 and 2 are missing (Bar-
bas et al. 2001, Barbas et al. 1991).   
Selectively -infective phages, generally called as SIP technology, may be used 
for identifying robust and proteolysis-resistant proteins by phage display selection 
(Krebber et al. 1995, Krebber et al. 1997). The method may also be called selection 
and amplification of phage (SAP) (Duenas, Borrebaeck 1994) or direct interaction 
rescue (DIRE) (Gramatikoff, Georgiev & Schaffner 1994). The principle of this 
method is to select interacting protein-ligand pairs by fusing a ligand-binding pro-
tein with the N-terminal domains of p3 protein. The N-terminal domains of p3 will 
be then linked to the ligand. Infectivity of the phage particle is only restored when 
the displayed protein binds to the ligand. This property leads to the rapid selection 
of high-affinity interactions (Krebber et al. 1997). 
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2.3.2.2 Ribosome display 
Ribosome display was first developed for peptide libraries (Mattheakis, Bhatt & 
Dower 1994). Ribosome display differs from phage display in that the ribosome 
complexes are constructed totally in vitro, and the capture of highly specific binding 
proteins is therefore faster (Hanes et al. 2000; Hanes, Pluckthun 1997). Further-
more, this method enables the generation of large gene libraries, up to even 1014 
members, and during the selection process, additional mutations can be easily added 
to bring about affinity maturation. The ribosome display method is closely related to 
mRNA display, which is another cell-free selection system. In mRNA display, the 
modified protein is covalently bound to mRNA (Weng et al. 2002). 
In this method, genotype and phenotype are linked through ribosomal complexes, 
which consist of mRNA, the ribosome, and the encoded protein. Protein is used for 
selection. In this in vitro selection method (for the principle of the method, see Fig-
ure 11), the first step is to amplify the DNA library by PCR, whereby a T7 pro-
moter, ribosome binding site, and stem-loops are introduced and transcribed into 
RNA. RNA is then purified and translated in vitro in an E. coli S-30 system. Trans-
lation is stopped, and complexes are stabilized by cooling on ice and by increasing 
the magnesium concentration. The desired ribosome complexes are affinity selected 
by binding to an immobilized ligand. The bound ribosome complexes are dissoci-
ated by EDTA or with free antigen. Finally, RNA is isolated from the complexes 
and reverse transcribed to complementary DNA. The cDNA is then amplified by 
PCR and used for the next cycle of selection (Hanes, Pluckthun 1997).  
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Figure 11. Principle of ribosome display. In the first step the DNA library is amplified 
by PCR and DNA is transcribed to RNA. RNA is then translated in vitro and the 
desired ribosome complexes are affinity selected by binding to immobilised lig-
and. The bound ribosome complexes are dissociated and RNA is isolated from 
the complexes and reverse transcribed to complementary DNA. Amplified DNA 
is used for the next cycle of selection. Figure reprinted by permission from Mac-
millan Publishers Ltd: [Nature Biotechnology] Hanes et al. (2000). 
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AIMS OF THE STUDY 
The aim of the present study was to apply and develop modified avidin proteins for 
biotechnology applications. In the first part of the study, the interactions between 
avidin and azo ligands were studied. In the study, both the structure and function of 
avidin were modified.  
  
More specifically, the aims were: 
 
I. To study and characterize the interaction between avidin/AVR4 and azo-
compounds. 
 
II. To produce and analyze the characteristics of second-generation dual-
chain avidins. 
 
III. To change the ligand-binding properties of avidin to generate novel af-
finity proteins based on the avidin scaffold. 
 
IV. To examine the properties of chimeric avidin as a bioactive molecule co-
valently immobilized on cellulose acetate film. 
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3. SUMMARY OF METHODS 
The materials and methods are described in more detail in the original publications 
(I-IV) and the references therein. 
3.1 Modification of the avidin gene 
In this study, both the structural and functional properties of avidin were changed 
using protein engineering techniques. The nucleotide sequences of the constructs 
used were verified by sequencing on an ABI PRISM 3100 Genetic Analyzer (Ap-
plied Biosystems) according to the protocols recommended by the manufacturer 
(ABI PRISM BigDye Terminator Cycle Sequencing Kit v.1.1, Applied Biosystems). 
3.1.1 Structural modifications (II) 
Circular permutations. To create chimeric dual-chain avidin DNA constructs of 
circularly permutated avidin cp54 was fused to the circularly permuted genes for 
streptavidin, avidin-related protein 2 (AVR2) and avidin-related protein 4 (AVR4) 
(cp65 SA/AVR2/AVR4). The cp65 strategy was applied as described in Nordlund et 
al.. Circularly permuted genes were inserted into the pBVboostFG plasmid 
(Laitinen et al. 2005) containing the region encoding the OmpA signal sequence, 
and the plasmid was transformed into chemically competent E. coli TOP10 cells 
(Invitrogen) by the heat-shock method as described in Section 3.2. 
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3.1.2 Functional modifications (IV) 
 
Construction of a phagemid vector. The avidin gene was first subcloned into the 
pCR®2.1-TOPO plasmid by TOPO TA-cloning (Invitrogen) and transformed into E. 
coli TOP10 cells. Plasmids were isolated from colonies that were determined to con-
tain inserts based on blue-white screening. Fragments were digested from the 
pCR®2.1-TOPO -plasmid using the NheI and NotI restriction enzymes and ligated 
into the phagemid vector (pBluescript SK+ -derived phagemid, VTT Technical Re-
search Center of Finland, Espoo, Finland). AVD cDNA the was subcloned into the 
phagemid vector as an N-terminal fusion to the C-terminal domain (amino acids 
198-406) of the minor phage coat protein III. The avidin phagemid vectors were 
transformed into chemically competent E. coli XL1-Blue cells (Stratagene) by the 
heat-shock method as described in Section 3.2. 
 
Construction of the Avd L1,2 library. To construct a Avd L1,2 library, amino 
acids N12, D13, L14, G15, and S16 in the loop between beta strands 1 and 2 of avi-
din were randomized. The libraries were constructed using a two-step PCR-strategy 
essentially as previously described (Barbas et al. 2001). Fragments were ligated into 
a phagemid vector (pBluescript SK+ -derived phagemid, Research Center of Fin-
land, Biotechnology, Espoo, Finland), and the resulting ligation product was trans-
formed into electrocompetent cells of the E. coli strain XL1-Blue (Stratagene) by 
electroporation as described in Section 3.2.  
 
Construction of the sbAvd L3,4 library. A DNA library based on steroid-binding 
avidin (sbAvd), was constructed and ligated into the phagemid to improve the speci-
ficity of sbAvd. In the created library (sbAvd library L3,4), amino acids T35, A36, 
V37, and T38 in the loop between beta-strands 3 and 4 of avidin were randomized. 
Library construction was performed as described above.  
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3.2 Escherichia coli strains and transformation methods  
Escherichia coli strains. The bacterial strain TOP10 [F- mcrA Δ(mrr-hsdRMS-
mcrBC) φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 
galK16 rpsL(StrR) endA1 λ-] (Invitrogen) was used for plasmid amplification. Strain 
BL21-AITM [F- ompT hsdSB (rB-mB-) gal dcm araB::T7RNAP-tetA] (Invitrogen) was 
used for protein expression. The XL1-Blue strain [endA1 gyrA96(nalR) thi-1 recA1 
relA1 lac glnV44 F'[::Tn10 proAB+ lacIq Δ(lacZ)M15] hsdR17(rK- mK+)] (Strata-
gene) was used for phage amplification. 
 
Transformations. Plasmids were transformed into bacterial cells by the heat-shock 
method or by electroporation. Heat-shock was used for standard transformations fol-
lowing the manufacturer’s instruction (Invitrogen). Electroporation was used to cre-
ate avidin gene libraries. Electroporation was preformed on ice with a Gene Pulser 
(Bio-Rad) following the instructions for the transformation of XL1-Blue cells 
(Stratagene). 
3.3 Selection of steroid-binding proteins (VI) 
Avidin display on M13 phage. The functionality of the avidin phages was first 
tested by competing avidin and avidin(N118M) phages. Amplification of the phages 
and panning on surfaces coated with BSA-conjugated HABA (HABA-BSA) (Hof-
stetter et al. 2000) was performed essentially as previously described (Barbas et al. 
2001). Vigorous shaking in hydrochloric acid containing D-biotin (Biochemica, 
Fluka, 14400) was used for elution. In total, three selection rounds were performed.  
 
Selection of steroid-binding proteins. Steroid-binding avidins were selected from 
the Avd (L1,2) library by panning against a testosterone-coated surface. The pan-
ning procedure was essentially performed as previously described (Barbas et al. 
2001). Three to four selection cycles were conducted, and acid treatment in the 
presence of the ligand was used for elution. After each panning round, the results 
were verified by sequencing, and the number of phage particles was determined by 
phage titration.  
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Improvement of the specificity of sbAvd. More specific steroid-binding avidins 
were selected from sbAvd library L3,4 by panning against a testosterone-coated sur-
face. The panning procedure was essentially performed as previously described 
(Barbas et al. 2001). Three to four selection cycles were conducted, and acid treat-
ment with testosterone was used for elution. After each panning round, results were 
verified by sequencing, and the number of phage particles was determined by phage 
titration. Additionally, every panning round was screened for binding proteins using 
anti-M13 as previously described (Kingsbury, Junghans 1995). 
3.4 Expression and purification of recombinant proteins 
(II, IV) 
The pET101-Directional TOPO (Invitrogen) was used as an expression vector. Re-
combinant proteins were produced in E. coli strain BL21-AI (Invitrogen). Small-
size cultivations were set up as previously described (Hytönen et al. 2004). 
 
Fermentation. The Infors Labfors 3 fermentor was used for protein fermentation. 
LB medium containing gentamycin and glucose was used for fermentation, supple-
mented with antifoam agent struktol J647 (Schill & Seilacher, Hamburg, Germany). 
At the beginning of fermentation, the pO2 of dissolved oxygen was 0 %, stirring 
speed 500 rpm and OD600 0.288. Fermentation was performed at 28 °C. The level of 
oxygen was slowly raised to obtain 20 % dissolved oxygen (pO2). A feedback loop 
to maintain the oxygen level at 20 % was set by adjusting the stirring speed between 
150 and 1100 rpm. Pumping of the feed solution (50 % glycerol, 2.5 g/l  MgSO4, 33 
ml/h) was initiated at OD ~1. rotein production was induced at OD ~1.5 and contin-
ued for 24 h.  
 
Purification by affinity chromatography. Bacterial pellets were lysed by sonica-
tion (Sonics & Materials Vibra Cell™) and DNaseI (New England Bio labs) treat-
ment. Proteins were purified from bacterial lysate by affinity chromatography using 
2-iminobiotin (Affiland) (as previously described (Hytönen et al. 2004)), biotin (Af-
filand), or polyhistidine-tag (QIAGEN) columns. For His-tag -purification ÄKTA-
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purifier™ HPLC was used. The concentration of purified protein was measured with 
a NanoDrop™ 3300 spectrometer, and samples were analyzed by SDS-PAGE gels 
stained with Coomassie Brilliant Blue. 
3.5 Summary of structural and functional analyses of 
proteins (I-IV) 
Table 5. Methods used for protein structure and ligand-binding analyses. 
Structural analyses Instruments/ 
programs 
Publication Reference(s) 
Gel-filtration ÄKTApurifier™ HPLC II, IV  
Thermal stability analysis  
(SDS-PAGE) 
 II Bayer, Ehrlich-Rogozinski 
& Wilchek (1996) 
Thermal stability analysis  
(DSC) 
Nano II DSC, 
capillary VP-DSC 
I, II, IV Nordlund et al. (2003) 
Antibody staining 
- rabbit α-avd IgG with goat anti-
rabbit IgG 
- mouse anti-pIII IgG with goat 
anti-mouse IgG 
 II, IV University of Oulu; 
Sigma-Aldrich, 
Biosite, Sweden  
Determination of 3D -structure Beamline X13 (EMBL) 
XDS,  
TLS,  
PROCHECK, 
WHATIF 
I PDB code 1VYO 
Laskowski et al. (1993)  
Laskowski et al. (1993) 
 Vriend (1990) 
Modeling Modeller 9v2,  
BODIL 
I, II, IV Eswar et al. (2006) 
Lehtonen et al. (2004) 
Docking and 
MD simulations 
Sybyl, 
Gold 2.2 
CHARMM 22,  
NAMD 2.6,  
VMD 1.8.6,  
PyMOL 1.3 
I,II Phillips et al. (2005) Hum-
phrey, Dalke & Schulten 
(1996) 
Functional analyses Instruments 
/programs 
Publication Reference(s) 
Microplate analysis Bio-Rad 680 XR IV Barbas et al. (2001) 
Fluorescence-labeled biotin assay QuantaMasterTM II Hytönen et al. (2004) 
Molecular recognition force microscopy 
(MRFM) 
Pico SPM I IV Kamruzzahan et al. (2004)  
Wildling et al. (2009) 
Surface plasmon resonance (SPR) Biacore X, BiaEvaluation 
software 
II, IV  
UV/Visible spectroscopy PerkinElmer spectrometer I  
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3.6 Synthesis of azo ligands (I) 
 
A set of azo dyes were synthesized by coupling diazotized aminobenzoic acid to 
phenol and naphthol derivatives. During the synthesis of 1,2-
dihydroxyazobenzenecarboxylic acid, 1,2,3-dihydroxyazobenzene carboxylic acid 
and 1,2-dihydroxy-3-methylazobenzenecarboxylic acid, hydroxyl groups were pro-
tected by aluminum sulfate before reaction. The resulting precipitates were col-
lected, washed with water and dried in vacuo. The product was recrystallized from 
the ethanol-water mixture and dried. The final products were confirmed using 1H 
NMR (Bruker Avance DPX 250 FT), 13C NMR (DPX 500) and ESI-MS.  
3.7 Generation of bioactive cellulose acetate films (III) 
Functionalization of the films. Cellulose acetate (CA) films were first amino-
functionalized by dip-coating the films into a sol-gel solution. Next, films were 
treated with a glutaraldehyde solution. After glutaraldehyde treatment, the films 
were washed with water, dried and stored at room temperature prior to use. Gas 
chromatography was used to measure the density of free amino groups on the amino 
functionalized CA film and amino-reactive groups on the glutaraldehyde functional-
ized CA film. The amino and amino-reactive groups on the surface of functionalized 
films were reacted with benzaldehyde and aniline analytes, respectively, to form im-
ine bonds. Scanning electron microscopy (SEM) images of prepared CA films were 
generated using Zeiss ULTRA plus field emission microscope. 
Avidin proteins (chimeric avidin, chicken avidin, rhizavidin, streptavidin) were 
added onto the films by incubating the films in the appropriate protein solution. 
Coated films were analyzed using tritium-labeled biotin as described below. The 
chimeric avidin-functionalized films were stored either at RT or at +4oC for three 
months, and the activity of these films was analyzed monthly.  
54 
 
Determination of biotin-binding activity. The biotin-binding capacity of the sur-
face-immobilized avidin layer was measured using tritium-labeled biotin (D-[8,9-
3H]-biotin, Amersham) with an LKB Wallac 1217 RackBeta liquid scintillation 
counter (Turku, Finland). Non-specific biotin binding was taken into account by 
measuring the bound [3H]-biotin after blocking the films with an excess of D-biotin. 
These results were subtracted from the results without D-biotin blocking to calculate 
the specific biotin-binding capacity. All biotin-binding capacity results were calcu-
lated as bound biotin per area of the film [mol/cm2].  
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4. SUMMARY OF RESULTS 
4.1 High-resolution crystal structure of avidin (I) 
Avidin contains a classical beta-barrel structure with eight antiparallel beta-strands 
(Figure 12). The X-ray structure of avidin has been previously described (Livnah et 
al. 1993b; Pugliese et al. 1993; Livnah et al. 1993a; Huberman et al. 2001; Nardone 
et al. 1998; Pazy et al. 2003; Pazy et al. 2002), but in this study, the structure of 
avidin was determined with high resolution (1.48 Å). In the determined structure, 
both the open and closed conformations of the loop between β-strands 3 and 4 were 
observed.  
 
 
Figure 12. The structure and sequence of avidin (PDB code 1VYO). (A) The deter-
mined structure of tetrameric avidin. Two glycerol molecules in the ligand-binding 
site are shown as ball and stick models. (B) Primary and secondary structures of 
avidin.  
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4.2  Structural modification of avidin (II) 
To overcome challenges limiting the further use of the dual-chain avidin, chi-
meric dual-chain avidins, tandem fusions of avidin and a homologous protein (strep-
tavidin (SA), avidin-related protein 2 (AVR2), or avidin-related protein 4 (AVR4)), 
were generated. All of these proteins were selected as chimeric fusion partners be-
cause they resemble avidin in their fold and 3D-structure (Weber et al. 1987; Eisen-
berg-Domovich et al. 2004; Hytonen et al. 2005a). Fusion proteins were modeled 
based on the previously determined 3D -structures of dcAVD (PDB 2C4I), SA 
(PDB 1MK5), and AVRs [AVR2 (PDB 1WBI), AVR4 (PDB 1Y53)]. Molecular 
dynamics (MD) were performed, and loop dynamics were analyzed by root mean 
square fluctuation (RMSF) (Figure 13). In the analysis, we observed that the linkers 
connecting the original termini of the domains were highly mobile. Additionally, in 
the tandem fusion of dcAVD and SA, there were unique mobile regions in the loop 
between strands β7 and β8 (residues 164-169) and in the loop between strands β4 
and β5 (residues 243-249), as compared to other tandem fusions. 
 
Figure 13. Molecular dynamic simulation of local dynamics in the chimeric dcAVD fu-
sions. The dynamics of the structure are illustrated by plotting 50 superimposed 
structural snapshots along the 4-ns simulation (A: dcAVD/AVR2; B: 
dcAVD/AVR4; C: dcAVD/SA). The loops showing a high amount of structural 
fluctuation (RMSF > 1.5Å) are indicated by numbers referring to the amino acid 
sequence. 
In the case of the tandem fusion of avidin and AVR4, an increase in protein produc-
tion (5 mg of pure protein per liter of production medium) and improved thermal 
stability (Table 6) were observed, as compared to the original dcAVD. Additionally, 
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PCR amplification of the hybrid gene was more efficient, thus enabling more con-
venient and straightforward modification of the dual-chain avidin. When the ligand-
binding properties of dcAVD/AVR4 were studied, biphasic biotin dissociation was 
detected. 
Table 6. Transition temperatures for subunit dissociation (Tr) and thermal unfold-
ing (Tm) determined as SDS-PAGE analysis and DSC. 
 SDS-PAGE  
Tr (°C) 
 
Tr(+BTN) (°C) 
DSC 
Tm (°C) 
 
Tm(+BTN) (°C) 
AVD 60a 95a 84b 117b 
AVR4(C112S) 90 95 110b 127b 
dcAVD 40 75c 80a 116a 
dcAVD/AVR4 70 85 86/91d 108/112d 
aValue from(Hytönen et al. 2004); b(Hytönen et al. 2004); c(Nordlund et al. 2004);  
d(two-peak analysis was applied to the data, and the minor peak is shown in italics).  
+BTN = with biotin. 
4.3 Functional modification of avidin (IV) 
The chicken-derived protein avidin is known for its extremely high affinity for the 
water-soluble vitamin H, D-biotin. To alter or change this extremely tight interac-
tion, the avidin gene was subjected to oligonucleotide-directed mutagenesis, and 
avidin gene libraries were created. To select avidin mutants with novel binding 
properties from the created gene libraries, a phage display method was used. Avidin 
was displayed monovalently (3+3) on the surface of the M13 phage as a single fu-
sion with the C-terminal region of the minor coat protein p3.  
To generate avidin gene libraries, the loops adjacent to the ligand-binding site 
were selected for randomization (Livnah et al. 1993b). In the libraries, four to nine 
amino acids were randomized (Table 7) using both NNN and NNY degenerate co-
dons. The NNN codon covers all 20 naturally occurring amino acids, whereas the 
use of the NNY codon limits the sequence space of the library by covering only 14 
amino acids, thus eliminating all of the stop codons. 
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Table 7. Avidin gene libraries generated and the randomized amino acids for 
each. 
Library Size 
×106 
Theoretical size 
×106 
Randomized residues Degenerate codon 
Avd L1,2 0.1 3.2 N12,D13,L14,G15,S16 NNN 
sbAvd-1 L3,4 1.4 0.38 T35,A36,V37,T38 NNY 
Avd L5,6* 2.1 0.16 F72,S73,E75,S75 NNN 
Avd L1,2+L5,6* 5.9 20661 N12,D13,L14,G15,S16 + 
F72,S73,E75,S75 
NNY 
The library size is calculated from the transformation efficiency. Randomized amino acids that form  
hydrogen bonds with biotin are shown in bold. *Unpublished results. 
4.3.1 Steroid-binding avidin capture 
In the first phage display panning rounds, a combination of acid and biotin was used 
for elution, but in the final panning round, testosterone was used instead of biotin to 
elute phage. During selection, the Avd L1,2 loop library phages were introduced 
onto testosterone-coated surfaces. The quality of the phage genomes carrying the 
mutated cDNA was evaluated by DNA sequencing after every panning round. The 
sequence logo depicted in figure 14 shows the most frequent amino acid residues in 
the randomized area. A clear enrichment of sequences in the randomized loop area 
was observed, indicating the success of the selection conditions. An Avd variant 
named sbAvd-1, carrying the sequence N12, R13, M14, N15, H16 was selected for 
further analysis. 
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Figure 14. Sequence logo from panning of Avd L1,2 library 
(http://weblogo.berkeley.edu/ 20.8.2011) describes the most frequent amino ac-
ids present in the randomized area. Logo is combination of 11 sequences from 
3rd panning round. The most conserved was amino acid number 12; asparagines 
(N), aspartic acid (D), and serine (S) were most frequently present in this posi-
tion. Wt avidin has amino acid sequence NDLGS in the corresponding site. 
To improve the specificity of sbAvd-1, the sbAvd-1 L3,4 library was screened by 
phage display panning on a testosterone-coated surface. Several different panning 
procedures were used with varying preincubation, washing, and elution conditions. 
Generally, washes were adjusted according to the number of output colonies, and a 
combination of acid and testosterone was used for elution. The quality of the phage 
genomes carrying the mutated cDNA was evaluated by DNA sequencing. Addition-
ally, phage clones were evaluated by microplate analysis using BSA-testosterone as 
a target ligand and using anti-M13 antibody to determine the amount of bound 
phage. The sbAvd-1 variant that showed the highest binding activity in the mi-
croplate assay had the sequence A35, T36, V37, N38 and was selected for further 
analyses in addition to several other clones (Table 8). 
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Table 8. Sequencing results from one round of sbAvd-1 L3,4 panning with testos-
terone (unpublished data). SbAvd-1 mutants captured from this panning 
experiment carrying the sequences V35Y36D37Y38, V35N36P37V38, 
V35V36T37H38, and L35L36R37G38 were produced and analyzed by micro-
plate analysis. These mutants are marked in bold in the table. 
Panning round Sample Elution T35 A36 V37 T38 
1 1 TES Y P T R 
1 2 TES V F T P 
1 3 TES N T L A 
1 4 TES I Y T V 
1 5 TES A S T R 
1 6 TES I R C Y 
1 7 TES P F S L 
1 8 TES R N V H 
3 1 TES N L I C 
3 2 TES L P C F 
3 3 TES C L P N 
3 4 TES T L L D 
3 5 TES F F H A 
3 6 TES V I I Y 
3 7 TES L T C T 
3 8 TES F I T T 
3 9 TES V I I L 
3 10 TES S Y W L 
3 11 TES R F N A 
3 12 TES I G D A 
3 13 TES G G V R 
3 14 TES S N S L 
4 1 TES V Y D Y 
4 2 TES V I S H 
4 3 TES T P D P 
4 4 TES F N P C 
4 5 TES C R A R 
4 6 TES V N P V 
4 1 DHEAS V V G R 
4 2 DHEAS H F L C 
4 3 DHEAS G D G D 
4 4 DHEAS V V T H 
4 5 DHEAS C D R L 
4 6 DHEAS L L R G 
4 7 DHEAS D C H I 
4 8 DHEAS S Y Y V 
4 9 DHEAS L R P H 
  TES = testosterone, DHEAS = dehydroepiandrosterone sulfate 
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4.3.2 Characteristics of steroid-binding avidins 
Proteins captured from the phage display selections were produced in soluble te-
trameric form (Table 9.) in the E. coli strain BL21-AI an using N-terminal OmpA 
bacterial secretion signal from Bordetella avium (Hytönen et al. 2004). Proteins 
were purified by Ni-NTA affinity chromatography, which yielded ~2 mg/L of pure 
protein. The produced proteins were screened using microplate assays, and the most 
promising candidates (sbAvd-1, sbAvd-2) were subjected to further analyses.  
Table 9. Properties of steroid-binding avidins as analyzed by gel-filtration, SPR, 
DLS, and MRFS. 
Protein Gel-filtration 
(kDa) 
Ligand SPR 
ka 
(1/Ms) 
 
kd 
(1/s) 
 
KD 
(µM) 
DSC
Tm 
(˚C) 
 
∆Tm 
(˚C) 
MRFS 
binding 
events 
-    85.5   
BNT n.d. n.d. n.d. 123.2 37.7  
wtAvd 53a 
TES no binding 86.2 0.7   
-    80.6  183 
BTN 420000 0.0006 0.0014 83.2 2.6  
sbAvd-1 51 
TES 1000 0.0095 9.0 81.5 0.9 67 
-    82.5  215 
BTN 1000 0.0007 0.7 83.0 0.5  
sbAvd-2 53 
TES 813 0.0085 11 83.1 0.6 21 
aResult from (Hytönen et al. 2004). 
 
Based on the differential scanning calorimetric (DSC) assays, the high thermal sta-
bility of wt avidin (temperature transition midpoint (Tm) = 85.5 °C) was preserved in 
the steroid-binding mutants; these proteins showed Tm values similar to that of wt 
avidin (sbAvd-1 Tm value of 80.6 °C and sbAvd-2 Tm value of 82.5 °C, Table 9). 
Molecular recognition force spectroscopy (MRFS) (Hinterdorfer, Dufrene 2006) 
was used to study the interaction between sbAvds and testosterone on the single-
molecule level. In these experiments, tip-tethered testosterone was found to form a 
complex with the sbAvds, and the most frequent unbinding force (Baumgartner, 
Hinterdorfer & Schindler 2000) was found to be similar for both of the testosterone-
sbAvd complexes: 40 pN at a constant pulling velocity of 600 nm/s. From 1,000 re-
corded force-distance cycles, sbAvd-1 showed 183 detected interactions, and 
sbAvd-2 showed 215 events (Table 9). Additionally, when the binding sites of the 
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proteins were preloaded with free testosterone, the number of binding events 
dropped to 67 from 183 in the case of sbAvd-1. In the case of sbAvd-2, the number 
of interactions dropped from 215 to 21 after the addition of free testosterone. These 
results indicate the specificity of the testosterone binding. 
The kinetic constants of testosterone and biotin binding to the steroid-binding 
proteins were determined using surface plasmon resonance (SPR). Purified sbAvd-1 
and sbAvd-2 bound to a testosterone-BSA-coated sensor chip with comparable af-
finities (Table 9), whereas wt avidin showed no binding to the testosterone-coated 
surface. Furthermore, testosterone binding was inhibited by varying testosterone 
concentrations (0.75-50 µM). In the case of sbAvd-1, 50% inhibition was achieved 
between 5 and 10 µM testosterone, which is consistent with the determined testos-
terone-coated surface-binding affinity. Interestingly, the sbAvd-2 measurements 
suggested a considerably higher binding affinity for free testosterone than that 
measured for surface-immobilized testosterone because 50% inhibition was already 
achieved at a testosterone concentration of 750 nM. 
Biotin binding by the steroid-binding proteins was analyzed using a biotin-coated 
sensor chip. A comparison of sbAvd-1 and sbAvd-2 revealed that the biotin-binding 
affinity decreased almost 500-fold due to the modification of the loop between β-
strands 3 and 4.  
The binding specificity of the proteins was analyzed by microplate assays, in 
which a set of different small molecules (progesterone, PRO; hydrocortisone, HYD; 
testosterone, TES; cholic acid, CHO) were used as target molecules (Figure 15). Wt 
avidin on a biotin-coated surface was used as a positive control along with sbAvd 
proteins on a BSA-conjugated testosterone-coated surface (TES-B). The negative 
controls PBS, BSA, and HSA did not show any response. sbAvd-1 and sbAvd-2 
showed clear binding to testosterone and progesterone, and binding to the surface-
immobilized ligands was inhibited by preincubating the proteins with 10 µM D-
biotin (Figure 15 (+BTN)). Free biotin significantly inhibited the binding of sbAvd-
1 to steroids, indicating a notable affinity of the protein for biotin. However, in the 
case of sbAvd-2, the binding of testosterone and progesterone was not affected by 
biotin, showing a clear decrease in biotin-binding affinity.  
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Figure 15. Determination of ligand-binding specificity of sbAvd-1 and sbAvd-2 proteins 
by microplate analysis.  The binding of wt avidin (blue bars), sbAvd-1 (red bars), 
and sbAvd-2 (green bars) to a set of different small ligands was detected using 
polyclonal anti-avidin antibody as a probe (A). Also the effect of free biotin (10 
µM) to ligand-binding was analyzed (B). Abbreviations used in the figure: PBS, 
Phosphate buffered saline; HSA, human serum albumin; PRO, HSA-conjugated 
progesterone; HYD, HSA-conjugated hydrocortisone; TES, HSA-conjugated tes-
tosterone; CHO, HSA-conjugated cholic acid; TES-B, BSA-conjugated testoster-
one; BTN, BSA-conjugated D-biotin; BSA, bovine serum albumin 
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The specificity of steroid binding was also analyzed using SPR by competing bi-
otin with the following steroids: testosterone, dehydroepiandrosterone sulfate 
(DHEAS), androstenedione, estradiol, and dihydrotestosterone (DHT). As expected, 
sbAvd-1 and sbAvd-2 behaved differently in the experiment. sbAvd-1 was found to 
be cross-reactive with androgens highly similar to testosterone (DHEAS and andros-
tenedione) and had a detectable affinity for biotin. Interestingly, DHT showed less 
efficient inhibition than testosterone, suggesting a lower binding affinity for sbAvd-
1 for this steroid. The binding of sbAvd-2 to testosterone was found to be most effi-
ciently inhibited by testosterone and DHEAS (Figure 16), whereas the inhibition 
caused by biotin was clearly weaker than in the case of sbAvd-1. This result is con-
sistent with the microplate analysis results and with the binding kinetic constants 
determined using SPR.  
 
 
Figure 16. Inhibition analysis of sbAvd-1 and sbAvd-2 proteins analyzed by the SPR 
method.  The binding of the sbAvd-1 and the sbAvd-2 to a CM5 sensor chip 
functionalized with testosterone-BSA was measured in the presence of 50 µM 
inhibitors. (A) The binding of the sbAvd-1 protein was totally inhibited by DHEAS, 
androstenedione, and biotin. (B) The binding of the sbAvd-2 protein was totally 
inhibited by DHEAS or testosterone, but not with biotin. This indicates markedly 
decreased affinity of the sbAvd-2 protein towards biotin. Samples: Protein sam-
ple, green; protein with estradiol, dark blue; protein with DHT, olive; protein with 
testosterone, black; protein with DHEAS, blue; protein with androstenedione, 
brown; protein with biotin, red 
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4.4 Binding of azo-ligands to avidin and AVR4 (I) 
Aside from biotin, avidin also binds dyes and peptides that share no significant 
structural similarity to biotin (Green 1975, Green 1970). The binding of HABA-
derived azo dyes to avidin and AVR4 was studied using DSC, UV/visible spectros-
copy, and molecular modeling. For this purpose a set of 15 azo dye compounds (Ta-
ble 10) were synthesized and characterized.  
Table 10. Functional groups of the synthesized azo compounds.  
 
 
Compound -COO- position R1 R2 
1b meta H H 
1c para H H 
2b meta H NO2 
2c para H NO2 
4a ortho CH3 CH3 
4b meta CH3 CH3 
4c para CH3 CH3 
5a ortho H OH 
5b meta H OH 
5c para H OH 
6b meta OH CH3 
6c para OH CH3 
p=para, m=meta, o=ortho 
 
Compound -COO- position 
3a ortho 
3b meta 
3c para 
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By DSC, HABA and five other azo dyes were found to significantly increase the 
stability of avidin (∆Tm<10˚C). In the case of AVR4, the stabilization effect was not 
as strong as for avidin. However, for both proteins, the highest stabilization effect 
was provided by the 1-naphthol derivative compound 3a (∆Tm=15.9˚C for avidin, 
∆Tm=7.0˚C for AVR4).  
According to UV/visible spectroscopy measurements, the addition of avidin or 
AVR4 caused spectral changes. After the addition of avidin, the largest spectral 
changes were detected for compounds 3a, 3c, 4a, and 5a. However, in the case of 
AVR4, the spectra of compounds 1c, 3a, 4a, 5a, and 5c were the most significantly 
changed among the compounds measured. 
4.5 Generation and analysis of bioactive films (III) 
The functionalization of cellulose acetate (CA) films was performed in two steps 
(Figure 17). Bioactivity was generated on the films by immobilization of avidin pro-
teins (chimeric avidin, chicken avidin, rhizavidin, streptavidin) onto the CA films. 
 
Figure 17. A schematic representation of functionalization and protein immobilization 
on the cellulose acetate surface.  
The specific biotin-binding capacity of the films was determined by comparing 
the total biotin-binding capacity with the results obtained after blocking the surfaces 
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with D-biotin before the [3H]-biotin assay. Importantly, no significant differences 
were observed in the binding capacities of control films (R1-R3) (Figure 18).  
For the chimeric avidin-coated films, the binding capacity was analyzed monthly 
throughout the three-month study period (Figure 18). At first, both non-
functionalized film (A1) and glutaraldehyde-activated film (A3) bound approxi-
mately the same amount of [3H]-biotin, indicating that the same amount of chimeric 
avidin was immobilized onto both films. The amino-functionalized film (A2) was 
found to have approximately 50% less immobilized chimeric avidin compared to the 
A1 and A3 films. The A3 film was found to be the most stable; covalently bound 
avidin remained fully active throughout the study in both storage conditions tested.   
   
 
 
Figure 18. The specific biotin-binding capacity of the CA films measured with [3H]-
biotin assay. The control films (R1=non-functionalized film, R2=amino-
functionalized film, R3=glutaraldehyde activated film) contained no avidin and as 
expected showed no biotin-binding activity. In the study the most stable film was 
glutaraldehyde activated CA films with chimeric avidin coating (A3). (The an-
mino-functionalized film with chimeric avidin coating (A2) stored at +4°C for 3 
months was not analyzed.) 
In the analysis of the films coated with chicken avidin, streptavidin and rhizavi-
din, the films coated with chicken avidin showed similar, high biotin-binding ca-
pacities to those detected in the case of chimeric avidin. Surprisingly, films coated 
with streptavidin and rhizavidin had low biotin-binding capacities.  
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5. DISCUSSION 
5.1 The structure of avidin provides a promising scaf-
fold for protein engineering 
Chicken avidin has been widely used in life science research applications (Laitinen 
et al. 2007). Avidin provides an attractive and robust scaffold for the development 
of novel receptors because avidin has many properties required of a novel affinity 
scaffold, such as high chemical and thermal stability, and an oligomeric nature ena-
bling signal amplification. The ligand-binding site of avidin resembles the CDRs of 
antibodies and is optimized for the binding of small molecules. Additionally, the 
structure of avidin is well characterized, and numerous engineered forms of avidin 
have been described (Laitinen et al. 2006).  
To expand our knowledge of the avidin structure and ligand binding, the high-
resolution crystal structure of avidin was solved in the first part of this study (I). The 
new structure revealed interesting details about the loop between beta-strands 3 and 
4, as in the previously determined structure of avidin (Livnah et al. 1993a), the loop 
is not visible. The loop between beta-strands 3 and 4 of wt avidin has high mobility, 
whereas in the other protein structure studied (AVR4), the flexibility of the loop is 
constrained by a salt bridge (Eisenberg-Domovich et al. 2005). For that reason, the 
mouth of the binding-pocket of AVR4 is wider than that of avidin. In this study, the 
spectral properties of azo compounds were studied by UV/visible spectroscopy in 
the absence and presence of the avidin and AVR4 proteins. Avidin is known to sig-
nificantly affect the absorption spectrum of HABA (Green 1965) because HABA 
forms conformational tautomers called hydrazone tautomers when bound to avidin 
(Livnah et al. 1993a). From the performed experiments, it can be concluded that av-
idin and AVR4 have different binding strategies; avidin prefers ortho derivatives for 
binding, whereas AVR4 prefers para derivatives of azo compounds. 
69 
5.1.1 Structural modification of avidin: dcAVD/AVR4  
A good example of the complicated genetic engineering possible with the robust 
structure of avidin is dual-chain avidin (dcAVD) (Nordlund et al. 2004, Hytonen et 
al. 2005b). DcAVD is generated avidin form, in which the two pairs of the binding 
sites can be independently manipulated. Also forms in which all four binding sites 
(single-chain avidin) can be independently manipulated, have been created (Nord-
lund et al. 2005). However, the PCR amplification of the dcAVD-encoding se-
quence has been challenging because primers recognize complementary sequences 
from both subunits, which would produce several different PCR products. This same 
issue also limits targeted mutagenesis of dcAVD.  
In the second part of the study (II), the usability of dcAVD was improved by cre-
ating chimeric dual-chain avidin consisting of fusions of wt avidin to streptavidin, 
AVR2 or AVR4. The chimeric tandem fusion of circularly permutated wt avidin and 
circularly permuted AVR4 showed enhanced protein expression and thermal stabil-
ity when compared to the original dcAVD. Additionally, the PCR amplification was 
more straightforward using the chimeric dual chain fusion gene. Interestingly, the 
binding analyses of dcAVD/AVR4 protein showed that the molecule exhibited het-
erogenous biotin-binding, and it was concluded that the exchange of the cp65-
subunit of dcAVD with a circularly permuted AVR4 subunit lowered biotin-binding 
affinity of the AVR4-derived cp65-subunit.  
DcAVD molecules offer a valuable base for development of bi-functional avidin 
tools for various applications such as bioseparation. This kind of study also provides 
novel information of the unfolding mechanisms of avidin proteins. 
5.1.2 Steroid-binding avidin prefers steroids to biotin as ligands 
Changing the binding properties of a high-affinity molecule without altering the 
structure is a challenging task. The natural ligand of avidin, biotin, is a water-
soluble vitamin that is composed of a ureido ring fused with a tetrahydrothiophene 
ring (Figure 19). A valeric acid substituent is attached to one of the carbon atoms of 
the tetrahydrothiophene ring. Testosterone is a steroid hormone derived from cho-
lesterol (Figure 19). Steroid hormones are hydrophobic molecules containing only a 
few functional groups. Therefore, the ligand-binding site for a steroid-binding mole-
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cule should be a deep hydrophobic cavity, where shape complementary is generated 
through aromatic side chains with appropriately placed hydrogen bond donors and 
acceptors (Schlehuber, Skerra 2005). 
 
Figure 19. The structure of D-biotin and testosterone. 
Although steroid hormones are, in many ways, highly problematic small molecules, 
several antibodies have been generated to recognize them with high affinity. The 
majority of commercially available immunodiagnostic kits for steroid hormones are 
based on polyclonal rabbit antibodies because of the lack of appropriate monoclonal 
antibodies (Hemminki 1998). Wilson et al. studied the binding of progesterone by 
the DB3 anti-progesterone antibody (Arevalo et al. 1993). This antibody has a na-
nomolar affinity for progesterone. However, it is also highly cross-reactive with 
progesterone-like steroids. Testosterone is recognized by the anti-testosterone anti-
body 3-C4F5 with subnanomolar affinity, and its cross-reactivity was decreased by 
stepwise optimization of the CDRs (Hemminki et al. 1998a, Hemminki et al. 
1998b). Antibodies that bind the hydrophilic steroid digoxigenin, frequently used in 
diagnostic applications, have been generated, and recently, a bispecific antibody 
with digoxigenin specificity has been introduced (Metz et al. 2011). Digoxigenin 
can be coupled to low molecular weight compounds such as fluorophores, chelating 
agents, nucleic acids, lipids, nanoparticles, and proteins (Kessler 1991). 
As an alternative to antibodies, molecules recognizing digoxigenin have been 
generated from the lipocalin fold (Figure 20) (Schlehuber, Beste & Skerra 2000a). 
Lipocalins have beta-barrel structures similar to avidin, and these proteins belong to 
the same calycin superfamily (Flower 1996). Therefore, it was likely that a steroid-
binding avidin variant could be engineered.  
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Figure 20. Comparison of the anti-digoxigenin antibody with the engineered lipocalin 
DigA16. (A) The structure of DigA16 with ligand. The hypervariable loop seg-
ments are colored yellow and the three aromatic side-chains of Tyr39, Tyr88, 
and Trp129 are shown in pink. (B) Fv fragment of the antibody in complex with 
digoxin (violet, at the centre; only one digitoxose sugar attached to C-3 is visible 
and colored gray). The VL and VH domains are colored green and violet, respec-
tively, while the CDRs are depicted in corresponding lighter colors. Figure is re-
printed from Korndorfer, Schlehuber & Skerra (2003) with permission from El-
sevier. 
In the present study (VI), the loop regions of avidin were subjected to targeted ran-
dom mutagenesis to change avidin into a steroid-binding molecule. At first, five res-
idues in the loop between β-strands 1 and 2 of avidin were totally randomized to 
generate a population of diverse avidin genes. From the phage display selections 
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(Smith 1985) the enrichment of avidin variants binding to testosterone was observed 
and an avidin mutant (sbAvd-1) that carried the sequence N12, R13, M14, N15, 
H16, was further analyzed and found to bind free testosterone with a micromolar 
affinity. However, the biotin-binding affinity of the protein was still high enough to 
inhibit sbAvd-1 from binding to testosterone-BSA.  
To decrease biotin binding and to improve steroid specificity sbAvd-1 was fur-
ther engineered. From the phage display selections, an sbAvd-1-derived protein, 
named sbAvd-2, with a mutated loop between β-strands 3 and 4 was captured. This 
mutant showed similar or slightly decreased binding affinity for immobilized testos-
terone, whereas the biotin-binding affinity was clearly decreased. We also noticed 
that sbAvd-2 bound more tightly to free testosterone than did sbAvd-1. In many 
cases, the determined affinities for immobilized ligands are lower than those deter-
mined for free ligands because of the different conditions used in the binding assays 
and due to ligand accessibility to the binding site. Significantly, sbAvd-2 was found 
to prefer steroids as a ligand to biotin, and the thermostability of the avidin was pre-
served in the developed molecules.  
However, there are still factors that may limit the use of the developed molecule, 
for instance, in diagnostic applications. Cross-reactivity of the molecules with ster-
oids other than testosterone would be highly problematic because the number of 
closely related steroid structures in serum samples is high. In addition, the micromo-
lar affinity of steroid-binding avidins would be too low for diagnostic applications. 
The in vivo concentrations of testosterone are low, down to the picomolar range. 
Additionally, the steroid-binding proteins were rather insoluble and were prone to 
aggregation, which would limit the large-scale production of these proteins. If the 
developed affinity proteins were used for therapeutic use, the problem of potential 
immunogenicity would be an issue to consider because the avidin protein is of for-
eign origin and will likely cause an immune response if no precaution is taken.  
5.2 Bioactive films  
In the third part of the study (III), a new method for the biofunctionalization of 
cellulose acetate films using a simple two-step protocol was developed. In the bio-
functionalization process, chimeric avidin was utilized for its stable structure in 
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harsh conditions and also for its efficient and scalable expression in E. coli. The de-
termined specific biotin-binding capacity of glutaraldehyde-functionalized films 
coated with chimeric avidin was 2.17 pmol/cm2. This value is clearly lower than that 
of a fully active avidin monolayer (6.6 pmol/cm2). If the obtained values are con-
verted to molecular density, there would be 0.33 biotin binding sites per surface area 
of an avidin tetramer. This suggests an average coverage of approximately 33% or 
less of the surface coated with functional chimeric avidins.  
 The developed material offers a valuable platform for the development of inex-
pensive in vitro diagnostics and also supports biosensing applications that are re-
quired to operate under demanding conditions. However, the advantages to the use 
of chimeric avidin instead of avidin should be carefully evaluated because there are 
already available diagnostic applications based on the avidin scaffold.  
5.3 Future directions 
5.3.1 Avidin gene libraries and selection strategies 
During construction of the gene libraries, two bottlenecks limited the library size: 1) 
the ligation of the insert into the digested phagemid vector and 2) the transforma-
tion. Traditional ligation was rather ineffective, and a considerable amount of DNA 
was required for successful ligation. Transformation was performed by electropora-
tion, which is a more powerful method than the heat-shock method. However, in 
this method, a limited amount of DNA can be added into the cells, thus limiting the 
size of the library. In the study, libraries up to 6×106 individuals were created, but 
increasing the efficiency of the ligation, for example with a Gateway-based cloning 
system, would result in larger libraries (Hiltunen S. et al., unpublished results).  
To be able to cover the entire sequence space and, at the same time, randomize 
several amino acids, a binary code or another variation-decreasing codon method 
(Table 4) should be used in the library design. A gene library with restricted diver-
sity provides knowledge about the capacity of different amino acid residues for me-
diating molecular recognition. As already mentioned in Section 2.1.1.1, the impor-
tance of serine, glycine and tyrosine in antigen recognition by antibodies has been 
discovered using binary code (Birtalan et al. 2008). 
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The phage display method was used as a selection system in study IV. At first, 
avidin was displayed on the phage surface. The successful display of avidin on the 
phage surface was expected because avidin can be efficiently expressed in a soluble 
form in E. coli (Hytönen et al. 2004), and the close relative of avidin, streptavidin, 
has been displayed on bacterial phages (Avrantinis et al. 2002; Sidhu, Weiss & 
Wells 2000). Two different avidin display modes were evaluated, in which the first 
developed mode produced only p3 fusions and the second produced both p3 fusions 
and avidin without phage protein. However, these methods did not include an amber 
stop codon-based system, which would enable production of the tetrameric protein 
and, thus, increase the display of avidin on the phage surface. Another challenge in 
the avidin phage display method was the culture medium, which contained biotin. 
Preliminary results show that the addition of free wt avidin in the phage amplifica-
tion step increases the amount of active phages. 
5.3.2 Steroid-binding avidins 
Engineered steroid-binding avidins (IV) could be used, for example, in biosepa-
ration applications, but as discussed in section 5.1.2, there are limiting factors for 
the use of the mutants in diagnostic applications. Encouragingly, however, the 
automated panning performed with multiple ligands conjugated to human serum al-
bumin (Antti Tullila, VTT Technical Research Center of Finland) showed success-
ful results (Hiltunen S. et al., unpublished data). These results suggest that it will be 
possible to further develop affinity molecules from the avidin scaffold.  
Finally, techniques developed in this study could be combined. The most suc-
cessful dcAVD-based molecule, dcAVD/AVR4, could be combined with other ge-
netically engineered avidins with modified or completely novel binding properties. 
By combining sbAvd with a dcAVD avidin platform, it would be possible to de-
velop avidin-based receptors with alternative binding affinities or with multiple 
ligand specificities to be used in in vitro diagnostics or in nanotechnology 
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6. SUMMARY AND CONCLUSION 
In this thesis, chicken avidin, a protein extensively utilized in the life science ap-
plications, was modified to produce novel molecules for avidin-biotin technology. 
First, the high-resolution 3D-structure of avidin was resolved, and binding to 15 azo 
molecules was analyzed. From the structure and ligand binding analysis of avidin 
and AVR4, the importance of the loop between β-strands 3 and 4 was observed. 
This loop was shown to seal the ligand-binding site in the closed conformation, thus 
acting as an important coordinator in ligand binding by avidin. 
Avidin was structurally modified by fusing circularly permuted avidin and circu-
larly permuted homologous protein in tandem to overcome the challenges associated 
with the original dual-chain avidin. The chimeric dual-chain avidin, a tandem fusion 
of avidin and avidin-related protein 4 (AVR4), showed increased protein production 
levels and increased thermal stability compared to the original dual-chain avidin. 
PCR amplification of the hybrid gene was also more efficient, thus enabling more 
convenient and straightforward modification of the dual-chain avidin. The generated 
dual-chain molecule offers a valuable base for developing bifunctional avidin tools. 
Additionally, this strategy could be helpful when generating hetero-oligomers from 
other oligomeric proteins with high structural similarity. 
The ligand-binding function of avidin was changed in this study; steroid binding-
avidin was created by combinatorial protein engineering techniques. The selection 
of a sequence-randomized avidin library led to the isolation of a steroid-binding av-
idin mutant (sbAvd-1) showing micromolar affinity for testosterone. Furthermore, 
the sbAvd-1 protein was further engineered to increase the specificity of the mole-
cule, and a steroid-binding protein with significantly decreased biotin-binding affin-
ity was obtained. Importantly, the properties that make avidin an attractive molecule 
for engineering, such as high thermal and chemical stability, were preserved in the 
engineered avidins. 
A novel and simple two-step protocol was developed for the biofunctionalization 
of cellulose acetate films. Highly thermostable chimeric avidin, which is a geneti-
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cally engineered version of the high-affinity biotin-binding protein avidin, was im-
mobilized on the films. The activity of the cellulose acetate with immobilized chi-
meric avidin was retained completely for three months, even when stored at room 
temperature. Avidin-coated cellulose acetate films could be used, for example, in 
the development of inexpensive and sensitive diagnostic tools to be used in person-
alized medicine platforms.  
In conclusion, this study presents the 3D -structure of avidin and analyses of the 
azo ligand-binding properties of the protein. Two different avidin modifications 
were performed; as a structural modification, a chimeric tandem fusion of dual-
chain avidin was created, and as functional modifications, steroid-binding avidins 
were obtained. Additionally, this study describes the development of biofunctional-
ized films that utilize the molecular recognition properties of the avidin molecule.  
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Summary
The chicken genome encodes several biotin-binding
proteins, including avidin and avidin-related protein
4 (AVR4). In addition to D-biotin, avidin binds an azo
dye compound, 4-hydroxyazobenzene-2-carboxylic
acid (HABA), but the HABA-binding properties of
AVR4 are not yet known. Differential scanning calo-
rimetry, UV/visible spectroscopy, and molecular mod-
eling were used to analyze the binding of 15 azo
molecules to avidin and AVR4. Significant differences
are seen in azo compound preferences for the two pro-
teins, emphasizing the importance of the loop between
strands b3 and b4 for azo ligand recognition; informa-
tion on these loops is provided by the high-resolution
(1.5 A˚) X-ray structure for avidin reported here. These
results may be valuable in designing improved tools
for avidin-based life science and nanobiotechnology
applications.
Introduction
Avidin, a basic glycoprotein from egg white, and strepta-
vidin, the bacterial relative of avidin, bind a small vitamin
molecule, D-biotin, with extremely high affinity (KD =
10213 to 10215 M) [1, 2]. The nature of the specific, strong
protein-ligand interaction has been extensively studied
in order to identify the structural determinants of the
high-affinity binding [3–5] and to engineer novel features
in the development of more sophisticated tools for
biotechnology applications [6–8]. Although the three-
*Correspondence: johnson4@abo.fi
4 Present address: Institute of Medical Technology, FI-33014 Uni-
versity of Tampere, Finland.
5 Present address: Department of Materials, ETH Zurich, CH-8093
Zu¨rich, Switzerland.
6 Present address: Department of Biological and Environmental
Science, P.O. Box 35, FI-40014 University of Jyva¨skyla¨, Finland.dimensional (3D) structures of both avidin and streptavi-
din in complex with D-biotin have been solved [9, 10],
understanding the details of the biotin-binding process
remains challenging [11].
Avidin belongs to a gene family that contains several
avidin-related genes (AVRs) [12, 13] whose biological
function is unknown. Previously, we produced AVRs in
recombinant forms in both E. coli [14] and insect cells
by utilizing a baculovirus expression system [15, 16].
AVRs possess fascinating properties: despite their
lower biotin-binding affinity compared with avidin [15,
16], some AVRs have higher thermal stability than avidin
[16, 17]. The 3D structures of AVR2 [17] and AVR4 [18]
have been solved to high resolution.
Avidin has a moderate level of affinity for a small mol-
ecule, an azo dye called HABA (4-hydroxyazobenzene-
2-carboxylic acid, also called 2-(40-hydroxybenzene)
azobenzoic acid; see the structure in Table 1) [19].
Avidin-HABA binding is accompanied by a change in
the spectral properties of the dye from yellow to red,
a property used to measure the number of biotin-
binding sites of avidin derivatives; the reaction is easily
reversed by D-biotin. The spectroscopic features of
HABA in avidin-based applications would obviate the
need for radioactive labels; however, because the disso-
ciation constant of the avidin-HABA interaction is only
6 3 1026 M [19], HABA derivatives with higher affinity
for avidin are needed for improved sensitivity. The 3D
structure of the avidin-HABA complex has been solved:
HABA binds to avidin as a hydrazone tautomer, planarity
is thus lost, and an intramolecular hydrogen bond is
formed [20]. Streptavidin also binds HABA as the hydra-
zone tautomer [21], although the affinity is lower (1 3
1024 M) than that of avidin [2]. The 3D structure of the
streptavidin-HABA complex has been solved [21].
Biotin binding to (strept)avidin leads to changes in the
conformation [9, 10], stability [22], and rigidity [23] of the
proteins. The most flexible part of avidin that interacts
with biotin is a loop located between b strands 3 and 4
(L3,4 loop). In the X-ray structure of apo-avidin, the
L3,4 loop is disordered [24]. The electron density maps
of the avidin-biotin complex structure are clearly inter-
pretable, and the L3,4 loop has a defined conformation
[10]. Similarly for streptavidin, the corresponding loop is
disordered in the absence of ligand [25]. Two states of
the L3,4 loop, ‘‘open’’ and ‘‘closed,’’ that are partially de-
termined by the properties of the bound ligand have been
observed in streptavidin [25]. In AVR4, the L3,4 loop
adopts nearly identical conformations with and without
bound biotin [18]. The L3,4 loop is disordered in the avi-
din-HABA structure [20], while the L3,4 loop adopts the
‘‘closed’’ conformation in structures of streptavidin
complexed with HABA and HABA derivatives [21, 26].
We have used various techniques to improve our
understanding of the binding process of azo com-
pounds to avidin and AVR4. We synthesized a set of
15 azo compounds (see Experimental Procedures and
Supplemental Data [available with this article online])
and studied their interactions with the biotin-binding
proteins by using differential scanning calorimetry
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ing. Moreover, to our knowledge, we present the first
high (1.48 A˚)-resolution X-ray structure of chicken avidin.
Results
High-Resolution Crystal Structure of Avidin
To our knowledge, we report the first high-resolution
X-ray structure of avidin at 1.48 A˚ resolution. The struc-
ture-determination statistics are in Table 2. The fold of
the two monomers in the asymmetric unit and tetrameric
assembly are nearly identical to the known avidin struc-
tures [20, 24, 27–31]: eight antiparallel b strands form
a classic b barrel, with one open end serving as the
biotin-binding site.
In contrast to other avidin structures, both the open
and closed conformations of the L3,4 loop are observed
in the electron density maps of this high-resolution
structure (Figure 1A). In the closed conformation, the
12 residue-long L3,4 loop seals the ligand-binding
pocket similarly to one of the avidin-biotin complexes
(PDB code 1AVD [31]). In the 1.48 A˚ resolution structure,
all residues within the L3,4 loop of the closed conforma-
tion could be traced in the electron density maps. The
open conformation of the L3,4 loop diverges from
the closed loop conformation at I34 and reunites with
the closed loop conformation at K45. V37–S41 of the
open loop conformation could not be traced through
the electron density map. Thus, T35–A36, at the start
of the L3,4 loop, and N42–K45, at the loop’s end, could
be built into the electron density of the open loop confor-
mation (Figure 2A).
Before data collection, an avidin crystal was soaked
with compound 3a. Despite the color change observed
Table 1. Functional Groups of the Synthesized Ligands
Compound -COO2 Position R1 R2
HABA ortho H H
1b meta H H
1c para H H
2b meta H NO2
2c para H NO2
4a ortho CH3 CH3
4b meta CH3 CH3
4c para CH3 CH3
5a ortho H OH
5b meta H OH
5c para H OH
6b meta OH CH3
6c para OH CH3
Compound -COO2 Position
3a ortho
3b meta
3c paraafter the soaking experiment, compound 3a was not ob-
served in the solved structure, but, instead, two glycerol
molecules are in the ligand-binding pocket. The lack of
detection of compound 3a in the binding pocket may
be explained by the low occupancy of the ligand in the
binding sites. Thus, the ligand might be ‘‘invisible’’ in
the crystal structure even though it might have bound
to some protein molecules in the soaking experiment.
DSC Analysis
The effect of the azo compounds on the stability of avi-
din and AVR4 was studied by using DSC (Table 3). Since
increases in protein thermal stability upon ligand bind-
ing depends on the binding affinity, we have calculated
the apparent binding constants at the temperature of
protein unfolding, Kb(Tm). Calculations are based on
the temperature of protein unfolding in the absence
and presence of ligand as well as on the change in
enthalpy and heat capacity upon unfolding of the protein
in the absence of ligand [32]. HABA, KD = 7 3 10
26 M at
pH 7 at room temperature [33], and 2,6-ANS, KD = 2 3
1024 M [34], which have moderate binding affinity for
chicken avidin, were used as the control ligands. We
also measured the stabilizing effect of the extreme affin-
ity ligand, D-biotin, for avidin (KDz 10
215 M) and AVR4
(KDz 10
214 M) [1, 16].
Of the 18 ligand molecules that were analyzed, bio-
tin produced the largest increase in avidin stability,
DTm = 34.5
C with Kb(Tm) (M
21) = 3.1 3 1011, and in
AVR4 increased stability DTm = 17.2
C with Kb(Tm)
Table 2. Structure Determination Statistics for Avidin
Data Collectiona
Wavelength (A˚) 0.804
Beamline X13
Detector CCD
Resolution (A˚) 20–1.48 (1.58–1.48)
Unique observations 41,811 (7320)
I/s 10.4 (2.9)
R factorb (%) 7.3 (47.0)
Completeness 99.3 (99.1)
Redundancy 4.0 (4.1)
Refinement
Space group P21212
Unit cell
a, b, c (A˚) 72.9, 78.8, 43.0
a, b, g () 90, 90, 90
Monomers per asymmetric unit 2
Resolution (A˚) 20–1.48
Rwork (%) 16.5
Rfree (%) 19.0
Protein atoms 2,066
Heterogen atoms 36
Solvent atoms 149
Rmsd
Bond lengths (A˚) 0.013
Bond angles () 1.5
Ramachandran plot
Residues in most favored regions 92.5%
Residues in additional
allowed regions
7.5%
The PDB code for avidin is 1VYO.
a The numbers in parentheses refer to the highest-resolution bin.
b Observed R factor was taken from XDS [38].
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Binding Mode of Some Azo Compounds
(A) The weighted 2Fo 2 Fc (blue) and Fo 2 Fc
(red) electron density maps of avidin show-
ing the branch site for the two alternative
L3,4 loops. The maps were calculated in
the absence of the amino acids of the L3,4
loop (residues 34–45) and are shown here
(a 2.2 A˚ radius around the atoms) along
with the residues Y33, I34, T35, and A36
of the final structure of avidin (PDB code
1VYO). Contours are shown at 1.0s and
3.0s for the 2Fo 2 Fc and Fo 2 Fc maps, re-
spectively. Carbon atoms of residues from
the ‘‘closed’’ (a) and ‘‘open’’ (b) conformation
of the L3,4 loop are colored yellow and blue,
respectively.
(B–E) The secondary structure of the protein
in question is shown as a gray coil. Amino
acids are represented as sticks; carbon
atoms are shown in gray, oxygen atoms are
shown in red, and nitrogen atoms are shown
in blue. Putative hydrogen bonds are shown
as dashed, yellow lines. (B) The suggested
binding mode of HABA (orange) and 3a
(cyan) to avidin with the open L3,4 loop con-
formation. HABA (with light-gray carbon
atoms) was also docked into the closed
loop conformation of avidin. (C) The sug-
gested binding mode of 2b (yellow) to avidin.
(D) The suggested binding mode of 3a (cyan)
to AVR4. (E) The suggested binding mode of
1c (orange), 2c (green), 4c (purple), and 6c
(pink) to AVR4. For details on the suggested
binding modes, see the main text.
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1032Figure 2. Two Conformations of the L3,4 Loop in Avidin, Structure-Based Sequence Alignment, and Comparison of the L3,4 Loop in Avidin and
AVR4
(A) The high-resolution crystal structure of avidin (PDB code 1VYO). The secondary structure is shown in gray, and the amino acids in the L3,4
loop (I34–E46) are shown as sticks. The closed L3,4 loop conformation is in gray, and the open conformation is in orange. The arrows indicate
the ends of the peptide chain in the open loop conformation.
(B) The structure-based sequence alignment of avidin (PDB code 1VYO), AVR4 (PDB code 1Y55), and streptavidin (PDB code 1SWE). The sec-
ondary structure elements of avidin are indicated, and the L3,4 loop of avidin, AVR4, and streptavidin is boxed. The key residues for azo com-
pound binding in avidin and AVR4 are in bold (and when conserved, they are also in bold for streptavidin). The shaded residues indicate the
most important differences (for details, see the text) between avidin and AVR4 sequences in the L3,4 loop. The alignment was performed with
Vertaa implemented in Bodil [51], and the picture was produced with Alscript [54].
(C) The L3,4 loop of avidin (PDB code 1VYO, green) and of AVR4 (PDB code 1Y55, yellow). The structures were superimposed with Vertaa in
Bodil [51]. Biotin, docked into the 1VYO structure with GOLD 2.2 [49], is shown in gray. Amino acids of the L3,4 loop, together with a conserved
arginine residue from b8, are labeled and shown as sticks.
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Protein: Avidin AVR4
Ligand Tm (
C) DTm (C) Kb(Tm)
a (M21) Tm (
C) DTm (C) Kb(Tm) (M
21)
— 82.5 — NDb 109.9 — NDb
HABA 92.8 10.3 2.9 3 105 110.9 1.0 3.2 3 103
1b 91.3 8.8 1.8 3 105 110.9 1.0 3.2 3 103
1c 86.3 3.8 2.0 3 104 114.9 5.0 4.2 3 104
2b 95.3 12.8 1.0 3 106 113.9 4.0 2.6 3 104
2c 87.1 4.6 2.6 3 104 115.6 5.7 5.8 3 104
3a 98.4 15.9 5.0 3 106 116.9 7.0 1.0 3 105
3b 91.5 9.0 1.8 3 105 111.1 1.2 4.0 3 103
3c 93.0 10.5 3.6 3 105 113.0 3.1 1.6 3 104
4a 95.6 13.1 1.2 3 106 113.6 3.7 2.2 3 104
4b 87.9 5.4 3.8 3 104 109.8 20.1 NDb
4c 84.3 1.8 5.4 3 103 114.9 5.0 4.2 3 104
5a 94.5 12.0 7.0 3 105 112.2 2.3 9.8 3 103
5b 90.4 7.9 1.1 3 105 112.1 2.2 9.2 3 103
5c 86.5 4.0 2.0 3 104 114.5 4.6 3.5 3 104
6b 86.5 4.0 2.1 3 104 111.5 1.6 5.9 3 103
6c 84.1 1.6 4.9 3 103 115.2 5.3 4.8 3 104
2,6-ANS 84.6 2.1 6.8 3 103 114.8 4.9 4.0 3 104
D-biotin 117.0c 34.5 3.1 3 1011 127.1 17.2 1.3 3 107
a The apparent binding constant (Kb) is calculated from data obtained at the Tm as described in Brandts et al. [32].
b Not determinable.
c From Hyto¨nen et al. [16].(M21) = 1.3 3 107. HABA significantly increased avidin
stability (DTm = 10.3
C, and Kb[Tm] [M
21] = 2.9 3 105),
as did the five other azo compounds (DTm > +10.0
C).
Three molecules are ortho-derivatives of HABA (3a, 4a,
and 5a), one is a meta-derivative (2b), and one is
a para-derivative (3c). Overall, the stabilizing effect of
the ortho-derivatives of HABA was largest: on average,
DTm = 12.8
C and Kb(Tm) (M
21) = 1.8 3 106. The meta-
derivatives showed somewhat poorer stabilization of
avidin (average DTm = 8.0
C; Kb[Tm] [M
21] = 2.5 3 105),
while the para-derivatives were the least effective in
terms of stabilizing the avidin complex (average DTm =
4.4C; Kb[Tm] [M
21] = 7.3 3 104). The control ligand,
2,6-ANS, stabilized avidin rather poorly, with DTm =
2.1C and Kb(Tm) (M
21) = 6.8 3 103.
In comparison to avidin, AVR4 showed somewhat dif-
ferent behavior in the presence of the azo compounds.
HABA was relatively inefficient in stabilizing AVR4
(DTm = 1.0
C and Kb[Tm] [M
21] = 3.2 3 103), as were
the other ortho-derivatives (average DTm = 3.5
C;
Kb[Tm] [M
21] = 3.43 104), in contrast to the para-deriva-
tives with, on average, aDTm of 4.8
C and Kb(Tm) (M
21) =
4.0 3 104. The meta-derivatives were the least effective
in stabilizing AVR4: with, on average, a DTm = 1.7
C
and Kb(Tm) (M
21) = 9.7 3 103. Interestingly, 2,6-ANS
stabilized AVR4 with a DTm = 4.9
C and Kb(Tm) (M
21) =
4.0 3 104, similar to the average values for the para-
derivatives.
Altogether, the DSC analyses suggest that avidin and
AVR4 do not have similar binding affinities for the azo
compounds. Avidin exhibits stronger binding for the
ortho-forms, whereas AVR4 binds the para-forms
more strongly. Furthermore, AVR4-2,6-ANS binding
appears to be stronger than that of avidin.
UV/Visible Spectroscopy
The spectral characteristics of the azo compounds in
aqueous solution were characterized by UV/visiblespectroscopy. Between 300 and 650 nm, two peaks
were found at 350.7 nm and 457.9 nm (average values)
in the absorption spectrum for most compounds. Avidin
is known to affect the absorption spectrum of HABA dra-
matically [33]. Consequently, we examined the spectral
properties of HABA derivatives in the presence of avidin
and AVR4. In general, changes in the absorbance spec-
trum reflect alterations in the physicochemical environ-
ment surrounding the ligand in the protein-bound form
as well as any changes in double bond conjugation
that result from binding. We mainly observed batho-
chromic shifts of the absorption maximum; however, in
some instances, hypsochromic shifts of the absorption
maximum were also observed. In the case of HABA,
there are two peaks, at 346 nm and 439 nm in the absor-
bance spectrum. These peaks are due to the two tauto-
meric conformations of HABA; upon binding avidin, the
conformation absorbing near 500 nm is favored. It has
been shown that HABA bound to avidin forms the hydra-
zone tautomer [20]. Thus, there are two simultaneous
changes that result from interactions with azo ligands:
(1) the accumulation of a specific ligand conformation,
which leads to absorption intensity differences between
peaks; and (2) spectral shifts that are the result of inter-
and intramolecular hydrogen bond formation and rear-
rangement of double bonds. Here, the spectral shifts
are most informative, since they provide information
on the relative strength of the avidin and AVR4 com-
plexes with the azo compounds. The measured absor-
bance peak maxima (Amax) are listed in Table 4.
Similarly to HABA, the presence of avidin caused the
longer-wavelength peak of the ortho-derivatives to
move toward longer wavelengths (the average DAmax =
34 nm). This increase in the maximum absorption wave-
length probably results from the formation of an intra-
molecular hydrogen bond in the ortho-derivatives of
the azo compounds [33]. Such radical changes were
not seen in the absorbance spectra of the meta- and
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spectively). Compounds 3a, 3c, 4a, and 5a with avidin
result in the largest spectral changes, suggesting that
the compounds have high affinity for avidin, while com-
pounds 1c, 3b, and 5c led to moderate spectral
changes. Compounds 1b, 4b, 4c, and 5b with avidin pro-
duced only negligible changes in the spectra. The spec-
troscopic data for compounds 2b and 2c is unclear, and
the affinity of these compounds for avidin cannot be
inferred from the data.
Like avidin, the presence of AVR4 induced similar
spectral changes in the maximum peak found at longer
wavelengths for the ortho-compounds (averageDAmax =
31.3 nm). For the meta-forms, AVR4 induced a slight de-
crease in Amax at longer wavelengths (average DAmax =
25.5 nm), while the Amax of the para-forms increased
by 14.5 nm in the presence of AVR4. According to the
spectroscopic studies, compounds 1c, 3a, 4a, 5a, and
5c seem to produce the most significant spectral
changes, which is indicative of high affinity for AVR4,
while HABA and compound 3b lead to moderate spec-
tral changes; compounds 1b, 2c, 3c, 4b, 4c, 5b, 6b,
and 6c produced only negligible changes to spectra in
the presence of AVR4, suggesting that AVR4 has a low
binding affinity for each compound.
In this analysis, the most interesting difference be-
tween avidin and AVR4 was found with compounds 1c
and 5c (Figure 3). In the presence of avidin, the spectral
changes of these compounds were negligible. The pres-
ence of AVR4, however, introduced a single peak cen-
tered at 393 nm in the case of 1c (Figure 3A) and at
479 nm in the case of 5c (Figure 3B). The induction of
a single peak upon protein-ligand interaction suggests
that a single tautomer of both 1c and 5c binds to AVR4
with higher affinity than for the corresponding avidin
complexes. Based on the available data, however, we
Table 4. Spectral Analysis of the Azo Molecules in the Absence
and Presence of Avidin and AVR4
+Avidin +AVR4
Ligand Amax(1)
a Amax(2) Amax(1) Amax(2) Amax(1) Amax(2)
HABA 346 439 343 496 339 494
1b 348 431 343 432 332 413
1c 354 438 357 441 393 NDb
2b 371 419 364 431 351 422
2c 378 430 389 456 382 452
3a 325 493 329 522 335 518
3b 324 482 331c 499 330d 488
3c 327 481 340 511 357 519
4a 350 477 323 500 325 497
4b 354 444 349 444 343 447
4c 360 456 360 457 358 469
5a 360 474 NDe 501 NDe 499
5b 359 454 375 442 363 453
5c 367 461 362 470 NDb 479
6b 343 472 340 477 318 446
6c 347 474 347 474 343 470
a The measured spectra of the azo molecules was analyzed by fitting
two Gaussian peaks to the data, and the absorption maxima (in nm)
were determined from the fitted curves.
b Only one peak was observed in the spectrum.
c A new peak with Amax at 405 nm also appeared.
d A new peak with Amax at 411 nm also appeared.
e The lower-wavelength peak was negligible.are not able to determine which tautomer of 1c and 5c
is in question. Heavy computational calculations or
high-resolution crystal structures would be needed to
answer that question. With 3b, a unique peak with an
Amax of w410 nm appeared with both avidin and
AVR4. This peak emerges at a wavelength between the
shorter (w300 nm)- and the longer (w500 nm)-wave-
length peaks seen for 3b and the other azo compounds.
This is an interesting observation requiring further study.
Overall, compared with avidin, AVR4 induced larger
changes in the spectra of the para-derivatives of the
azo compounds (average DAmax = 11.5 nm for avidin
and 14.5 nm for AVR4).
Ligand Docking Studies
All 15 azo compounds that were synthesized (Table 1),
as well as HABA and 2,6-ANS, were docked into 3 differ-
ent structures: the avidin structure (PDB code 1VYO) in
both the closed and open conformations and the AVR4
structure (PDB code 1Y55). The sequences of avidin
and AVR4 are 77% identical [18], and the major differ-
ences that could affect ligand binding are located along
the L3,4 loop (residues 35–46). The sequence alignment
between avidin and AVR4 is shown in Figure 2B. The
L3,4 loop in avidin and AVR4 is 12 amino acids long,
but there are several large differences in the properties
of residues forming the loop in each protein: a salt
bridge is formed in AVR4 between D39 (A39 in avidin)
Figure 3. UV/Visible Spectra of 1c and 5c
(A) The UV/visible spectra of 4-hydroxyazobenzene-4-carboxylic
acid (1c; black) with avidin (gray) and AVR4 (containing the muta-
tion C122S; red).
(B) The UV/visible spectra of 30,4-dihydroxyazobenzene-4-carbox-
ylic acid (5c; black) in the presence of avidin (gray) and AVR4
(C122S; red).
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residue at position 41 is S41 in avidin.
Altogether, the experimental studies identified five
azo compounds with affinities for avidin that are similar
to (3c) or larger (2b, 3a, 4a, and 5a) than the affinity of
HABA for avidin. According to the docking studies, the
benzoate group of the three best ortho-compounds,
3a, 4a, and 5a, would form interactions identical to those
observed in the avidin-HABA complex structure [20]. An
oxygen atom in the benzoate group of 3a, 4a, and 5a is
positioned so that it could hydrogen bond with S16
and T35 (unless specified otherwise, interactions are
with the side chain of the indicated residue), while a sec-
ond oxygen atom would form up to three hydrogen
bonds with N12, S16, and Y33 (Figure 1B). In addition,
the benzoate ring would interact with F79, W97, and
W110 from the adjoining monomer. The docking studies
indicate that the additional phenyl ring of 3a fully oc-
cupies a pocket formed by W70, F72, S73, S75, and
L99. Similarly, one of the methyl groups found in 4a
and the additional hydroxyl group of 5a are also docked
into this pocket (the hydroxyl group hydrogen bonding
with S73), but the methyl and the hydroxyl groups on
their own are not bulky enough to fill the pocket.
Compound 2b is a meta-derivative of HABA and has
an additional NO2 group. As docked, themeta-carboxyl-
ate group would be buried deeper within the binding
pocket of avidin compared to the ortho-derivative.
According to the docking results, it appears likely that
there is a hydrogen bond between one of the carboxyl-
ate oxygens of the ligand and S16, as well as two hydro-
gen bonds between the other carboxylate oxygen and
N12 and Y33 (Figure 1C). Upon avidin binding, the NO2
group of 2b is most likely accommodated at a solvent-
accessible site next to S75, S101, and R114, where the
NO2 group would be positioned to form hydrogen bonds
with R114.
The para-compound 3c has a similar affinity to avidin
as HABA. The interactions of 3c, at the bottom of the
ligand-binding pocket, include possible hydrogen
bonds with N12 and N118 and hydrophobic interactions
with F79, W97, and W110 from the adjoining monomer.
3c is longer than the ortho-compound 3a; as a conse-
quence, 3c would extend further out of the binding
pocket.
Experimental results show that 2,6-ANS binds to
AVR4 with a significantly higher affinity than to avidin,
in good agreement with our docking studies that
showed that 2,6-ANS fits nicely into the binding pocket
of AVR4 and that the phenyl ring of 2,6-ANS would stack
with W68 and F70. In addition, the interaction of the SO3
group of 2,6-ANS with AVR4 appears more favorable
than with avidin: the SO3 group could hydrogen bond
to N12, S16, Y33, and N116 of AVR4. When docked to
avidin, the phenyl ring of 2,6-ANS would clash with res-
idues of the L3,4 loop, especially with T40.
Interestingly, the experimental studies indicate that all
but two of the HABA derivatives (1b and 4b) have affini-
ties for AVR4 that are higher than the affinity of HABA for
AVR4. The docking studies indicate that regardless of
the closed conformation of the L3,4 loop of AVR4, the
azo compound with the highest affinity for AVR4 (and
for avidin), 3a, can fit into the binding pocket of AVR4.
The naphthalene group of 3a is capable of forming p-pstacking interactions with W68. In addition, a hydrogen
bond could form between S71 (Figure 1D) and the hy-
droxyl group of 3a. Interactions with the benzoate group
of 3a in the docked complexes are identical to those
observed for the avidin-HABA complex [20].
The para-derivatives of HABA, 1c, 2c, 4c, 5c, and 6c,
have very similar affinity for AVR4, and according to the
docking studies, the binding mode of these compounds
to AVR4 is also similar to each other. The benzoate group
of thepara-compounds is positioned where it could form
hydrogen bonds with N12 and N116, at the bottom of the
ligand-binding pocket of AVR4 (Figure 1E), as well as hy-
drophobic interactions with Y33, F77, W95, and W108
from the adjacent monomer. In addition, the phenolic
part of the compounds is nicely docked between the hy-
drophobic side chains of A38, W68, F70, and L97, and
a hydrogen bond can be positioned to link the phenolic
hydroxyl group and the hydroxyl group of S71. The
para-compound with the highest affinity for AVR4, 2c,
has an NO2 group attached to the phenol ring. The dock-
ing studies show that this polar group could hydrogen
bond with S73 and R112 (Figure 1E). The additional hy-
droxyl group of 6c seems capable of hydrogen bonding
with D39 and S73, while the additional methyl group is
docked between the side chains of W68 and F70. Com-
pounds 1c and 4c show equal affinity for AVR4. 1c
more closely resembles HABA in that no additional
groups are attached to the phenol ring, whereas 4c has
two additional methyl groups on the ring. One of the
methyl groups is docked between the side chains of
W68 and F70, and the other methyl group is accommo-
dated within a region formed by D39, S73, L97, and R112.
Discussion
In egg white, biotin binding is virtually irreversible and is
needed to protect the growing embryo from infection by
microbes. For applications in biotechnology, however,
such irreversible binding is not always useful. While
there is no need, and it is probably not even possible,
to design any ligands with affinity better than that of
D-biotin, research has focused on finding compounds
with high, but reversible, affinity for avidin. The organic
dye compound HABA (4-hydroxyazobenzene-2-carbox-
ylic acid), with moderate affinity for avidin, is a good
starting point for the design of novel avidin-binding
compounds. Due to the spectroscopic features of
HABA and its derivatives, their use in avidin-based
applications would be safer than assays employing
radioactive labels.
The formation of the complex between HABA and
avidin is accompanied with a change in the spectral
properties of HABA [33]. In the original paper, Green
also reported that a meta-derivative of HABA bound to
the avidin biotin-binding site, although the spectral
changes were less dramatic. Similar spectral changes
were observed for the complex of HABA and streptavi-
din, but the affinity of HABA for streptavidin (KD =
100 3 1026 M) is less than for avidin (KD = 6 3 10
26 M)
[19, 33]. Green has also reported the specific binding
of other similar dye compounds to the biotin-binding
site of avidin [33]. Much later, Weber et al. [26] success-
fully developed derivatives of HABA that show higher
affinity toward streptavidin.
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activity, meaning that avidin is capable of enhancing the
hydrolysis of biotinyl ester derivatives, whereas strepta-
vidin efficiently protects the same derivatives from
hydrolysis [27]. This and other studies on the pseudoca-
talytic activity of avidin and streptavidin demonstrate the
importance of the L3,4 loop as a molecular regulator in
constraining the binding of biotin and biotin derivatives
and in converting the protein into a pseudoenzyme [18,
35]. Comparisons of the crystal structures of streptavidin
have shown that the L3,4 loop can adopt two structural
states depending on the bound ligand [25]. In the case
of avidin, the corresponding loop is disordered in the
apo form [24], but biotin binding stabilizes the conforma-
tion of the loop and ‘‘locks’’ it into the closed state [10].
According to the experimental studies presented
here, the ortho-derivatives of HABA bind better to avi-
din, whereas the para-derivatives bind better to AVR4.
The avidin and AVR4 sequences are very similar
throughout the secondary structure elements, except
for the L3,4 loop (Figure 2B). Based on the docking stud-
ies, we suggest that the ortho-derivatives of HABA bind
avidin with a conformation of the L3,4 loop that is more
open. The results previously reported by Ellison et al.
[36] also support this hypothesis. They have shown
that HABA increases the affinity of proteinase K for
avidin, and that, as a result, the L3,4 loop of avidin is
cleaved. Furthermore, in the crystal structure of the
avidin-HABA complex the L3,4 loop is not visible [20],
suggesting that it is mobile. According to the docking
results, if the benzoate group of HABA is docked into
the closed loop conformation of avidin, it is not able to
maintain hydrogen-bonding interactions with residues
(N12, S16, T35, and Y33) along the ‘‘bottom’’ of the bind-
ing pocket (Figure 1B). Taken together, the current ex-
perimental data and docking studies support a model
for HABA binding to avidin in which HABA increases
the mobility of the L3,4 loop.
In the AVR4 structure, the conformation and flexibility
of the L3,4 loop is constrained by the salt bridge formed
between the side chains of D39 and R112 [18]. In con-
trast, the L3,4 loop of avidin is not constrained by
a salt bridge, resulting in more conformational flexibility.
Consequently, the ortho-compounds cannot be accom-
modated within the AVR4-binding pocket as well as in
avidin. Due to the proline residue (P41) in the L3,4 loop
of AVR4, the loop also becomes somewhat ‘‘shorter’’
than the L3,4 loop in avidin. As a result, the mouth of
the binding pocket of AVR4 is wider than in the avidin
structure (Figure 2C). Since the para-derivatives of
HABA are more elongated than the ortho- and meta-
derivatives, they extend further out from the binding
pocket. In avidin, the para-derivatives collide with T40,
but, in AVR4, there is sufficient space to accommodate
the longer para-derivatives (Figure 2C). These docking
studies are in good agreement with our DSC studies,
which show that AVR4 binds the the para-compounds
more strongly, while avidin has stronger binding affinity
for the ortho-compounds.
The exception from the previous pattern is naphthyl-
HABA, compound 3a, which, according to the DSC stud-
ies, has the highest affinity for both avidin and AVR4.
According to the docking studies, avidin would bind
this ortho-compound with the open conformation of theL3,4 loop, in contrast to AVR4 with the added salt bridge
that suggests binding might involve the closed loop
conformation. The crystal structure of the streptavidin
complex and compound 3a shows that 3a is bound
to a closed loop conformation [26]. It seems that the
shorter length of the L3,4 loop of streptavidin (Figure 2B)
is the reason it adopts the closed loop conformation. Al-
though the L3,4 loop of AVR4 also appears to be some-
what shorter than that of avidin (due to a kink in the loop
introduced by P41), there are other features of the loop
contributing to the mode of ligand binding. First of all,
the salt bridge between the L3,4 loop and the b8 strand
holds the loop tightly in its position. Second, in the L3,4
loop of AVR4, the methyl group of A38 would form a
hydrophobic interaction with the two-ring system of
compound 3a. The corresponding residue in avidin is
threonine (T38), which, due to its larger volume and polar
hydroxyl group, hinders the binding of compound 3a to
the closed L3,4 loop conformation of avidin.
Significance
The avidin family of biotin-binding proteins is widely
exploited in biotechnological applications and, more
recently, in nanobiotechnology. There are obvious ad-
vantages to using a high-affinity ligand that alters its
spectral characteristics when bound to an avidin pro-
tein, allowing one to measure spectrophotometrically
the degree of successful complexation that has oc-
curred. The organic azo dye, HABA (4-hydroxyazoben-
zene-2-carboxylic acid), does undergo such spectral
changes when the avidin-HABA complex is formed,
but the binding affinity of avidin for HABA is much
less than the extremely tight binding that occurs with
biotin. Thus, in order for a HABA-type molecule to be
of use, the affinity must be substantially improved or
another avidin-like molecule with tighter binding for
a HABA compound should be identified. Here, we syn-
thesized 15 derivatives of HABA, and we analyzed their
binding characteristics with avidin and with a related
protein, AVR4, by using DSC and UV/visible spectros-
copy. We show that a number of these derivatives do
have higher affinity for avidin, but that some com-
pounds prefer to bind to AVR4. To our knowledge,
we have solved the first high-resolution 1.5 A˚ structure
of avidin that reveals novel structural details about the
L3,4 loop, a loop that appears to be a major determi-
nant defining the binding preferences of avidin and
AVR4 for the HABA compounds. Molecular modeling
was used to help position the compounds within the
ligand-binding sites in the 3D structures of avidin and
AVR4. These studies reveal the molecular basis for dif-
ferences in ligand binding and provide firm details that
can be used to determine how to proceed with the pro-
tein structure-based approach used to modify azo
compounds to achieve higher affinity and selectivity
for avidin or AVR4.
Experimental Procedures
Chemicals
2-aminobenzoic acid, 2-nitrophenol, and 1,2-dihydroxybenzene
were purchased from Fluka (Buchs, Switzerland), and 4-aminoben-
zoic acid, 2,6-dimethylphenol, and 1-napthol were purchased from
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purchased from Aldrich Chemical Company. 2-anilinonaphthalene-
6-sulfonic acid (2,6-ANS) was from Invitrogen. D-biotin was
purchased from Sigma, and chicken avidin was a generous gift
from Belovo S.A., Bastogne, Belgium.
Synthesis and Characterization of Azo Molecules
HABA derivatives (for a table of the molecular structures, see Table 1)
were synthesized by coupling diazotized aminobenzoic acid to
the phenol and naphthol derivatives [26]. Ice-cooled aqueous
NaNO2 (7.3 mmol) was slowly poured into a stirred solution of
ortho-/meta-/para-aminobenzoate (7.3 mmol) in hydrochloric acid
(18%) while the temperature was kept below 5C. The mixture con-
taining the diazonium salt was cautiously poured into an ice-cooled
aqueous solution of the phenol/naphthol derivatives (14.0 mmol)
and NaOH (16.8 mmol). The reaction mixture was stirred at 5C for
1 hr and neutralized with hydrochloric acid/sodium acetate. The
resulting precipitates were collected, washed with water, and dried
in vacuo. The product was recrystallized from the ethanol-water
mixture and dried.
In the synthesis of 1,2-dihydroxyazobenzene carboxylic acid,
1,2,3-dihydroxyazobenzene carboxylic acid, and 1,2-dihydroxy-3-
methylazobenzene carboxylic acid, the reactions were slightly dif-
ferent because the hydroxyl groups were protected by aluminium
sulfate. Ice-cooled aqueous NaNO2 (25 mmol) was poured into
a stirred solution of ortho-/meta-/para-aminobenzoate (25 mmol)
in hydrochloric acid (4.5%) while the temperature was kept below
5C. 1,2-dihydroxybenzene/1,2,3-dihydroxybenzene/1,2-dihydroxy-
3-methylbenzene (25 mmol) was diluted with aqueous Al2(SO4)3 (14
mmol), and the diazonium salt solution was poured cautiously into
this ice-cooled solution. The reaction mixture was stirred at 5C
for 40 min, and 25 ml CH3COONa (20%) was added to the reaction
mixture. The solution was acidified by adding 10 ml concentrated
HCl, and the resulting reddish precipitates were collected, washed
with water, and dried in vacuo. The products were recrystallized
from an ethanol-water mixture and dried in vacuo.
The final products were confirmed by 1H-NMR (Bruker Avance
DPX 250 FT), 13C-NMR (Bruker Avance DPX 500), and by MS. The
1H-NMR spectra were recorded at 250 MHz, and 13C spectra were
recorded at 500 MHz in d-DMSO at 30C. The detailed list of synthe-
sized compounds with confirmed compound characteristics is in
Supplemental Data.
Differential Scanning Calorimetry Analysis
The thermodynamics of the denaturation process of avidin isolated
from chicken (Belovo S.A., Bastogne, Belgium) and the AVR4 protein
produced in E. coli [14, 37], in the presence of different ligands (3:1
molar ratio), were studied by using a Nano II differential scanning
calorimeter (Calorimetric Science Corporation, Provo, UT) as previ-
ously described [7]. AVR4 carried a mutation, C122S, that prevents
intermolecular disulfide bridge formation without affecting either li-
gand binding or thermostability [16]. Sodium phosphate buffer
(50 mM, pH 7.0) containing 100 mM NaCl was used in the measure-
ments. Thermograms were analyzed with Origin 6.0 software. The
apparent binding constant at the temperature of protein unfolding
Kb(Tm) was calculated as described in Brandts et al. [32] by using
the following equation:
KbðTmÞ = ½exp½2DHðT0Þ=Rð1=Tm2 1=T0Þ
+DCp=RðlnTm=T0 +T0=Tm2 1Þ2 1=½LTm; ð1Þ
where DH(T0) is the change in enthalpy upon unfolding in the ab-
sence of ligand, R is the gas constant, Tm is the unfolding tempera-
ture in the presence of ligand, T0 is the unfolding temperature in the
absence of ligand, DCp is the change in heat capacity upon unfold-
ing, and [L]Tm is the free ligand concentration at Tm. It is assumed
that the unfolding process is a two-state transition and that the
ligands bind only to the low-temperature, native conformation. In
the calculation of the binding constants, we used the respective
values for avidin and AVR4: DH(T0), 329 kJ/mol and 460 kJ/mol;
DCp, 15.3 kJ/(K mol) and 9.1 kJ/(K mol) [16]. The value of DCp used
for AVR4 originates from measurements performed on AVR4 protein
produced in insect cells and not in bacteria. Even a significant devi-
ation in the value of DCp would, however, only have a very smallimpact on the calculated Kb(Tm)s. Such a deviation would not affect
the relative binding affinities for one protein and several different
ligands.
UV/Visible Spectroscopy
The optical properties of the synthesized azo compounds were
characterized with a PerkinElmer UV/visible spectrometer. Spectra
were obtained for samples in 50 mM Na-phosphate buffer (pH 7.0)
containing 100 mM NaCl. The azo compounds were diluted to a final
concentration of 20 mM, and the spectrum for each compound was
measured at wavelengths between 300 and 650 nm. Furthermore,
the spectrum of each of the azo compounds (20 mM) in the presence
of 1 mg/ml chicken avidin (Belovo S.A., Bastogne, Belgium) or AVR4
(produced inE. coli [14]) was measured. The spectrum for each com-
pound was analyzed by using multipeak analysis (Microcal Origin
7.0), fitting two Gaussian peaks to the data.
Crystal Structure Determination
The recombinant chicken avidin protein used for structure determi-
nation with X-ray crystallography was produced in E. coli, purified,
and crystallized as previously described [14]. Briefly, bar-like crys-
tals were obtained at +22C by using the hanging drop vapor diffu-
sion method. Equal volumes (1 ml) of protein (0.5 mg/ml) in 50 mM
Na acetate (pH 4) + 20 mM NaCl and well solution of 0.1 M MES
(pH 6.6) + 24% PEG 8000 + 0.2 M Mg acetate were employed. Before
data collection, a crystal was soaked with compound 3a (1 mM in
drop) for several hours at +22C. Glycerol (23% v/v) was added to
the crystallization drop to serve as a cryoprotectant just prior to flash
freezing in a 100 K nitrogen stream.
Diffraction data were collected at 100 K at the synchrotron beam-
line X13 (EMBL-Hamburg) from a single crystal. The data were in-
dexed, integrated, and scaled with the program package XDS [38].
The structure was solved with the molecular replacement technique
and by applying programs from the CCP4i Suite [39]. An existing
2.7 A˚ avidin structure (PDB code 1AVD [31]) was used as a trial
model in molecular replacement, which was carried out with the pro-
gram AMoRe [40]. The X-ray structure was refined with Refmac5 [41]
by using TLS [42] and was modified and rebuilt with the program O
[43]. Solvent atoms were added to the model with the automatic pro-
cedure of ARP/wARP [44], whereas sulfate ions and glycerol mole-
cules were added manually in O. The final model was analyzed
with the programs PROCHECK [45] and WHATIF [46].
Docking Studies
The 3D structures of 2,6-ANS and the azo compounds (Table 1), in-
cluding two different tautomers for each azo compound, were built
and energy minimized in Sybyl (Tripos, St. Louis, MO). The Conju-
gate Gradient minimization method was used along with the
MMFF94s force field and MMFF94 charges [47, 48]. The termination
gradient was set to 0.05 kcal/mol, and the calculations were iterated
until convergence was reached. The program GOLD 2.2 [49] was
used for docking experiments, and all ligands, including both tauto-
mers of the azo compounds, were docked. The standard default set-
tings of GOLD were used, and the active site radius was set to 15 A˚
centered on the Hz atom of F79 of the avidin structure (PDB code
1VYO) and F81 of the AVR4 structure (PDB code 1Y55) [18]. The
docking studies were performed based on the assumption that avi-
din binds the azo compounds in a manner similar to what has been
observed for the avidin-HABA complex [20, 50]. In the docking stud-
ies, two distance constraints were used; otherwise, the program
GOLD would not have managed to dock the azo compounds into
the assumed conformation. The distance constraints were defined
so that one of the carboxylate oxygens of the azo compounds was
forced to be in the vicinity of the Hg atom of S16 and the Hh atom
of Y33 (both in avidin and AVR4). The range of separation was
from 1.5 A˚ to 3.5 A˚, with a spring constant of 5.0.
Visualization
The Bodil modeling environment [51] was used for the visualization
of the crystal structures as well as for the visualization of the docking
results. Figures were produced with PyMOL version 0.99 [52], and
labels were added by Gimp 2.2.
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Supplemental Data include additional Experimental Procedures,
which contain data on the isolation and characterization of the syn-
thesized azo compounds, and are available at http://www.chembiol.
com/cgi/content/full/13/10/1029/DC1/.
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Abstract
Background: Avidin is a chicken egg-white protein with high affinity to vitamin H, also known as D-biotin. Many
applications in life science research are based on this strong interaction. Avidin is a homotetrameric protein, which
promotes its modification to symmetrical entities. Dual-chain avidin, a genetically engineered avidin form, has two circularly
permuted chicken avidin monomers that are tandem-fused into one polypeptide chain. This form of avidin enables
independent modification of the two domains, including the two biotin-binding pockets; however, decreased yields in
protein production, compared to wt avidin, and complicated genetic manipulation of two highly similar DNA sequences in
the tandem gene have limited the use of dual-chain avidin in biotechnological applications.
Principal Findings: To overcome challenges associated with the original dual-chain avidin, we developed chimeric dual-
chain avidin, which is a tandem fusion of avidin and avidin-related protein 4 (AVR4), another member of the chicken avidin
gene family. We observed an increase in protein production and better thermal stability, compared with the original dual-
chain avidin. Additionally, PCR amplification of the hybrid gene was more efficient, thus enabling more convenient and
straightforward modification of the dual-chain avidin. When studied closer, the generated chimeric dual-chain avidin
showed biphasic biotin dissociation.
Significance: The improved dual-chain avidin introduced here increases its potential for future applications. This molecule
offers a valuable base for developing bi-functional avidin tools for bioseparation, carrier proteins, and nanoscale adapters.
Additionally, this strategy could be helpful when generating hetero-oligomers from other oligomeric proteins with high
structural similarity.
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Introduction
Improving the performance and accuracy of molecular tools
used in life science research is essential for developing better and
more precise methods. Chicken avidin (AVD) and its bacterial
analogue streptavidin (SA) from Streptomyces avidinii, collectively
called (strept)avidin, are proteins widely used in life science
research applications. (Strept)avidin has been used for quantitative
measurements by radioligand-binding methods [1], enzyme assays
[2,3] and photometric/fluorometric methods [4–6]. AVD has also
been successfully used in biosensors as an immobilization platform
[7]. The specific characteristics of AVD, such as the high positive
charge (pI 10.5) and high biotin-binding affinity (Kd<10215 M),
have resulted in a number of different drug-targeting applications
that use the (strept)avidin-biotin interaction [8].
Although widely used, (strept)avidin’s homotetrameric struc-
ture restricts its use in some applications. To overcome this
limitation, dual-chain avidin (dcAVD) was generated [9] by
fusing two circularly permuted chicken avidin monomers into one
polypeptide chain. This molecular engineering approach pro-
duced a protein that resembles wt avidin in 3-D structure [10]
but allows independent manipulation of ligand-binding sites
within a single protein particle. To create dual-affinity deriva-
tives, dcAVD was modified by site-directed mutagenesis. This
form of dcAVD exhibited a tight biotin affinity for two binding
sites, whereas the other two binding sites had reduced affinity due
to the mutations [11]. Recently, a point mutation S16C was
targeted into one of the biotin-binding sites of dcAVD [12].
The introduction of a chemically active thiol group into the
binding site made it possible to selectively control the biotin-
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20535
binding activity of the dcAVD domains by a mild chemical
treatment.
Despite recent improvements, some challenges that could limit
the use of dcAVD persist. For instance, PCR amplification of the
dcAVD-encoding sequence has been challenging because primers
recognize complementary sequences from both subunits, which
would produce several different PCR products. This same issue
also limits targeted mutagenesis of dcAVD. This study uses a new
approach for developing the dcAVDs. Instead of constructing a
tandem gene by combining two differently circularly permuted
chicken avidins [9] or streptavidins [13], two related avidin genes
were used as building blocks for the chimeric tandem fusion. The
raw materials of the chimeras were selected from a group of
homologous proteins. Streptavidin (SA), the most widely used
protein in biotechnological applications in the avidin family, and
avidin-related proteins 2 and 4 (AVR2 and AVR4) [14,15] were
selected as fusion partners for the circularly permuted chicken
avidin. By combining homologous genes into the chimeric tandem
gene, we were able to address the problems associated with the
original dcAVD. According to our knowledge, this is the first study
showing such forced hybridization of different types of biotin-
binding proteins into an oligomeric assembly.
Results and Discussion
The chimeric dcAVD fusions were designed according to
previously described principles [9]. The loop connecting the
original termini of the circularly permuted SA, AVR4, and
AVR2 was shortened when compared to the original dcAVD,
as presented in Figure 1. This shortening was performed
because the loop was largely invisible in the X-ray analysis of
dcAVD, indicating high mobility of the loop region [10].
Figure 1. The homology model of dcAVD/AVR4 and the sequences of chimeric dcAVDs. The molecular model of dcAVD/AVR4 is
generated by exploiting the existing 3-D structures of the dcAVD and AVR4. In the model, cpAVD is illustrated in light gray, and cpAVR4 is illustrated
in dark gray. Amino acid sequence of cpAVD is in the light gray box, and the amino acid sequences of cpAVR2, cpAVR4, and cpSA are in the dark gray
boxes. The linkers and the corresponding linker sequences connecting the original termini are shown in red. The linkers connecting the circularly
permuted subunits and the corresponding linker sequences are shown in blue. The schematic representation of the protein expression cassette is in
the bottom of the figure.
doi:10.1371/journal.pone.0020535.g001
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Chimeric dcAVD genes performed well in PCR
Two conditions were used to evaluate performance of the
dcAVD forms in PCR amplification. When primers recognizing
the sequence that flank the tandem fusion gene were used, the
amplification resulted in no notable differences between dcAVD
and chimeric fusions. Amplification of the four dual-chain genes
produced appropriately sized (,1000 bp) PCR products; however,
a shorter product (700 bp) was clearly observed, except for
dcAVD/SA (not shown). The short product could be a result of
the amplification of a self-hybridized tandem gene. No clear
differences were observed for reactions using the different thermal
cycling parameters.
In contrast, when primers recognizing regions inside the tandem
fusion gene were used, a clear difference in the behavior between
dcAVD and the chimeric fusions was detected (Figure 2A). A
number of side products were generated during the PCR
amplification of the dcAVD gene, which was probably due to
primers binding to multiple positions in the tandem gene and
homologous recombination during the amplification process. In
contrast, for the chimeric fusions, only two main PCR products
were detected, which were the appropriately sized products. The
dcAVD/SA showed the most efficient amplification. Using the
chimeric fusion genes significantly improves PCR amplification
and would allow targeting of mutagenesis to only a part of the
gene, such as using the Quik-Change (Stratagene, La Jolla, CA,
US) protocol. Moreover, this would enable the broader modifica-
tion of dcAVD molecules, including targeted random mutagenesis
of several amino acids.
The chimeric fusion dcAVD/AVR4 can be efficiently
expressed in E. coli
All proteins selected as chimeric fusion partners resemble avidin
in their fold and 3-D structure [16–18]. Therefore, we assumed that
chimeric dual-chain avidins could be produced where one circularly
permuted subunit would be based on the avidin sequence, and the
other subunit would be based on another biotin-binding protein
(AVR2, AVR4, SA). The chimeric dual-chain fusions were
produced in E. coli using the periplasmic signal peptide from the
Bordetella avium ompA protein [19]. The chimeric fusion dcAVD/
AVR4 produced the best levels of the proteins analyzed, and the
protein was almost entirely intact (,35 kDa) after 2-iminobiotin
affinity chromatography (Figure 2B). To further study the usability
of this chimeric protein, a pilot-scale expression of the dcAVD/
AVR4 protein was performed in a 7.5 L fermentor. The pilot-scale
fed-batch fermentation in standard LB medium yielded greater than
5 mg of pure dcAVD/AVR4 protein per liter of production
medium with low amounts of protein fragments (Figure S1).
When dcAVD/AVR2 and dcAVD/SA proteins were produced,
there was a significant amount of fragmented (,15 kDa) products
in the SDS-PAGE analysis (Figure 2B). The low-sequence identity
of SA with avidin (only ,30%, AVR’s identity with avidin ,80%
[20]) may explain the modest performance during the production of
the chimeric dual-chain fusion with SA. Because some full-length
protein was detected in the SDS-PAGE analysis of dcAVD/SA
(Figure 2B), it might be possible to genetically tune this AVD/SA-
hybrid to enhance its performance. The possible targets for such
optimizations are discussed later in the text.
Figure 2. The performance of the chimeric dual-chain avidins in the PCR analysis and in E. coli expression. The usability of the
generated chimeric dual chain avidin fusions was evaluated by amplifying the fusion genes by PCR and by expressing the proteins in E. coli. A) In the
PCR analysis with primers recognizing regions inside the chimeric dcAVD genes (PCR 2), a clear difference between the behavior of the dcAVD genes
(A) and the chimeric fusion genes (AA2, dcAVD/AVR2; AA4, dcAVD/AVR4; SA, dcAVD/SA) was detected. The chimeric fusion genes showed only two
main PCR products; the appropriately sized product had the highest concentration. When the dcAVD gene was used as a template, several different-
sized products were produced. The results from the PCR2 reaction (see Table S1) from two different conditions (I, II) are shown in the figure. (L, 1 kb
DNA ladder). B) SDS-PAGE analysis of the purified chimeric dcAVDs showed that dcAVD/AVR4 was the most successfully expressed in its functional
form in E. coli. The upper arrowhead indicates the location of the intact protein, and the lower arrowhead indicates the location of the proteolytically
cleaved product. (M, molecular weight standard; AA2, dc-AVD-AVR2; AA4, dc-AVD-AVR4; AS, dc-AVD-SA, bA, chicken avidin control sample (protein
expressed in E. coli [19]); cA, chicken avidin control sample).
doi:10.1371/journal.pone.0020535.g002
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Size-exclusion chromatography was used to determine the
oligomeric state of the produced proteins. The analysis revealed
that the dcAVD/AVR4 protein was mostly in a pseudo-tetrameric
form (Figure S2). Some higher molecular weight species were also
detected, which could be explained by the oligomerization of
pseudo-tetramers often detected in wt avidin samples [19]. Size-
exclusion chromatography analysis of dcAVD/AVR2 revealed a
significant proportion of clearly higher molecular weight species
than dcAVD/AVR4. Interestingly, both dcAVD/SA and
dcAVD/AVR2 appeared mostly in a pseudo-tetrameric form in
gel-filtration analysis (results not shown). This result may indicate
that the truncated protein forms observed in the SDS-PAGE
analysis (Figure 2B) might be able to form oligomeric species,
resulting in homotetrameric proteins. In any case, further studies
are needed to better understand the properties of dcAVD/AVR2
and dcAVD/SA. In this study, dcAVD/AVR4 protein was
selected to further biochemical analyses.
Differences in the subunit interfaces reveal possible
reasons for the characteristics of chimeric dual-chain
avidins
To analyze the possible reasons for the behavioral differences of
the chimeric dual-chain avidins, the fusion proteins were modeled
based on previously determined 3-D structures of dcAVD (PDB
2C4I), SA (PDB 1MK5), and AVRs (AVR2 (PDB 1WBI), AVR4
(PDB 1Y53)). The model of dcAVD/AVR4 is presented in
Figure 1. Molecular dynamics (MD) were performed for the
predicted chimeric dual-chain avidin models. The simulations
were performed in explicit water using the CHARMM force field.
The interaction energy during the MD simulation was measured
between subunits, which is the most obvious region in the structure
that would cause problems in the dcAVD assembly. In the MD
simulation analyses, dcAVD/SA had clearly the least favorable
electrostatic interaction energy (Figure 3A), whereas there were no
significant differences in the van der Waals energies between
chimeric dcAVD forms (Figure 3B). A closer inspection of the MD
simulation data of dcAVD/SA revealed three putative electro-
statically repulsive interactions (Figures 3C and 3D). These
residues (D247-E15-D241, K12-R239 and D27-E165) are poten-
tial targets for further engineering of dcAVD/SA to improve its
characteristics.
To investigate how the chimeric dcAVD forms differ in terms of
loop dynamics in MD simulations, we analyzed a root mean
square fluctuation (RMSF), measuring main chain motion for a
10 ps time window (Figure 4). The analysis revealed that the
linkers connecting the original termini of the domains (Figure 1,
red linkers) were highly mobile, particularly in the avidin domain
(GGSGGS, residues 70–75 connecting the original termini). We
also detected regions behaving differently between the chimeric
dcAVD forms; for dcAVD/SA, there were unique mobile regions
in the loop between the strands b7 and b8 (residues 164–169) and
in the loop between the strands b4 and b5 (residues 243–249) that
corresponded to the potential electrostatic repulsion (Figure 3C
and 3D). Overall, however, no dramatic differences were observed
in the loop mobility between different dcAVD forms, suggesting
that there were no significant problems in the molecular design of
the chimeric dcAVDs.
The chimeric dcAVD/AVR4 showed an increase in
thermal stability when compared to dcAVD
A thermal stability assessment of the dcAVD/AVR4 by SDS-
PAGE revealed a significant improvement when compared to that
of dcAVD. The determined transition temperature of subunit
dissociation (Tr) was 25uC higher for dcAVD/AVR4 (Table 1).
The presence of D-biotin in the binding site stabilized the
dcAVD/AVR4 quaternary structure, and the determined transi-
tion temperature of oligomeric disassembly (Tr) increased from
65uC to 85uC; however, when compared to dcAVD, the increase
in transition temperature due to ligand binding was less (Table 1).
Differential scanning calorimetry (DSC) was used to analyse the
thermodynamics of the heat-induced unfolding. In a DSC analysis
of dcAVD/AVR4, a two-phase melting profile was observed both
with and without biotin (Figure 5B). This melting profile was not
detected in the dcAVD samples, in which the heat induced
unfolding resulted in a single peak in the thermogram (Figure 5A).
The thermograms recorded with dcAVD/AVR4 samples were
deconvoluted in order to separate the two peaks (Figure 5C &
Figure 5D). The main peak in the dcAVD/AVR4 thermogram
revealed a melting point (Tm) at 91.3uC (Figure 5C), which is
about 11uC higher compared to that measured for dcAVD
(80.2uC). The smaller secondary peak showed a melting point at
86.3uC. In the presence of biotin, the main peak showed a melting
point at 112.3uC, and a secondary peak at 107.8uC (Figure 5D).
Interestingly, in the presence of biotin, dcAVD/AVR4 was
denatured at a lower temperature compared to the melting
temperature (115.9uC) of dcAVD. Overall, dcAVD/AVR4 had
improved thermal stability in the absence of biotin, but the
addition of biotin did not produce as significant thermal
stabilization as in the case of dcAVD or wt AVD. Therefore,
the exchange of the cp65-subunit of dcAVD with a circularly
permuted AVR4 subunit increased the thermal stability of the
chimeric fusion protein, while the other domain of the tandem
gene remained unchanged (AVD-derived cp54). The lower biotin-
binding affinity of the introduced AVR4-derived subunit reflected
the thermal stability of the whole fusion protein in the presence of
biotin. These results are clear indications of structural coopera-
tivity between the subunits of the tetramer during thermal
unfolding; however, previous studies have shown that (strept)avi-
din has relatively little or no structural cooperativity between
subunits [21–23]. One reason for the apparently low cooperativity
has been attributed to the subunit exchange between partially
unfolded proteins [24]. For dcAVD, the covalent attachment of
the subunits might block or at least significantly reduce the subunit
exchange in the thermal unfolding process. Therefore, the dual
chain concept allows a novel type of approach in studies
elucidating the unfolding mechanisms of avidin proteins. The
unfolding process was irreversible, which is typical for avidin
proteins.
The biotin-binding properties of dcAVD/AVR4 differed
from those of the parental proteins
Fluorescently labeled biotin and surface plasmon resonance
(SPR) biosensor were used to study the biotin-binding character-
istics of dcAVD/AVR4. In the experiment with fluorescently
labeled biotin a bi-phasic ligand-dissociation process was detected,
where roughly 50% of the protein subunits released biotin with
rapid (kdiss = 1.1610
23 s21) dissociation kinetics (Figure 6). It is
probable that the rapid biotin-dissociation phase was associated
with the AVR4-derived cp65 domain. As we have previously
shown, the biotin-binding affinity of the circularly permuted avidin
cp65 is slightly less than wt AVD. In contrast, the cp54 version
appears to behave more like wt AVD in terms of biotin-binding
[9]. The previous studies have shown that the AVR4 protein has a
slightly lower biotin-binding affinity (Kd = 3.6610
214 M) than
avidin (Kd = 1.1610
216 M) [25]; however, the measured increase
in the biotin dissociation rate of dcAVD/AVR4 was higher than
expected based on previous studies, possibly reflecting the
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cooperativity between different parts of the biotin-binding site
[26,27].
In the SPR analysis using the Biacore X instrument, the
biotin derivative 2–iminobiotin was coupled to the sensor chip
using amino-coupling chemistry. For the dcAVD/AVR4, we
measured an apparent equilibrium dissociation constant of
9.661026 M, which is greater than the constant measured for
the parental proteins (wtAVD Kd = 1.2610
27 M, AVR4(C112S)
Kd = 7.2610
27 M). The binding of dcAVD strongly resembled
the wtAVD that was analyzed in the SPR assay in our preceding
study [9].
The results from the fluorescent biotin interaction and the SPR
analyses were consistent with each other; however, for the SPR
measurements, the 2-iminobiotin ligand was attached onto the
surface, and therefore, the interaction between the immobilized
ligand and free protein was measured. For the measurements using
the fluorescently labeled biotin, the ligand moved freely in
solution. Therefore, SPR analysis could overestimate the binding
affinity of chimeric dcAVDs because the protein might preferably
bind the immobilized ligand with the subunit that has the greater
binding affinity.
The biotin-binding properties of dcAVD/AVR4 and those
measured for dcAVDs carrying point mutations in the biotin-
binding site [11] suggested that the modification of the loop
connecting beta strands 5 and 6 in the C-terminal domain of dual-
chain avidin had negative effects on biotin-binding. In both
studies, the dissociation rate constant for the C-terminal domain
(cp 65, see Figure 1) was decreased more than expected, based on
Figure 3. Interactions between the subunit interfaces of chimeric dcAVD fusions by MD simulation. The electrostatic interaction energy
was measured between the circularly permuted subunits in chimeric dcAVDs (A). The analysis was performed for both subunit pairs independently,
and the interaction energy is plotted over the 4-ns MD simulation. The van der Waals energy between subunits was measured during the simulation
time (B). The potential sources of electrostatic repulsion for dcAVD/SA were examined by visual inspection of the MD simulation data. Three clusters
of residues (D247-E15-D241, K12-R239 and D27-E165) potentially causing electrostatic repulsion between cpAVD and cpSA were detected. These
residues are shown in a liquorice representation (C, D). The figures were prepared using the program PyMOL (www.pymol.org) and numbered
according to Figure 1. All the calculations were performed with 5-ps resolution.
doi:10.1371/journal.pone.0020535.g003
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the sequence of the domain. Therefore, it would be logical to
engineer the C-terminal domain of the dcAVD for novel
characteristics while preserving the wt AVD-like characteristics
of the N-terminal domain (cp54). This would exploit the
existing biotinylated molecular tools maximally in dcAVD-based
applications.
Conclusions
Dual-chain avidin is an example of the complicated genetic
engineering possible with the robust structure of avidin [9]. In the
current study, the usability of dcAVD was improved by creating
chimeric dual-chain avidin proteins. As a fusion partner with wt
AVD, we used three different proteins from the avidin protein
family: streptavidin, AVR2 and AVR4. The most successful was a
chimeric tandem fusion of circularly permutated wt AVD and
circularly permuted AVR4. Enhanced protein expression and
thermal stability resulted when compared to the original dcAVD.
Also, the PCR amplification was more straightforward when
using chimeric dual chain fusion. Closer analyses of dcAVD/
AVR4 protein showed that the molecule exhibited heterogenous
biotin-binding. This might be advantageous in applications where
two different biotin-binding affinities are needed. To further this
technique, the dcAVD/AVR4 format can be combined with
other genetically engineered avidins with modified or completely
Figure 4. Local dynamics in the chimeric dcAVD fusions measured by MD simulation. To probe the local structural dynamics, the root
mean square fluctuation (RMSF) per residue was measured for a short time window (10 ps) for the last 3 ns of the 4-ns MD simulation. The resulting
values were averaged and plotted in graphs A–C (A: dcAVD/AVR2; B: dcAVD/AVR4; C: dcAVD/SA). The dynamics of the structure are illustrated by
plotting 50 superimposed structural snapshots along the 4-ns simulation (D–F). The loops showing a high amount of structural fluctuation
(RMSF.1.5 A˚) are indicated by numbers referring to the amino acid sequence (see also Figure 1). The structural snapshots are colored according to
timestep, as illustrated by the scale bar (please note that the color scale is illustrative only because of the rendering method). Figures D–F were
prepared using the program VMD 1.8.7 [35].
doi:10.1371/journal.pone.0020535.g004
Table 1. Transition temperatures of the subunit dissociation
(Tr) and thermal unfolding (Tm) determined by SDS-PAGE and
DSC.
SDS-PAGE DSC
Tr (6C) Tr(+BTN) (6C) Tm (6C) Tm(+BTN) (6C)
AVD 60a 95a 84b 117b
AVR4(C112S) 90 95 110b 127b
dcAVD 40 75c 80a 116a
dcAVD/AVR4 70 85 86/91d 108/112d
aValue from [19];
b[25];
c[9];
d(two-peak analysis was applied to the data, and the minor peak is shown in
italics).
doi:10.1371/journal.pone.0020535.t001
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new binding properties. For instance, avidins with steroid-binding
have been developed in our group by random mutagenesis and
selected by phage display (Riihima¨ki et al., manuscript). By
combining these modified avidins to a dcAVD or single-chain
(scAVD, [28]) avidin platform, it will be possible to develop
avidin-based receptors with alternative binding affinities or with
multiple ligand specificities to be used in in vitro diagnostics or in
nanotechnology.
Materials and Methods
Evaluation of the PCR performance of the chimeric
dcAvd fusions
PCR amplification of the chimeric tandem fusion genes was
performed to evaluate their suitability for genetic modification.
The first PCR experiment was performed using four conditions;
the second PCR experiment was performed using two conditions
(Table S1). Pfu polymerase (Fermentas) was used and reactions
were performed following the manufacturer’s instructions. All
PCR products were analyzed by 1.5% agarose gel electrophoresis
using a 1-kbp DNA ladder as a standard.
Production of chimeric dcAVD fusion proteins
DNA constructs of circularly permutated avidin cp54 were
fused to circularly permuted streptavidin, AVR2 and AVR4 (cp65
SA/AVR2/AVR4) [9]. Circularly permuted genes were inserted
into the pBVboostFG plasmid containing the region encoding the
OmpA signal sequence, and the plasmid was transformed into
chemically competent E. coli TOP10 cells (Invitrogen) by the
standard heat-shock method. The plasmids were harvested using
the Qiagen Plasmid Miniprep kit according to the manufacturer’s
instructions, and the inserts were verified by DNA sequencing.
Figure 5. DSC analysis shows the biphasic thermal denaturation mode of the dcAvd/AVR4 protein. Heat-induced unfolding of the
proteins was analysed by differential scanning calorimetry. The measured thermogram of dcAVD (A) and dcAVD/AVR4 (B) is shown without and with
biotin (With Btn). Deconvoluted thermograms of dcAVD/AVR4 without (C) and with (D) biotin are also shown. The thermogram of dcAVD/AVR4
shows a melting point (Tm) at 91.3uC (C), which is about 11uC greater than for dcAVD (80.2uC, [11]). The smaller secondary peak shows a melting point
at 86.3uC. Biphasic thermal denaturation mode is also detected in the presence of biotin (D); the melting point of the main peak is at 112.3uC, and the
secondary peak is at 107.8uC. Interestingly, in the presence of biotin, dcAVD/AVR4 was denatured at a slightly lower temperature compared with
dcAVD 115.9uC [11].
doi:10.1371/journal.pone.0020535.g005
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The amino acid sequences of the recombinant proteins and the
cloning cassette are shown in Figure 1.
For protein production, the plasmids were transformed into E.
coli BL21-AI cells (Invitrogen) by the heat-shock method. After
overnight induction at 26uC, the avidin proteins were purified by
affinity chromatography on a 2-iminobiotin column (Affiland,
Lie`ge, Belgium) [19,29]. The avidin concentration was measured
with a NanoDropTM 3300 spectrometer using a molar absorption
coefficient (for dcAVD/AVR4; e= 50 880 M21 cm21 and
M = 29 045 g/mol, for dcAVD/AVR2; e= 48 320 M21 cm21
and M = 28 866 g/mol and for dcAVD/SA e= 65 980 M21
cm21 and M = 28 316 g/mol) at 280 nm. The produced hybrid
dcAVD proteins were analyzed by SDS-PAGE stained with
Coomassie Brilliant Blue.
Production of dcAvd/AVR4 by pilot-scale fermentation
For pilot-scale fermentation of dcAVD/AVR4 protein, the
Infors Labfors 3 fermentor was used. LB medium containing
gentamycin (7 mg/ml) and 0.1% glucose (w/v) was used for
fermentation, supplemented with antifoam agent struktol J647
(Schill & Seilacher, Hamburg, Germany). Overnight bacterial
culture in LB medium was used for inoculation. In the beginning
of fermentation, the pO2 of dissolved oxygen was 0%, stirring
speed 500 rpm and OD600 0.288. Fermentation was performed at
28uC. The level of oxygen was slowly raised to obtain 20%
dissolved oxygen (pO2). A feedback loop to maintain the oxygen
level at 20% was set by adjusting the stirring speed ranging from
150 to 1100 rpm. Pumping of the feed solution (50% glycerol,
2.5 g/l MgSO4, 33 ml/h) was initiated at OD,1. The induction
of protein production was performed at OD,1.5 by adding
0.25 mM IPTG (Fermentas) and 0.2% (w/v) L–arabinose (Sigma).
Induction was continued for 24 h. The cells were harvested by
centrifugation (50006g, 15 min, 20uC), lysed by sonication and
subjected to 2-iminobiotin affinity chromatography as previously
described [19].
Oligometric state of the produced chimeric dual chain
fusions
Size-exclusion chromatography was used to determine the
oligomeric state of the produced fusion proteins with an A¨kta
Purifier P10 instrument (Amersham Biosciences) equipped with a
TricornTM High Performance Column SuperdexTM 75 10/300
GL. A 50-mg sample of protein diluted in liquid phase (50 mM
NaPO4 pH 7, 650 mM NaCl) was used. Bio-Rad standard proteins
ranging from 1.5 to 67 kDa were used to calibrate the column.
Thermostability of dcAVD/AVR4 protein
For SDS-PAGE thermostability analysis, the purified proteins
were first in situ acylated [30]. Sulfosuccinimidyl acetate (Pierce
#26777) was used for protein acylation. D-biotin (140 mM) was
added to half the samples, and an equal volume of water was
added to the other half. Samples were diluted with SDS- and 2-
mercaptoethanol-containing sample buffer and incubated at
different temperatures (without biotin: RT (20–22uC), 40uC,
50uC, 60uC, 70uC, 100uC; with biotin: RT, 70uC, 80uC, 90uC,
100uC) for 20 min. After incubation, the samples were analyzed
by SDS-PAGE stained with Coomassie Brilliant Blue. Thermo-
stability of AVR4(C122S) protein was also determined. The
temperatures used for AVR4(C122S) protein were without biotin:
RT, 60uC, 70uC, 80uC, 90uC, 100uC; and with biotin: RT, 80uC,
90uC, 100uC, 120uC.
The thermodynamics of dcAVD/AVR4 unfolding was char-
acterized by differential scanning calorimetry (DSC) [31]. In the
DSC measurements, wt dcAVD was used as a control. The
Figure 6. Determination of ligand dissociation kinetics with a fluorescent-biotin conjugate. The dissociation of fluorescently labeled
biotin from various avidin forms was studied by replacing the labeled biotin with an excess of free biotin. AVD, AVR4(C122S) and dcAVD showed a
slow dissociation. For dcAVD/AVR4, a clearly biphasic dissociation process was observed. The analysis of the first part of the measurement (0–300 s,
inset) reveals an estimate for the dissociation rate constant of 1.1361023 s21 for the rapid dissociation phase of dcAVD/AVR4, which is about 1006
greater when compared to avidin or AVR4(C122S).
doi:10.1371/journal.pone.0020535.g006
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proteins were analyzed in 50 mM sodium phosphate buffer
(pH 7.0) containing 100 mM of sodium chloride. The temperature
was increased from 20 to 130uC with a 1uC/min heating rate.
Determination of the dissociation rate constant of
fluorescent biotin
The dissociation rate constant of conjugated biotin was
examined by fluorescence spectroscopy using fluorescently labeled
biotin (Bf560–BTN, Arcdia, Turku, Finland). A 50-nM biotin-
fluorochrome solution diluted in 50 mM sodium phosphate buffer
(pH 7.0) containing 650 mM of sodium chloride was mixed with
the protein solution (50 nM or 100 nM), followed by incubation
(5 min). The dissociation process was illuminated by adding 100-
fold excess of D-biotin (5 mM), which was measured after 1 hour.
The measurements were performed at 25uC or 50uC with
QuantaMaster Spectrofluorometer System equipped with thermo-
stated water bath [19].
Determination of 2-iminobiotin binding kinetics by
surface plasmon resonance biosensor analysis
The SPR analysis was performed for wt AVD, dcAVD/AVR4
and AVR4 proteins. The CM5 chips functionalized with 2-
iminobiotin were used for the interaction analysis. The Biacore X
instrument (GE Healthcare) was used and the measurements were
performed at 25uC using 50 mM sodium carbonate buffer (pH 11)
containing 1 M of sodium chloride as the running buffer. The
kinetic data were calculated from the sensograms using Langmuir-
ian binding model implemented in the BIAevaluationH program.
Molecular modeling and molecular dynamics simulations
The predicted models of chimeric dual-chain fusion proteins
were generated by exploiting the existing 3-D structures of dcAVD
(PDB 2C4I), SA (PDB 1MK5), AVR2 (PDB 1WBI) and AVR4
(PDB 1Y53) as templates. The sequence forming the cp65-subunit
of dcAVD (PDB 2C4I) was first replaced with a corresponding
sequence from another protein that had its sequence reorganized
equally (for details, see Figure 1 and [9]). The program Modeller
9v2 [32] was then used to generate a homology model of the
pseudodimer. Structural water molecules were included according
to their template structures, and the following structures were also
used to position the structural water molecules: PDB 1SLF, PDB
1AVE, and PDB 2AVI. The pseudotetrameric forms were then
generated by positioning two pseudodimers by structural super-
imposition with BODIL [33]. The generated homology models
were subjected to molecular dynamics simulation using the
program NAMD 2.6 and the CHARMM22 force field [34]. First,
the models (including structural waters extracted from PDB-files)
were placed in a box filled with TIP3 waters (box size
approximately 80 A˚680 A˚670 A˚) using the SOLVATE algo-
rithm in the program VMD 1.8.6 [35]. Na+ or Cl2 ions were
added to neutralize the system. The complete systems contained
58377 (dcAVD/AVR4), 56803 (dcAVD/AVR2), and 53207
(dcAVD/SA) atoms. The systems were then subjected to
minimization as follows: the first minimization was performed by
fixing all the protein atoms and allowing water molecules to move
according to minimization procedure implemented in NAMD for
4000 steps. The second 4000 step minimization was performed by
releasing all the atoms in the system except Ca atoms. Finally, the
system was minimized without constraints for 4000 steps.
The minimized system was thermalized by increasing the
temperature to 310 K in 31 ps with a Berendsen barostat (1 atm).
This step was followed by the production of the coordinate
trajectories under NPT conditions using the Berendsen barostat (1
atm) and the Berendsen thermostat at 310 K. The resulting data
were analyzed using the programs VMD 1.8.7, PyMOL 1.3, and
MS Excel 2010. RMSF calculations were run such that the Ca
atoms of one peptide chain were first aligned, and RMSF
(deviation over the last 10 ps) values were calculated for the Ca
atoms of the aligned chain. RMSF values were taken every 5 ps for
the last 3 ns of equilibration (600 time points) and averaged. The
force-field interaction energies between domains of dcAVDs were
calculated from the simulation trajectories by the NAMD 2.7
program using 5-ps time step.
Supporting Information
Figure S1 Oligomeric state of the dcAVD/AVR4 protein
determined by gel filtration. Gel-filtration chromatography
analysis showed a main peak corresponding to a dimeric (pseudo-
tetrameric) dcAVD/AVR4 (estimated molecular weight of 46 kDa).
Additionally, some higher molecular weight species are detected.
(TIF)
Figure S2 The SDS-PAGE analysis of the pilot-scale
production and the 2-iminobiotin purification of the
dcAVD/AVR4 protein. A Labfors Infors 3 bioreactor was used
for a pilot-scale production of the dcAVD/AVR4 protein. The
pilot-scale fed-batch fermentation in standard LB medium yielded
over 5 mg of the pure dcAVD/AVR4 protein per liter of
production medium. A, chicken avidin (10 mg); T, total sample
from culture; L, unbound fraction after incubation with 2-
iminobiotin; f2–f17 samples of elution fractions. The PageRulerTM
Plus prestained protein ladder (Fermentas) was used as a molecular
weight standard.
(TIF)
Table S1 Conditions used in the PCR amplification
analysis. In the first PCR experiment, four conditions were used
by varying annealing and elongation times. In the second PCR
experiment, two different conditions were used as described in the
table.
(DOC)
Acknowledgments
The authors acknowledge the contribution of Dr. Henri Nordlund in the
early stage of this research. He passed away 21st of July in 2008. The
valuable discussions with Dr. Einari Niskanen are acknowledged. We
acknowledge the skilled technical support provided by Irene Helkala and
Ulla Kiiskinen. CSC – IT Center for Science Ltd is acknowledged for the
use of their supercomputer resources for the MD simulations.
Author Contributions
Conceived and designed the experiments: VPH TAR MSK. Performed the
experiments: SV TAR SK TKMN JH VPH. Analyzed the data: TAR SK
VPH. Contributed reagents/materials/analysis tools: MSK VPH. Wrote
the paper: TAR SK SV TKMN MSK VPH.
References
1. Groman EV, Rothenberg JM, Bayer EA, Wilchek M (1990) Enzymatic and
radioactive assays for biotin, avidin, and streptavidin. Method Enzymol 184: 208–217.
2. Bayer EA, Ben-Hur H, Wilchek M (1990) Analysis of proteins and glycoproteins
on blots. Method Enzymol 184: 415–427.
3. Barbarakis MS, Qaisi WG, Daunert S, Bachas LG (1993) Observation of ‘‘hook
effects’’ in the inhibition and dose-response curves of biotin assays based on the
interaction of biotinylated glucose oxidase with (strept)avidin. Anal Chem 65:
457–460.
Chimeric Dual-Chain Avidin
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e20535
4. Green NM (1970) Spectrophotometric determination of avidin and streptavidin.
Method Enzymol 18: 418–424.
5. Lin HJ, Kirsch JF (1979) A rapid, sensitive fluorometric assay for avidin and
biotin. Method Enzymol 62: 287–289.
6. Mock DM, Horowitz P (1990) Fluorometric assay for avidin-biotin interaction.
Method Enzymol 184: 234–240.
7. Zacco E, Pividori MI, Alegret S (2006) Electrochemical biosensing based on
universal affinity biocomposite platforms. Biosens Bioelectron 21: 1291–1301.
8. Lesch HP, Kaikkonen MU, Pikkarainen JT, Yla¨-Herttuala S (2010) Avidin-
biotin technology in targeted therapy. Expert Opin Drug Deliv 7: 551–564.
9. Nordlund HR, Laitinen OH, Hyto¨nen VP, Uotila ST, Porkka E, et al. (2004)
Construction of a dual chain pseudotetrameric chicken avidin by combining two
circularly permuted avidins. J Biol Chem 279: 36715–36719.
10. Hyto¨nen VP, Ho¨rha¨ J, Airenne TT, Niskanen EA, Helttunen KJ, et al. (2006)
Controlling quaternary structure assembly: Subunit interface engineering and
crystal structure of dual chain avidin. J Mol Biol 359: 1352–1363.
11. Hyto¨nen VP, Nordlund HR, Ho¨rha¨ J, Nyholm TK, Hyre DE, et al. (2005)
Dual-affinity avidin molecules. Proteins 61: 597–607.
12. Leppiniemi J, Ma¨a¨tta¨ JA, Hammaren H, Soikkeli M, Laitaoja M, et al. (2011)
Bifunctional avidin with covalently modifiable ligand binding site. PLoS One 6:
e16576.
13. Aslan FM, Yu Y, Mohr SC, Cantor CR (2005) Engineered single-chain dimeric
streptavidins with an unexpected strong preference for biotin-4-fluorescein. Proc
Natl Acad Sci U S A 102: 8507–8512.
14. Keina¨nen RA, Walle´n MJ, Kristo PA, Laukkanen MO, Toimela TA, et al.
(1994) Molecular cloning and nucleotide sequence of chicken avidin-related
genes 1–5. Eur J Biochem 220: 615–621.
15. Ahlroth MK, Kola EH, Ewald D, Masabanda J, Sazanov A, et al. (2000)
Characterization and chromosomal localization of the chicken avidin gene
family. Anim Genet 31: 367–375.
16. Weber PC, Cox MJ, Salemme FR, Ohlendorf DH (1987) Crystallographic data
for streptomyces avidinii streptavidin. J Biol Chem 262: 12728–12729.
17. Eisenberg-Domovich Y, Hyto¨nen VP, Wilchek M, Bayer EA, Kulomaa MS,
et al. (2005) High-resolution crystal structure of an avidin-related protein: Insight
into high-affinity biotin binding and protein stability. Acta Crystallogr D Biol
Crystallogr 61: 528–538.
18. Hyto¨nen VP, Ma¨a¨tta¨ JA, Kidron H, Halling KK, Ho¨rha¨ J, et al. (2005) Avidin
related protein 2 shows unique structural and functional features among the
avidin protein family. BMC Biotechnol 5: 28.
19. Hyto¨nen VP, Laitinen OH, Airenne TT, Kidron H, Meltola NJ, et al. (2004)
Efficient production of active chicken avidin using a bacterial signal peptide in
Escherichia coli. Biochem J 384: 385–390.
20. Laitinen OH, Hyto¨nen VP, Ahlroth MK, Pentika¨inen OT, Gallagher C, et al.
(2002) Chicken avidin-related proteins show altered biotin-binding and physico-
chemical properties as compared with avidin. Biochem J 363: 609–617.
21. Gonzalez M, Bagatolli LA, Echabe I, Arrondo JLR, Argarana CE, et al. (1997)
Interaction of biotin with streptavidin. thermostability and conformational
changes upon binding. The Journal of Biological Chemistry 25: 11288–11294.
22. Sano T, Cantor CR (1990) Cooperative biotin binding by streptavidin.
Electrophoretic behavior and subunit association of streptavidin in the presence
of 6 M urea. J Biol Chem 265: 3369–3373.
23. Jones ML, Kurzban GP (1995) Noncooperativity of biotin binding to tetrameric
streptavidin. Biochemistry 34: 11750–11756.
24. Green NM, Toms EJ (1972) The dissociation of avidin-biotin complexes by
guanidinium chloride. Biochem J 130: 707–711.
25. Hyto¨nen VP, Nyholm TK, Pentika¨inen OT, Vaarno J, Porkka EJ, et al. (2004)
Chicken avidin-related protein 4/5 shows superior thermal stability when
compared with avidin while retaining high affinity to biotin. J Biol Chem 279:
9337–9343.
26. Hyre DE, Le Trong I, Merritt EA, Eccleston JF, Green NM, et al. (2006)
Cooperative hydrogen bond interactions in the streptavidin-biotin system.
Protein Sci 15: 459–467.
27. DeChancie J, Houk KN (2007) The origins of femtomolar protein-ligand
binding: Hydrogen-bond cooperativity and desolvation energetics in the biotin-
(strept)avidin binding site. J Am Chem Soc 129: 5419–5429.
28. Nordlund HR, Hyto¨nen VP, Ho¨rha¨ J, Ma¨a¨tta¨ JA, White DJ, et al. (2005)
Tetravalent single chain avidin: From subunits to protein domains via circularly
permuted avidins. Biochem J 392: 485–491.
29. Airenne KJ, Oker-Blom C, Marjoma¨ki VS, Bayer EA, Wilchek M, et al. (1997)
Production of biologically active recombinant avidin in baculovirus-infected
insect cells. Prot Exp Pur 9326: 100–108.
30. Bayer EA, Ehrlich-Rogozinski S, Wilchek M (1996) Sodium dodecyl sulfate-
polyacrylamide gel electrophoretic method for assessing the quaternary state and
comparative thermostability of avidin and streptavidin. Electrophoresis 17370:
1319–1324.
31. Hyto¨nen VP, Laitinen OH, Grapputo A, Kettunen A, Savolainen J, et al. (2003)
Characterization of poultry egg-white avidins and their potential as a tool in
pretargeting cancer treatment. Biochem J 372: 219–225.
32. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, et al.
(2006) Comparative protein structure modeling using modeller. Curr Protoc
Bioinformatics, DOI: 10.1002/0471250953.bi0506s15.
33. Lehtonen JV, Still DJ, Rantanen VV, Ekholm J, Bjo¨rklund D, et al. (2004)
BODIL: A molecular modeling environment for structure-function analysis and
drug design. J Comput Aided Mol Des 18: 401–419.
34. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable
molecular dynamics with NAMD. J Comput Chem 26: 1781–1802.
35. Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics.
J Mol Graph 14: 33–8, 27–8.
Chimeric Dual-Chain Avidin
PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e20535
1 Covalent Biofunctionalization of Cellulose Acetate with Thermostable
2 Chimeric Avidin
3 Jarkko J. Heikkinen,† Tiina A. Riihim€aki,‡ Juha A.E. M€a€att€a,‡ Sini E. Suomela,† Jukka Kantomaa,†
4 Markku S. Kulomaa,‡ Vesa P. Hyt€onen,*,‡ and Osmo E.O. Hormi*,†
5
†Department of Chemistry, University of Oulu, P.O. BOX 3000, FI-90014 Oulu, Finland
6
‡Institute of Biomedical Technology, University of Tampere and Tampere University Hospital, FI-33014 Tampere, Finland
26 1. INTRODUCTION
27 The interest in protein immobilization techniques for biochips
28 and biosensors has grown rapidly. A number of reviews have been
29 published on the immobilization of proteins.17 However, despite
30 extensive studies, it is still challenging to immobilize proteins onto
31 surfaces in such away that their three-dimensional structure, function-
32 ality, and binding sites are well retained. One way to overcome this
33 challenge is to use a tetrameric avidin containing four identical
34 binding sites for biotin as an adaptor protein. The avidin-functiona-
35 lized surface is used in many life science applications as a bioaﬃnity
36 capturing tool for controlled immobilization of biotinylated protein.8
37 This is based on avidins ultratight aﬃnity toward the H-vitamin, also
38 called as biotin (Kd≈ 1 1015M).9 Avidin belongs to the chicken
39 avidin family that also contains several related proteins including
40 avidin related protein 4 (AVR4). AVR4 is one of the most thermally
41 stable proteins among theprotein family and inour previous study the
42 stabilizing structural elements of AVR4 were transferred to wt avidin.
43 The resulting chimeric avidin mutant ChiAVD(I117Y) (hereinafter
44 referred to as chimeric avidin) was found to possess signiﬁcantly
45 increased thermal and chemical stabilities as compared to those of wt
46 (strept)avidin.10,11 Another valuable property of this protein is that it
47 can be inexpensively produced in E. coli in a functionally active form.
48 Because of these favorable characteristics theuseof chimeric avidin for
49 the immobilization may enable cost-eﬀective manufacturing of
50 biochips and biosensors that remain stable during long periods of
51 storage or under demanding production conditions.
52The main objective of this research was the development of a
53method for covalent immobilization of chimeric avidin on a
54cellulose acetate (CA) surface. CA, also known as zyl or zylonite,
55is valuable material utilized widely in manufacturing of ﬁlms and
56ﬁbers. A solgel-based method was chosen to ﬁrst introduce free
57amino groups onto CA ﬁlm using mixture of 3-aminopropyltri-
58methoxysilane (APTMS) and tetraethoxysilane (TEOS). This
59amino-functionalized CA ﬁlm was then reacted with glutaralde-
60hyde to form an activated CA ﬁlm, which could then be used
61directly for covalent protein immobilization. The biotin-binding
62capacity of immobilized chimeric avidin was determined using
63tritium-labeled biotin ([3H]-biotin). We also studied the dur-
64ability of the surfaces functionalized with diﬀerent methods over
65a three-month period. Finally, a comparative study was per-
66formed using other biotin-binding proteins chicken avidin,
67streptavidin and rhizavidin as linker proteins.11
682. EXPERIMENTAL SECTION
692.1. Materials. Cellulose diacetate film (CA) was obtained from
70Clarifoil (P27, thickness 150 μm). 3-Aminopropyltrimethoxysilane
71(APTMS), tetraethoxysilane (TEOS), glutaraldehyde (25% (w/v) in
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8 ABSTRACT:A stable, bioactive cellulose acetate (CA) surfacewas
9 developed by functionalizing the surface with highly thermostable
10 avidin form.TheCAﬁlmswere ﬁrst functionalizedwith amixture of
11 3-aminopropyltrimethoxysilane and tetraethoxysilane to introduce
12 free amino groups onto the surface of CA ﬁlms. Free amino groups
13 were functionalized with glutaraldehyde to obtain an activated
14 surface for covalent biomolecule immobilization. A genetically
15 engineered, high-aﬃnity biotin-binding protein chimeric avidin,
16 ChiAVD(I117Y), was used for biofunctionalization of the surface.
17 The chimeric avidin protein has an increased stability in chemically harsh conditions and at high temperature when compared to wt
18 (strept)avidin. The biological activity, i.e., biotin-binding capacity, of the immobilized protein was probed by [
3H]-biotin. The activity of the
19 chimeric avidin on functionalized CA ﬁlms was fully retained over the three months’ study period. The biotin-binding capacity of the
20 immobilized chimeric avidin was compared to that of immobilized streptavidin, chicken avidin, and rhizavidin and signiﬁcant diﬀerences
21 between proteins were detected. The developed material oﬀers a valuable platform for the development of inexpensive in vitro diagnostics
22 and also supports biosensing applications that are required to operate under demanding conditions.
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72 H2O) and bovine serum albumin (BSA) were purchased from Aldrich
73 and used without further purification.
74 Chimeric avidin and rhizavidin core were produced in BL21-AI E. coli
75 cells by using pilot-scale fermentor and puriﬁed with 2-iminobiotin aﬃnity
76 chromatography as described previously.12 Chicken avidin was purchased
77 from Belovo (Bastogne, Belgium) and streptavidin from Calbiochem
78 (18973010MG). D-biotin was purchased from Sigma (B-4501) and
79 D-[8,9-3H]-biotin from Amersham (Buckinghamshire, England).
80 2.2. Functionalization and Characterization of CA Films.
81 Amino-Functionalization of CA Film. To prepare a solgel stock
82 solution for CA film amino-functionalization, we dissolved TEOS
83 (0.75 mL) in ethanol (4 mL) and 10 μL of 4 M hydrochloric acid was
84 added. In a separate flask, APTMS (1.5mL) was dissolved in ethanol (4mL)
85 and 4 mL of water was added. Both solutions were stirred for 30 min after
86 TEOS solution was added to the APTMS solution. This mixture was stirred
87 for 15min and then diluted 5-fold by adding 48mLof ethanol. The obtained
88 stock solution was stored at fridge (þ4 C). After the dilution of the stock
89 solution by ethanol (1:5) CA films were dip-coated by immersing the film to
90 the solgel solution for 2 min. The functionalized CA films were dried at
91 room temperature (RT, 2123 C) and stored in andesiccator prior the use.
92 Glutaraldehyde Functionalization. Amino-functionalized CA slides
93 were placed in a glutaraldehyde solution (10% in H2O) for 1 h at RT.
94 After glutaraldehyde treatment, the CA slides were washed with water,
95 dried, and stored in an desiccator at RT prior the use.
96 CA Film Characterization.Gas chromatography was used to measure
97 the density of free amino groups on the amino functionalized CA film
98 and amino-reactive groups on the glutaraldehyde functionalized CA film.13
99 The amino and amino-reactive groups on the surface of functionalized films
100 were reacted with benzaldehyde and aniline analytes, respectively, to form
101 imine bonds when refluxed in anhydrous toluene solution for 4 h. Anisole
102 was used as a standard in the GCmeasurements to calculate the amount of
103 reacted analyte with the functionalized surface. The amounts of amino and
104 amino-reactive groups were calculated per area of 1 cm2. Scanning electron
105 microscope (SEM) images of prepared CA films were analyzed using field-
106 emission scanning electron microscope Zeiss ULTRA plus.
107 2.3. Immobilization of Avidins onto the CA Films. Films
108 were cut to 1 cm 1 cm size and placed into the wells of 24-well plate. A
109 200 μL aliquot of avidin solution (0.1 mg/mL in PBS: 0.137 M sodium
110 chloride, 2.8 mMpotassium chloride, 11.9mMNa-phosphate buffer, pH
111 7.4) was added to each well and films were incubated in the avidin
112 solution for one hour at 37 C. The films were washed three times with 300
113 μL of PBST buffer (PBS with 0.05% of TWEEN 20) and blocked with 3%
114 BSA solution in PBS for one hour. The films were finally washed five times
115 with 300 μL of PBST and dried at RT. The avidin functionalized films were
116 either stored at RT or in a fridge atþ4 C prior the biotin-binding capacity
117 measurements. Following abbreviations are used for the films studied: 1 =
118 unmodified CA film, 2 = amino-functionalized CA film, 3 = glutaraldehyde
119 functionalized CA film, A = chimeric avidin coated film, wtA = wt avidin
120 coated film, RA = rhizavidin coated film, SA = streptavidin coated film, and
121 R = control films without avidin coating.
122 2.4. Determination of Biotin-Binding Capacity with [3H]-
123 Biotin. The biotin-binding capacity of surface-immobilized avidin layer
124 was measured using D-[8,9-3H]biotin thereafter referred to as [3H]-biotin.
125 Nonspecific binding of the biotin was taken into account by measuring the
126 bound [3H]-biotin after blocking the filmswith an excess ofD-biotin. These
127 results were subtracted from the results without D-biotin blocking to
128 calculate specific biotin-binding capacity. All biotin-binding capacity results
129 are calculated as a bound biotin per area of the film [mol/cm2].
130 General [3H]-Biotin Assay Protocol. The CA films (1  1 cm) were
131 incubated for 2 h at RT in a 1 mL sodium phosphate solution (50 mM
132 NaH2PO4/Na2HPO4, 100 mM NaCl, pH 7.0) to wash the films. The
133 solution was removed and 1 mL of 12.8 nM [3H]-biotin solution
134 (50 mM NaH2PO4/Na2HPO4, 100 mM NaCl, 10 μg/mL BSA, pH
135 7.0) was added and incubated for 1 h at RT. A sample (90 μL) was taken
136from the solution and added to 4 mL of Opti-Phase scintillation solution
137(PerkinElmer). The scintillations were counted with LKB Wallac 1217
138Rackbeta liquid scintillation counter (Turku, Finland). The amount of
139bound [3H]-biotin was calculated based on counts measured from free
140[3H]-biotin solution before used for the experiment.
141[3H]-Biotin Assay Protocol with D-Biotin Blocking. The CA films
142were washed first with 1 mL of sodium phosphate -solution for 1 h. The
143solution was removed and 1 mL of D-biotin solution (50 mM NaH2-
144PO4/Na2HPO4, 100 mM NaCl, pH 7.0 with 150 μM D-biotin) was
145added and the films were incubated in this solution for one hour. The
146D-biotin solution was removed and [3H]-biotin assay was then carried
147out as described above.
1483. RESULTS AND DISCUSSION
1493.1. Functionalization of CA Films. The functionalization
150was done in two steps (Figure 1 F1). During the first step, the CA
151films were treated with a solgel solution made from APTMS and
152TEOS in ethanol to functionalize CA films with free amino groups.
153A ratio of 2:1 between APTMS and TEOS were found to yield
154stable amino-functionalized CA film surface.14 In the second step, a
155glutaraldehyde treatment was done by stirring the amino-functio-
156nalized CA films in a 10% glutaraldehyde solution in water for 1 h.
157During the glutaraldehyde treatment, the CA slides turned slightly
158red, indicating a reaction between glutaraldehyde and amino groups.
159To measure the aging eﬀect of solgel stock solution, a series
160of functionalized ﬁlms were prepared where the solgel stock solu-
161tion aging time varied from zero days to ten days. Determination of
162the free amino groups by gas chromatography revealed that seven
163days old solgel stock solution gave the highest amount of amino
164groups (64.8 nmol/cm2) after amino-functionalization (Figure 2 F2).
165However, all ﬁlms regardless of the aging time clearly had a very high
166amount of amino groups (2665 nmol/cm2). In the SEM analysis,
167a rough surface structure with high surface area was observed
168(Figure 3 F3). This can explain the high amino content on the R2
169ﬁlms. Similar high amino densities have been reported for amino-
170functionalized poly(ethylene-co-acrylic acid) polymer ﬁlms, which
171were functionalized by using amino-modiﬁed silica nanoparticles.15
Figure 1. Schematic representation of functionalization and protein
immobilization on the CA surface. For clarity, the chemistry of
glutaraldehyde on the surfaces of CA ﬁlms is shown as a monomeric
dialdehyde.
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172 All prepared glutaraldehyde-functionalized R3 ﬁlms were found
173 to have roughly ten times more amino-reactive groups (500
174 560 nmol/cm2) compared to free amino groups after amino func-
175 tionalization. Several studies have shown that commercially available
176 glutaraldehydewater solution represents multicomponent mix-
177 tures including aldehydes, monohydrates, dihydrates, cyclic hemi-
178 acetals, and oligomers and polymers of these.16 All these forms can
179 react with amino groups, which can explain the high density of
180 amino-reactive groups on the surface of R3 ﬁlms. Also, because the
181 commercial glutaraldehyde can exist as a polymer form, especially
182 when stored at RT, a low density of free amino groups before
183 glutaraldehyde functionalization (26.2 nmol/cm2, 0 day) resulted in
184 the same level of amino-reactive groups after GA functionalization
185 when compared to other ﬁlms with higher (4465 nmol/cm2)
186 amino group density.
187 3.2. Immobilization of Avidin Proteins. The immobilization
188 of avidin proteins (chimeric avidin, chicken avidin, rhizavidin,
189 streptavidin) onto the CA films was performed by incubating the
190 CA films in a solution containing 0.1 mg/mL avidin protein for
191 one hour at 37 C (Figure 1). Thorough washing with PBST
192buffer was effective in the removal of the weakly bound avidin
193proteins from the surface. Measured SEM images of chimeric
194avidin immobilized films after PBSTwashing period are shown in
195Figure 4 F4, indicating the stability of amino and glutaraldehyde
196functionalization after protein immobilization.
1973.3. Biotin-Binding Capacity. The specific biotin-binding
198capacity of the films was determined by comparing the measured
199total biotin-binding capacity with the results obtained after
200blocking the surfaces with D-biotin before [3H]-biotin assay.
201No significant differences were observed between different
202control films (R1-R3) in their binding capacities.
203All chimeric avidin-coated ﬁlms showed high biotin-binding
204capacity. Initially (the ﬁrst day) both nonfunctionalized ﬁlm (A1)
205and glutaraldehyde activated ﬁlm (A3) bound almost the same
206amount of [3H]-biotin, indicating that the same amount of
207chimeric avidin was immobilized onto both ﬁlms. The amino-
208functionalized ﬁlm (A2) was found to have one-half less im-
209mobilized chimeric avidin compared to A1 and A3 ﬁlms.
Figure 2. Density of free amino groups on R2 surface [nmol/cm2] and amino-reactive groups on R3 surface as a function of the solgel aging time.
Figure 3. Scanning electron microscopy analysis of functionalized CA
ﬁlms. R1 = unmodiﬁed CA ﬁlm, R2 = solgel amino-functionalized CA
ﬁlm, R3 = glutaraldehyde functionalized CA ﬁlm.
Figure 4. Scanning electron microscopy analysis of CA ﬁlms after
incubation with chimeric avidin. A1 = unmodiﬁed CA ﬁlm treated with
chimeric avidin, A2 = amino functionalized CA ﬁlm treated with
chimeric avidin, A3 = glutaraldehyde functionalized CA ﬁlm treated
with chimeric avidin.
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210 During the 3 month study period, the A3 ﬁlm was found to be
211 the most stable: covalently bound avidin remained fully active.
212 Additionally, there were no signiﬁcant diﬀerences in binding
213 capacities between A3 samples stored at diﬀerent temperatures.
214 The biotin-binding activity of A1 ﬁlm stored at RT already
215 showed a signiﬁcant decrease after one month’s storage, whereas
216 the decay was slower when the ﬁlm was stored at þ4 C
217 (Figure 5F5 ). The diﬀerence between the behavior of A3 and A1
218 ﬁlms can be explained by the means of protein attachment to the
219 ﬁlms. In the case of A1 ﬁlm, avidin is physisorbed on the ﬁlm,
220 whereas in the case of A3 ﬁlm the protein is covalently bound to
221 the surface. It is well-known that glutaraldehyde has preservative
222 properties against biomolecular unfolding, since the covalent
223 multipoint attachment, presumed to occur with glutaraldehyde,
224 prevents the unfolding of proteins.17 Moreover, the polymeric
225 nature of glutaraldehyde provides a long leash, attaching the
226 protein to the matrix, which may permit greater ﬂexibility for
227 protein conformational changes required for activity. Under the
228 used neutral conditions used for protein immobilization, a
229 reaction between cyclic hemiacetal or its polymeric form and
230an amino group in protein is reported to form the most stable
231bond,18 but several diﬀerent reactions can proceed simulta-
232neously leading to protein immobilization (Figure 6 F6). Amino-
233functionalized ﬁlm (A2) lost biotin-binding capacity completely
234after three months when stored at room temperature. Unfortu-
235nately, we were not able to analyze the sample of A2 stored
236at þ4 C after 3 months, so the diﬀerence between storage
237conditions can not be evaluated.
238The binding capacity of chimeric avidin coating can also be
239evaluated based on molecular dimensions. According to the 3D-
240structure,12 chimeric avidin can be described as a box with a
241dimension of about 5 nm, and a full monolayer of the avidins
242would result in a protein density of 6.6 pmol/cm2. The measured
243speciﬁc biotin-binding capacity of A3 surface was 2.17 pmol/cm2
244(1 day). Therefore, the generated surface had a capacity that is
245clearly lower than a fully active avidin monolayer, and, by
246converting the obtained values for molecular density, there were
2470.33 biotin-binding sites per surface area of an avidin tetramer.
248Based on the crystal structure, (chimeric) avidin is quite sym-
249metric. Therefore, the number of available binding sites on
Figure 5. Botin-binding capacity of the CA ﬁlms. The control ﬁlms (R1, R2, R3) showed no biotin-binding activity. The most stable ﬁlm was the
solgel- and glutaraldehyde-functionalized CA ﬁlm with chimeric avidin coating (A3), because the binding activity of that ﬁlm did not decrease during
the 3-month storage period. Furthermore, no diﬀerence was observed between the diﬀerent storage conditions in the case of A3. The A1 ﬁlm stored at
RT already showed a signiﬁcant decrease in binding capacity after one month of storage, whereas the ﬁlm stored atþ4 C showed slower decay of the
binding capacity. (The A2 sample stored at þ4 C for 3 months was not analyzed.).
Figure 6. Reactions of diﬀerent glutaraldehyde forms with protein (A) under neutral conditions: (a) glutaraldehyde, (b) cyclic hemiacetal, (c)
polymeric hemiacetal.
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250 surface-immobilized avidin would be two or less, and only one
251 binding site per immobilized protein would be a fair assumption.
252 Therefore, in the case of A3 ﬁlms, the determined speciﬁc
253 binding capacity suggests an average coverage of approximately
254 33% or less of the surface with functional chimeric avidins. In
255 reality, because of the roughness of the surface (Figures 3 and 4),
256 the coverage may be signiﬁcantly smaller.
257 We also analyzed ﬁlms coated with chicken avidin, streptavidin
258 and rhizavidin. Interestingly, chimeric avidin and chicken avidin
259 showed similar high biotin-binding capacities, whereas ﬁlms
260 coated with streptavidin and rhizavidin had low biotin-binding
261 capacities (Figure 7F7 ). This may reﬂect the chemical reactivity of
262 the proteins with the activated surface. Other possible explana-
263 tions are the physicochemical diﬀerences between proteins.
264 Rhizavidin is dimeric avidin form, which has signiﬁcantly lower
265 thermal stability when compared to chicken avidin.11 Streptavi-
266 din in turn, has thermal stability similar to chicken avidin, but
267 appears to be more sensitive to treatment with diﬀerent chemi-
268 cals, such as methanol.12 Therefore, it is possible that the result
269 reﬂects the chemical stress applied to the immobilized protein
270 because of the adjacent surface. Chimeric avidin was selected for
271 the experiment instead of wt avidin, due to its more stable
272 structure in harsh conditions. Also, the eﬃcient and scalable
273 expression in E. coli supported the use of chimeric avidin in the
274 study. However, the long-term stability of wt avidin on the CA
275 ﬁlms should be studied more closely in the future.
276 4. CONCLUSION
277 A new method for biofunctionalization of cellulose acetate
278 ﬁlms by a simple two-step protocol was developed. A solgel
279 solution containing 3-aminopropyltrimethoxysilane and tetra-
280 ethoxysilane was ﬁrst used to introduce free amino groups onto
281 the surface of cellulose acetate (CA) ﬁlm. The amino groups
282 were then reacted with glutaraldehyde to obtain a reactive
283 glutaraldehyde layer on the surface of CA ﬁlm. The protein
284 immobilization was studied with highly thermostable chimeric
285 avidin, which is a genetically engineered version of the high-
286 aﬃnity biotin-binding protein avidin. The activity of CA-immo-
287 bilized chimeric avidin retained completely for three months
288 when stored at RT or atþ4 Cwhen assayed by a tritium-labeled
289 biotin assay. Immobilization of other avidins (streptavidin,
290 chicken avidin, and rhizavidin) was also analyzed and chimeric
291avidin and avidin were found to behave similarly. In contrast,
292streptavidin and rhizavidin yielded notably weaker biotin-bind-
293ing capacities. The method developed in the study opens up a
294great potential for the use of avidin-coated CA-ﬁlms as universal
295base for various applications, for example, in the development of
296an inexpensive and sensitive diagnostic tools to be used in
297personalized medicine platforms.
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Abstract 
Background: Engineered proteins, with non-immunoglobulin scaffolds, have become an important 
alternative to antibodies in many biotechnical and therapeutic applications. When compared to 
antibodies, tailored proteins may provide advantageous properties such as a smaller size or a more 
stable structure.  
Results: Avidin is a widely used protein in biomedicine and biotechnology. To tailor the binding 
properties of avidin, we have designed a sequence-randomized avidin library with mutagenesis 
focused at the loop area of the binding site. Selection from the generated library led to the isolation 
of a steroid-binding avidin mutant (sbAvd-1) showing micromolar affinity towards testosterone (Kd 
~ 9 µM). Furthermore, a gene library based on the sbAvd-1 gene was created by randomizing the 
loop area between β-strands 3 and 4. Phage display selection from this library led to the isolation of 
a steroid-binding protein with significantly decreased biotin binding affinity compared to sbAvd-1. 
Importantly, differential scanning calorimetry and analytical gel-filtration revealed that the high 
stability and the tetrameric structure were preserved in these engineered avidins. 
Conclusions: The high stability and structural properties of avidin make it an attractive molecule 
for the engineering of novel receptors. This methodology may allow the use of avidin as a universal 
scaffold in the development of novel receptors for small molecules.  
 
Keywords:  protein engineering, avidin scaffold, phage display, steroid hormone, testosterone 
 
Background 
Antibodies are the most widely used biomolecules for therapeutic, diagnostic and research 
applications, because they can be generated against virtually any molecule using protein 
engineering techniques (for a review see [1]). However, antibodies have certain fundamental 
disadvantages such as the complex architecture of their antigen-binding site, low stability, and a 
rather large size [2-5]. Moreover, the production of full-size antibodies is relatively expensive [6]. 
To overcome these limitations and to improve therapeutic antibodies, antibodies have been 
extensively engineered [7]. For example the size of the antibody molecule has been reduced by 
producing single-domain antigen-binding derivatives [8]. In addition to extensive antibody 
engineering, a versatile repertoire of tailored biomolecules from non-immunoglobulin protein 
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scaffolds have been generated [4, 9, 10]. Anticalins, derived from the lipocalin fold, are a good 
example of engineered proteins [11]. The β-barrel structure of lipocalins is thermostable and robust 
and serves as an excellent scaffold for engineering novel receptors. They have been modified to 
bind novel ligands, such as fluorescein and digoxigenin, with affinities comparable with antibodies 
[12].  
 
Chicken avidin (Avd), known for its extremely high affinity towards the water-soluble vitamin H, 
D-biotin, has been widely used in life science research applications [13]. Aside from biotin, Avd 
also binds dyes and peptides, which share no significant structural similarity with biotin [14, 15]. 
Avd provides an attractive robust scaffold for the development of novel receptors, and Avd has 
many advantageous properties such as high chemical and thermal stability, a deep ligand binding 
site optimized for the binding of small molecules, and an oligomeric nature enabling signal 
amplification. Moreover, the structure of Avd is well characterized [16, 17] and numerous 
engineered forms of Avd have been described [18]. Engineered Avd forms, in which the two pairs 
of the binding sites (dual-chain Avd) [19, 20, 21] or all four binding sites (single-chain Avd) [22] 
can be independently manipulated, have been developed.  
 
In the present study Avd was modified to bind steroid hormones. Avd mutant sbAvd-1, which was 
captured using the phage display selection [23], has a micromolar affinity to testosterone. The 
steroid-binding protein sbAvd-1 was characterized and further engineered to decrease cross-
reactivity towards other molecules, especially towards Avd’s natural ligand biotin. The resulting 
sbAvd-2 mutant with a modified loop between β-strands 3 and 4 was found to prefer steroid 
hormones over biotin in ligand binding. 
 
Results 
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Functional display of Avd protein on the M13 phage 
Avd was displayed on the surface of the M13 phage as a fusion with the C-terminal region of the 
minor coat protein pIII. Two different strategies for displaying the Avd scaffold in the active form 
on the M13 phage were evaluated. In the first display construct, Avd was produced solely as a 
fusion with pIII (Avd-pIII; Figure 1A), whereas in the Avd/Avd-pIII display construct, free Avd 
subunits were produced in addition to the pIII fusion (Figure 1B).  
 
The size and oligomeric state of the Avd-pIII fusions were analyzed by SDS-PAGE and by western 
blot. Polyclonal anti-Avd (Figure 2A) indicated expression of both the Avd-pIII fusion (upper 
arrow, ~38 kDa) and the free Avd (lower arrow, ~15 kDa). The production of free subunits should 
enhance the functional assembly of the tetrameric Avd scaffold, especially if membrane anchoring 
of Avd by the pIII fusion partner has a negative effect on the oligomerization of Avd subunits. This 
strategy mimics the generally used amber-stop codon technique, in which free subunits are 
produced by the read-through of amber stop codon by the tRNA. We assume that the 
oligomerization of Avd, secreted by the pelB signal sequence, occurs in the periplasmic space of E. 
coli, allowing the display of functional Avd on the phage, as is the case for the display of the 
antibody Fab fragment, which requires folding of the heavy and light chains for the assembly of a 
functional antibody molecule [24]. 
 
A portion of the Avd-pIII fusion was partially proteolytically cleaved, as can be seen from the blot 
analyzed with the anti-pIII monoclonal antibody (Figure 2B, ~35 kDa band). Because Avd display 
constructs designed in this study were based on the monovalent display mode (3+3), the intact pIII 
(migrating at ~58 kDa) expressed from the helper phage was also detected from the blot (Figure 2B, 
uppermost arrow). 
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Avd-displaying phages were functional because they bound specifically to the biotin-coated 
surfaces, and phages were efficiently amplified even after several panning rounds. Moreover, 
phagemid DNA with the Avd display expression unit, which was confirmed by the restriction 
enzyme digestion analysis, was stable during the panning rounds (data not shown).  
 
To analyze the functionality of phages, the mixture of amplified Avd and Avd mutant N118M 
phages were screened by panning against 4-hydroxyazobenzene-2-carboxylic acid (HABA). As 
determined in our previous study, the biotin binding affinity of the Avd mutant N118M was 
reduced ~1,000,000-fold (Kd = 4.2 × 10–9 M) and HABA-affinity was increased ~1.5-fold (Kd = 5.2 
× 10–6 M) compared to wtAvd [25] (Additional file 1). During the panning procedure a clear 
enrichment of Avd(N118M) phages over wt Avd phages was detected, which was an indication of 
the high selectivity of the produced phages. After only three rounds of selection phages displaying 
the Avd mutant N118M outcompeted the wtAvd phage population (Additional file 2).  
 
Capture of a steroid-binding avidin 
The loops adjacent to the ligand-binding site were selected for randomization [16]. First we created 
a library (Avd L1,2 library) in which residues N12, D13, L14, G15, and S16 were randomized. 
These amino acids form a loop between β-strands 1 and 2 (Figure 3). Codon NNN was used for 
randomization, and therefore, all 20 different amino acids were present, including all stop codons. 
The Avd L1,2 library was ligated into a phagemid as a sole fusion with the C-terminal portion of 
pIII. Based on sequencing results and transformation efficiency, the Avd L1,2 library was found to 
consist of approximately 1×105 individual members. When a stretch of five amino acid residues is 
completely randomized, the theoretical library size is 3.2×106.  
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In the panning experiments Avd L1,2 loop library phages were introduced onto a testosterone-
coated surface. The phage genomes carrying the mutated cDNA were found to be stable during the 
selection. A clear enrichment of sequences in the randomized loop area was observed, indicating the 
success of the selection conditions. Interestingly, we detected N12 as being a highly conserved 
amino acid residue among the enriched pool of proteins. An Avd variant, named sbAvd-1, that 
carried the sequence N12, R13, M14, N15, H16 was selected for further analysis.  
 
The specificity of sbAvd-1 can be tuned by additional mutations in the loop between β-strands 3 and 
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To further lower the biotin-binding affinity and to decrease the cross-reactivity of steroid-binding 
Avd, a library (sbAvd-1 L3,4) was generated in which the loop area between β-strands 3 and 4 was 
randomized (Figure 3). The loop between β-strands 3 and 4 is highly important for biotin binding of 
Avd because this loop ‘locks’ biotin into the binding site. In this process, three amino acid residues 
in the loop form direct interactions with biotin [16]. In the library four amino acids (T35, A36, V37 
and, T38) were randomized using the NNY codon. The use of this codon covers 14 of the 20 
naturally occurring amino acids while eliminating all of the stop codons. The library consisted of 
approximately 1.4×106 individual members, when calculated from the sequencing results and 
transformation efficiency, which exceeds the theoretical size of the library calculated based on the 
possible combinations of amino acid residues (3.8 × 104). 
 
Binders from the sbAvd-1 L3,4 library were selected by phage display panning against a 
testosterone surface. In every panning round washes were adjusted according to the number of 
output colonies. The quality of the phage genomes carrying the mutated cDNA was evaluated by 
DNA sequencing at various stages during selection. A combination of acid and testosterone was 
used for elution. The selected sbAvd-1 phage clones were evaluated by microplate analysis using 
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BSA-testosterone as a target ligand and utilizing M13-antibody to determine the amount of bound 
phages. The sbAvd-1 variant that showed the highest binding activity in the microplate assay (data 
not shown) had the sequence A35, T36, V37, N38. This mutant, named sbAvd-2 was selected for 
comparative analysis with sbAvd-1.  
 
Production and purification of Avd mutants 
Proteins were produced in soluble form in the E. coli strain BL21-AI using N-terminal OmpA 
bacterial secretion signal from Bordetella avium [26]. Proteins were purified by Ni-NTA affinity 
chromatography that yielded ~2 mg/L pure protein. According to gel-filtration analysis, in solution, 
both sbAvd-1 (51 kDa) and sbAvd-2 (53 kDa) showed tetrameric state (Additional file 3) similar to 
that of wtAvd (Avd expressed in E. coli 53 kDa, chicken Avd 60 kDa [26]). The slight decrease in 
molecular weight of Avd expressed in bacteria can be explained by the lack of glycosylation.  
 
Determination of ligand-binding specificity of Avd forms by microplate assay  
The binding specificity of proteins was analyzed by microplate assay, in which a set of different 
small molecules were used as a target molecules (Figure 4A). WtAvd was used as a negative 
control, and we detected no affinity towards the ligands except biotin. Importantly, sbAvd-1 and 
sbAvd-2 did not bind the proteins used as carriers for small molecules (bovine serum albumin 
(BSA) and human serum albumin (HSA)). However, these modified Avds showed clear binding to 
testosterone and progesterone.  
 
The binding to the surface-immobilized ligands was inhibited by pre-incubating the proteins with 
10 µM D-biotin (Figure 4B). Free biotin significantly inhibited the binding of sbAvd-1 to steroids, 
indicating notable affinity towards biotin. However, in the case of sbAvd-2 the binding of 
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testosterone and progesterone was not affected by biotin, showing a clear decrease in biotin-binding 
affinity. 
 
Biosensor analyses of steroid-binding Avds 
The kinetic constants of testosterone- and biotin-binding to steroid-binding proteins were 
determined with surface plasmon resonance (SPR) analysis. The purified sbAvd-1 and sbAvd-2 
bound to a testosterone-BSA-coated sensor chip with similar affinities (Table 1), whereas wtAvd 
showed no binding to the testosterone surface. Furthermore, testosterone-binding was inhibited with 
varying testosterone concentrations (0.75-50 µM, data not shown). In the case of sbAvd-1, the 50% 
inhibition was achieved between 5-10 µM testosterone, which is consistent with the determined 
testosterone surface binding affinity. Interestingly, the 50% inhibition was already achieved in 750 
nM testosterone concentration in the sbAvd-2 measurements. This result suggests a much higher 
binding affinity towards free testosterone than that measured towards surface-immobilized 
testosterone. 
 
The biotin binding of the steroid-binding proteins was analyzed by the biotin-coated sensor chip.  
The comparison of sbAvd-1 and sbAvd-2 revealed that the biotin-binding affinity decreased almost 
500-fold due to the modification of the loop between β-strands 3 and 4 (Table 1). This result 
appears to be consistent with the previous study in which mutation of T35A alone decreased the 
biotin-binding affinity of wtAvd approximately 200-fold [20]. 
 
The specificity of the steroid-binding was analyzed by binding competition using the following 
steroids: testosterone, dehydroepiandrosterone sulfate (DHEAS), androstenedione, estradiol, and 
dihydrotestosterone (DHT). In addition, the binding to the surface was also competed for by biotin. 
SbAvd-1 was found to be cross-reactive with androgens highly similar to testosterone (DHEAS and 
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androstenedione), and had noticeable affinity towards biotin (Figure 5A). Interestingly, DHT 
showed less efficient inhibition compared to testosterone, suggesting lower binding affinity towards 
this steroid form. The binding of sbAvd-2 to testosterone was found to be most efficiently inhibited 
by testosterone and DHEAS (Figure 5B), whereas the inhibition caused by biotin was clearly 
weaker than that in the case of sbAvd-1. This result is consistent with the microplate analysis results 
and with the binding kinetic constants determined with SPR analysis.  
 
Interaction analysis of steroid-binding Avds by MRFS  
Molecular recognition force spectroscopy (MRFS) [27] was used to study the interaction between 
sbAvds and testosterone on a single molecule level. An atomic force microscopy (AFM) tip was 
functionalized with a single testosterone molecule [28] and repeatedly approached and retracted 
from the sbAvd-1- or sbAvd-2-coated surface (Figure 6A). The binding forces were measured in 
force-distance cycles, whereby the deflection (force) of the cantilever was recorded as a function of 
the tip-sample distance. For evaluation, 1,000 force-distance cycles were recorded, and probability 
density functions (pdf) were generated from the detected interaction forces [29]. The tip-tethered 
testosterone was found to form a complex with the sbAvds; the retraction led to a downward 
bending of the cantilever until a particular force was reached resulting in the rupture of the bond 
between testosterone and sbAvd (Figure 6B and 6C). The most probable unbinding force [29] was 
found to be similar for both of the testosterone-sbAvd complexes: 40 pN at a constant pulling 
velocity of 600 nm/s. From 1,000 recorded force-distance cycles, sbAvd-1 showed 183 detected 
interactions and sbAvd-2 showed 215 events. 
 
To prove the specificity of the measured interactions, control experiments were performed. For 
these experiments, free testosterone was injected into the measuring solution to preoccupy the 
binding sites of the steroid-binding protein immobilized on the surface. The retraction curve 
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identical to the approaching curve was detected (insets of Figure 6B and 6C), which indicated the 
total inhibition of the binding by free testosterone. Additionally, when the binding sites were 
preoccupied with free testosterone, the number of binding events dropped down to 67 from 183 
detected interactions in the case of sbAvd-1. In case of sbAvd-2 the number of interactions dropped 
from of 215 to 21 after addition of free testosterone. 
 
Differential scanning calorimetry reveals the high stability of the engineered proteins 
The high thermal stability of wtAvd (temperature transition midpoint (Tm) = 85.5 °C) was preserved 
in the steroid-binding mutants; these proteins showed similar Tm values compared to wtAvd 
(sbAvd-1 Tm value of 80.6 °C and sbAvd-2 Tm value of 82.5 °C) (Table 1, Additional file 4). 
Ligand binding often stabilizes a protein and raises the Tm value. As expected, the addition of biotin 
stabilized wtAvd effectively, increasing the Tm value almost 40 °C. This Tm indicates a very high 
binding affinity.  
 
The effect of biotin-binding on the protein stability of steroid-binding proteins was much smaller 
than in the case of wtAvd, thus showing decreased biotin affinity. In fact, sbAvd-2 showed a 
negligible increase in Tm in the presence of biotin (∆Tm = 0.5 °C). The presence of testosterone only 
slightly increased the Tm values of sbAvds (∆Tm = 0.6-0.9 °C). Actually, a similarly small increase 
was detected in the ∆Tm value of wtAvd when testosterone was added. However, because the 
testosterone-binding of wtAvd was not detected in other analyses (SPR and microplate analysis) the 
mechanism of stabilization remains unclear. 
 
Discussion 
In the present study, Avd proteins were displayed on the M13 phage in a monovalent form fused 
with the C-terminal region (aa residues 198-406) of the coat protein pIII. The crucial requirement 
 11 
for the functional display on phage is successful expression of the protein in E. coli. As has been 
earlier reported Avd protein can be efficiently expressed in a soluble form in E. coli [26]. The close 
relative of Avd, streptavidin, has been displayed on bacterial phages as a pVIII fusion [30, 31]. 
However, to our best knowledge, chicken Avd has not been previously displayed on phages for 
screening purposes.  
 
To evaluate the different modes for Avd display, we generated constructs expressing pIII fused to 
Avd and constructs that expressed free Avd subunits in addition to the pIII fusions. Based on the 
expression analysis, binding properties and selection experiments, the construct that expressed both 
fusion and free Avd showed an enhanced assembly of functional, tetrameric Avd on the phage 
compared to the Avd-pIII fusion alone (Additional file 2). However, the construct that expressed 
pIII-fused Avd was chosen for use in the selection system for the generation of gene libraries 
because the use of only one Avd gene in the protein display would ensure that the selected proteins 
could be assembled to homotetramers.  
 
The potential of the developed platform for screening novel Avd-based receptors was investigated. 
Five residues in the loop between β-strands 1 and 2 of Avd were randomized to generate a 
population of diverse Avd genes. The gene population was screened for novel binding properties 
using the phage display method [23]. We observed the enrichment of Avd phages binding to 
testosterone-coupled BSA. The Avd variant sbAvd-1, which carried the sequence N12, R13, M14, 
N15, H16, was further analyzed and found to bind free testosterone with an affinity similar to BSA-
conjugated testosterone. Moreover, we detected that the biotin-binding affinity of sbAvd-1 was not 
completely diminished; it was still high enough to inhibit sbAvd-1 from binding to testosterone-
BSA (Table 1, Figures 4 and 5). This finding confirmed that testosterone occupies the same binding 
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site in Avd as does biotin. Based on the cross-creativity measurements, sbAvd-1 also binds other 
steroid hormones, such as progesterone and DHEAS (Figures 4 and 5). 
 
SbAvd-1 was further engineered to decrease biotin binding and to improve steroid specificity. From 
the phage display selections, the sbAvd-1-derived protein, named sbAvd-2, with a mutated loop 
between β-strands 3 and 4 was captured. This mutant showed similar or slightly decreased binding 
affinity towards immobilized testosterone, whereas the biotin-binding affinity was clearly decreased 
(Table 1, Figures 4 and 5). We also noticed that sbAvd-2 bound more tightly to free testosterone 
than did sbAvd-1 (Figure 5). Significantly, sbAvd-2 preferred steroids as a ligand over biotin; this 
finding is important when considering the applications for biofluids, in which biotin is often present 
in relatively high concentrations. 
 
This study and our preliminary results from experiments with a number of different target ligands 
(Hiltunen S, Riihimäki TA et al., unpublished data) suggest that Avd-based receptors for various 
different small molecules can be tailored. These Avd-based receptors may be valuable tools for 
diagnostic use in the future.  
 
Conclusions  
The current study provides a promising platform for the selection of tailored ligand-binders evolved 
from the Avd scaffold in the monovalent pIII protein display. The Avd scaffold has characteristics 
that are beneficial in protein engineering, such as high thermal and chemical stability, simple 
folding and an optimal structure for small ligands. Furthermore, Avd can be modified rather freely 
without major change in the fold [18]. Novel Avds that can simultaneously bind multiple ligands 
could become next-generation molecular tools for clinical and diagnostic applications [22, 32]. 
Importantly, novel Avd-based receptors could be used in applications that require harsh conditions.  
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Methods 
Construction of phagemid vectors  
All of the basic recombinant DNA methods were performed essentially as previously described 
[33]. Appropriate restriction sites were added to the cDNA of the Avd core sequence [34] by PCR 
using the primers Avd_NheI_5’ and Avd_NotI_3’ (Additional file 5). PCR products were first 
subcloned into the pCR®2.1-TOPO plasmid by TOPO TA-cloning (Invitrogen) and the plasmids 
were transformed into E. coli TOP10 cells. Plasmids were isolated from colonies that contained the 
inserts based on the blue-white screening. Avd fragments were cut out from the pCR®2.1-TOPO-
plasmid using the NheI and NotI restriction enzymes and ligated into the phagemid vector 
(pBluescript SK+ derived phagemid, Research Center of Finland, Biotechnology, Espoo, Finland). 
The cDNA of the Avd was cloned into the phagemid vector as an N-terminal fusion to the C-
terminal domain (amino acids 198-406) of the minor phage coat protein III. In the Avd/Avd-pIII 
constructs, the coding sequence of the free Avd was subcloned using the primers Avd_NheI_5’ and 
Avd_AscI_stop_3’ (Additional file 5). The Avd-pIII expression cassette was generated by 
subcloning a fragment amplified from the primers Avd_SfiI_5’ and Avd_NotI_3’ (Additional file 
5). The nucleotide sequences of the Avd constructs were verified by sequencing on an ABI PRISM 
3100 Genetic Analyzer (Applied Biosystems) according to the protocols recommended by the 
manufacturer (ABI PRISM BigDye Terminator Cycle Sequencing Kit v.1.1, Applied Biosystems). 
 
Amplification of phage particles 
All of the basic phage display methods were performed essentially as previously described [35]. 
Phagemid vectors with the Avd insert were transformed into chemically competent E. coli XL1-
Blue cells (Stratagene, La Jolla, CA) with the heat shock method. Phage stocks of the different Avd 
display constructs were made from individual colonies picked from the transformation plates into 
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super broth (SB) medium supplemented with the appropriate antibiotics and glucose. The bacterial 
cultures were infected with the helper phage (1012 pfu/ml) VCS-M13 (Stratagene, LaJolla, CA) for 
amplification of Avd phages. Phages were PEG precipitated and analyzed by SDS-PAGE and 
western blotting following immunostaining with the polyclonal rabbit α-avd IgG (University of 
Oulu, 1:5000) and the monoclonal mouse anti-pIII IgG (Biosite, Sweden, 1:2000) antibodies. 
 
Functionality test of Avd-displaying phages 
The functionality of the Avd phages was tested by panning the phages on surfaces coated with BSA 
conjugated to HABA (HABA-BSA) [36]. As a positive control for selection, the Avd mutant 
N118M was also displayed on the phages. Panning was performed essentially as previously 
described [35]. For elution, vigorous shaking in 100 mM hydrochloric acid containing 10 µM D-
biotin (Biochemica, Fluka, 14400) was performed. In total, three selection rounds were performed. 
After each round the integrity of the Avd expression units was analyzed by restriction enzyme 
digestions of the phagemid DNA samples. Importantly, both single and double Avd and 
Avd(N118M) construct phages were competed against each other. Equivalent amounts of phages 
displaying Avd or Avd(N118M) mutant were mixed and biopanned. The ratio between constructs 
was determined with DNA sequencing.  
 
Construction of Avd L1,2 library 
To construct an Avd DNA library, amino acids N12, D13, L14, G15, and S16 in the loop between 
beta strands 1 and 2 (L1,2) were randomized. The libraries were constructed essentially as 
previously described [35]. A nucleic acid fragment of 105 base pairs was amplified with the primers 
Avd_NheI_5’ and Loop 1-2 _R1_3’ (Additional file 5) using wt Avd cDNA as template. Parallel to 
this fragment, a nucleic acid fragment with 357 base pairs was PCR-amplified with the primers 
Loop 1-2_R2_5’ and Avd_NotI_3’ (Additional file 5) using wt Avd as a template. The PCR 
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strategy is presented in Additional file 6. The desired amplification products were separated by 
agarose gel electrophoresis and isolated from the gel using the Nucleo Spin Extract II kit 
(Macherey-Nagel) according to the manufacturer’s instructions. PCR products were combined in 
the second amplification step in the presence of the PCR primers Avd_NheI_5’ and Avd_NotI_3’ 
(Additional file 5). This amplification resulted in a DNA fragment of 462 base pairs. The fragment 
was isolated from the gel and cut with the restriction enzymes NheI and NotI (Fermentas) followed 
by purification using the Nucleo Spin Extract II kit (Macherey-Nagel). Fragments were ligated into 
the phagemid vector and the resulting ligation product was transformed into electrocompetent cells 
of the E. coli strain XL1-Blue (Stratagene) by electroporation. Transfected bacteria were infected 
with the VCS-M13 helper phage (Stratagene) and phages were harvested from the culture and 
purified with PEG precipitation. The amount of phage particles was determined by titration.  
 
Selecting steroid-binders from the Avd L1,2 library 
The Avd L1,2 library was panned against the steroid hormone testosterone. As a negative control, 
wtAvd-displaying phages were also panned against testosterone. NUNC immunosorp plates were 
coated with a testosterone-BSA conjugate (Sigma, T-3392, 1 µg). Phages were preincubated in the 
BSA-coated wells to prevent non-specific binding. Three to four selection cycles were conducted, 
and the stringency of washing conditions was increased every panning round to decrease 
nonspecific binding. In the first panning round wells were washed three times with phosphate 
buffered saline containing 0.05% Tween (PBS-Tween) and five times with phosphate buffered 
saline (PBS). Phages were eluted by vigorous shaking for 10 minutes in 100 mM hydrochloric acid 
containing 10 µM D-biotin (Biochemica, Fluka, 14400). Biotin was used for elution because it was 
probable that after randomization of the loop L1,2 the resulting Avd would still have a rather high 
affinity towards biotin. In the final panning round 10 µM testosterone (Steraloids Inc., USA) was 
used in addition to 100 mM hydrochloric acid for elution. The eluted phage solutions were 
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neutralized with 2 M Tris. Eluted phages were used to infect E. coli XL1-Blue cells and aliquots of 
the infected bacteria were plated to quantify the amount of eluted phages. Phages were amplified 
and purified as described earlier. Precipitated phages were then used for the next round of selection. 
After every panning round, results were verified by sequencing (20 sequences), and the number of 
phage particles was determined by phage titration.  
 
Generation and screening of the SbAvd-1 L3,4 library 
An SbAvd-1-derived DNA library was constructed and ligated into the phagemid as described 
above. In the library amino acids T35, A36, V37, and T38 in the loop between beta strands 3 and 4 
(L3,4) were randomized; thus, in the construction of the library the primers Avd_NheI_5’ and 
3_4R_1_3’ and primers 3_4R_2_5’ and Avd_NotI_3’ (Additional file 5) were used in the PCR. 
SbAvd-1 cDNA was used as a template. Ligated phagemid was transformed into electrocompetent 
cells of E. coli strain XL1-Blue (Stratagene) by electroporation. Transfected bacteria were infected 
with the VCS-M13 helper phage (Stratagene) and phages were harvested from the culture and 
purified with PEG precipitation. The amount of phage particles was determined by titration.  
 
The sbAvd-1 L3,4 library was biopanned against the steroid hormone testosterone similarly as 
described above, with some exceptions. NUNC immunosorp plates were coated with a testosterone-
BSA conjugate (Sigma, T-3392, 200 ng). Phages were preincubated in BSA-coated wells before the 
panning procedure. Four selection cycles were performed. Phages were eluted by vigorous shaking 
for 10 minutes in 100 mM hydrochloric acid containing 35 µM testosterone (Steraloid Inc., USA). 
After each panning round, results were verified by sequencing (20 sequences), and the number of 
phage particles was determined by phage titration. Additionally, every panning round was screened 
for binders by anti-M13 as previously described [37]. For the ELISA, (NUNC) immunosorp plates 
were coated with a testosterone-BSA conjugate (Sigma, T-3392, 1 µg), wells were blocked with 5% 
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milk solution, and detection was performed with Anti-M13/HRP (GE Healthcare) and read with a 
microplate reader (Bio-Rad 680 XR). 
 
Production and purification of Avd mutants 
For biochemical analyses, the proteins were produced in E. coli strain BL21-AI (Invitrogen) using 
expression vector pET101/D (Invitrogen) [26]. After sonication (Sonics & Materials Vibra Cell™) 
and DNaseI (New England Bio Labs) treatment of E. coli cells, the purification of the proteins was 
conducted using Ni-NTA affinity chromatography according to the instructions of the manufacturer 
(QIAGEN).  
 
The oligomeric state of the proteins was assayed with fast protein liquid chromatography (FPLC) 
gel-filtration using an ÄKTApurifier™ HPLC equipped with a Superdex 200 10/300 GL column 
(Tricorn, Amersham Biosciences, GE Healthcare). The column was calibrated using the gel-
filtration mixture (thyroglobulin, γ-globulin, ovalbumin, myoglobin, and vitamin B12; Bio-Rad 
Laboratories) as a molecular-mass standard. Sodium phosphate buffer (20 mM, pH 7.4) with 1M 
NaCl and, 20mM imidazole was used as the liquid phase. Protein samples of 90–193 µg in a 
volume of 500 µl were used in the analysis.  
 
DSC measurements of wtAvd and steroid-binding Avds. 
Proteins (0.225 mg/ml) were analyzed in sodium phosphate buffer (20 mM, pH 7.4), containing 20 
mM imidazole and 1 M NaCl. D-biotin (Biochemica, Fluka, 14400) and testosterone (Steraloids 
Inc., USA) were diluted with the measurement buffer to a final concentration of 50 µM. All 
solutions were degassed prior to measurements to avoid air bubbles. An automated capillary VP-
DSC instrument (GE Healtcare, MicroCal, Northampton, USA) was used to measure the stability of 
the proteins with or without ligands. During the measurement, protein samples were heated from 20 
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°C to 130 °C at a scanning rate of 120 °C/h. Feedback mode was set to low and the filler period was 
8 s. Temperature transition midpoints (Tm) were recorded from the highest peaks and the 
calorimetric heat changes (∆H) were calculated using the MicroCal Origin 7 software (GE 
Healtcare, MicroCal, Northampton, USA). 
 
Determination of ligand-binding specificity of Avd forms by microplate assay  
MaxiSorp F96 microplate wells (NUNC) were coated with 500 ng of conjugated ligand (HSA-
conjugated progesterone, hydrocortisone, testosterone, and cholic acid (Technical Research Center 
of Finland, Espoo, Finland); or BSA-conjugated testosterone (A6958-000, Steraloids Inc., USA), 
and biotin (Jenni Leppiniemi, University of Tampere, Finland)), and with 500 ng of the carrier 
proteins HSA and BSA (A7906, Sigma) in 100 µl of PBS for 2 hours 37 °C.  Carrier proteins were 
used as negative controls. Plates were washed three times with PBS-Tween, blocked with 0.5 % 
BSA-PBS for 30 min, and then washed again. Proteins (0.9 µg/ml) in sodium phosphate buffer (20 
mM, pH 7.4) with 1M NaCl and 20mM imidazole, were added to the wells and incubated for 1h. A 
portion of wtAvd (Belovo, Bastogne, Belgium), sbAvd-1 and sbAvd-2 was preincubated with 10 
µM D-biotin (Biochemica, Fluka, 14400). Bound Avd was detected by rabbit α-avd IgG (University 
of Oulu) and with alkaline phosphatase conjugated goat anti-rabbit IgG (A3937, Sigma). After 
adding the phosphatase substrate solution (1 mg/ml pNPP (S0942, Sigma) in 1 M diethanolamine 
pH 9.8, with 0.5 mM MgCl2), the plates were read after 15 minutes at A405 with a microplate 
reader (Bio-Rad 680 XR). 
 
Biosensor analyses of steroid-binding Avds  
A BIAcore X optical biosensor (Biacore, Uppsala, Sweden) was used for the analysis of binding 
kinetics. Testosterone-BSA was coupled to the carboxymethylated dextran layer of a sensor chip 
using standard amine coupling chemistry (1000 RU, 40 µl/min flow rate). Samples of sbAvd-1, and 
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sbAvd-2 were diluted in 50 mM sodium phosphate containing 1 M NaCl, and the same buffer was 
used in the measurements. The binding of the sbAvd-1 and sbAvd-2 samples on testosterone-BSA 
coated chips was measured and the kinetic constants were determined from the measurements 
performed with different protein concentrations using the BiaEvaluation software according to the 
manufacturer’s instructions. WtAvd was used as a negative control. 
  
The binding of steroid-binding proteins to the testosterone-BSA surface was competed with free 
steroid hormone molecules (testosterone, DHEAS, androstenedione, estradiol, and DHT (Steraloids 
Inc., USA)) and free biotin (Biochemica, Fluka, 14400) to evaluate the specificity of binding. 
Additionally, steroid-binding was more closely detected by measuring the binding in the presence 
of varying concentrations (0.75 µM-50 µM) of inhibiting testosterone. 
  
For the determination of biotin-binding kinetics, a sensor chip was prepared as follows:  
diaminoethylene was first attached to the surface using a mixture containing 0.2 M 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 0.05 M N-hydroxysuccinimide 
(NHS) in water. Second, to introduce amino groups to the surface, 1 M ethylenediamine (Fluka 
03550) in water was applied. Finally, 5 mM biotin N-succinimidyl ester (Biochemica, Fluka, 
14405) in 50% DMSO was injected on the surface (40 µl/min flow rate, ~130 RU; please note that 
the determination of the bound mass is not very accurate in case of small molecules because the 
immobilization can change the physicochemical properties of the surface). 
 
Molecular Recognition Force Spectroscopy experiments 
Molecular recognition force spectroscopy (MRFS) was used to study the interaction of the produced 
proteins with testosterone and biotin. Steroid-binding proteins were covalently bound to modified 
mica sheets via lysines as previously described [38]. Testosterone was coupled to the AFM tip via 
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the heterobifunctional Fmoc-PEG-NHS crosslinker as previously described [28], resulting in a 
covalent attachment of testosterone via a flexible spacer (Figure 6A).  
 
All MRFS experiments were performed on a Pico SPM I (Agilent Technologies, Santa Clara, CA). 
All modified cantilevers used had nominal spring constants between 10–30 pN/nm (Veeco 
Instruments, Santa Barbara, CA). The effective spring constants of the cantilevers were determined 
by the thermal noise method [39, 40]. Force-distance cycles were completed using a z-range of 200 
and 300 nm. Sweep durations were adjusted between 0.25 and 4 s. During one data set of 1000 
force-distance curves, the lateral tip position was changed (a few hundred nm) about every 100 
curves to ensure that the binding events were statistically reasonable. The specificity of the binding 
was proved by adding free testosterone (200 nM) into the measuring solution and incubating for 
approximately 1 h to block the ligand-binding sites of the proteins. 
 
Abbreviations: AFM, atomic force microscopy; BSA, bovine serum albumin: BTN, D-biotin;  
DHEAS, dehydroepiandrosterone sulphate; DHT, dihydrotestosterone; DMSO, dimethyl sulfoxide; 
EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride; HABA, 4’-
hydroxyazobenzene-2-carboxylic acid; HSA, human serum albumin; MRFS, molecular recognition 
force spectroscopy; NHS, N-hydroxysuccinimide; PBS, phosphate buffered saline; PEG, 
polyethylene glycol; sbAvd, steroid-binding avidin; SB, super broth; SDS-PAGE, sodium-dodecyl 
sulfate polyacrylamide gel electrophoresis; wtAvd, wild type avidin 
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Figure legends 
Figure 1. Schematic presentation of the Avd display expression constructs. (A) The 
phagemid constructs for Avd and Avd(N118M) display, in which Avd protein is produced solely as 
a fusion with pIII. (B) The phagemid constructs for Avd/Avd-pIII and Avd(N118M)/Avd(N118M)-
pIII display, in which the pelB signal sequence is used for secretion of the Avd-pIII fusions and the 
free Avd. The cloning sites used are shown by vertical arrows.  
 
Figure 2. Immunoblot analysis of Avd phages with anti-Avd and anti-pIII antibodies. (A) 
The location of the Avd-pIII fusion protein recognized by anti-Avd is indicated by the upper 
arrowhead. The theoretical mass of the Avd-pIII fusion protein is 38 kDa. The produced free Avd 
(~14 kDa) is indicated with the lower arrowhead. (B) From the immunoblot analyzed with anti-pIII 
antibody the full-length pIII expressed from the helper phage (VCSM13) can be seen migrating at 
~60 kDa (the upper arrowhead). The Avd-pIII fusion is indicated by the middle arrowhead. In 
addition, some proteolytically truncated Avd-pIII forms were detected (~33 kDa; lower arrowhead).  
Lane 1: Avd-pIII phage; lane 2: Avd(N118M)-pIII phage; lane 3: Avd/Avd-pIII phage; lane 4: 
Avd(N118M)/Avd(N118M)-pIII phage. The molecular weights of standard proteins are shown as 
kilodaltons on the left side of each blot. 
 
Figure 3. Three-dimensional structure of wtAvd with the loops chosen for random 
mutagenesis marked. One subunit of tetrameric wtAvd with bound biotin (PDB: 2AVI) [16] is 
shown in the figure. The randomized amino acid residues are N12, D13, L14, G15, and S16 (shown 
in blue) in the loop between β-strands 1 and 2, and T35, A36, V37, and T38 (shown in purple) in 
the loop between β-strands 3 and 4. 
 
Figure 4.  Determination of ligand-binding specificity of sbAvd-1 and sbAvd-2 proteins by 
microplate analysis.  The binding of sbAvd-1 and sbAvd-2 to a set of different small ligands was 
detected using polyclonal anti-avidin antibody as a probe (A) and the effect of free biotin (10 µM) 
to ligand-binding was analyzed (B).  
Abbreviations used in the figure: PBS, Phosphate buffered saline; HSA, human serum albumin; 
PRO, HSA-conjugated progesterone; HYD, HSA-conjugated hydrocortisone; TES, HSA-
conjugated testosterone; CHO, HSA-conjugated cholic acid; TES-B, BSA-conjugated testosterone; 
BTN, BSA-conjugated D-biotin; BSA, bovine serum albumin 
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Figure 5.  Inhibition analysis of sbAvd-1 and sbAvd-2 proteins by the SPR method.  The 
binding of the sbAvd-1 and the sbAvd-2 to a CM5 sensor chip functionalized with testosterone-
BSA was measured in the presence of 50 µM inhibitors. (A) The binding of the sbAvd-1 protein 
was totally inhibited by dehydroepiandrosterone, androstenedione, and biotin. (B) The binding of 
the sbAvd-2 protein was totally inhibited by dehydroepiandrosterone or testosterone, but not biotin. 
This result is due to the markedly decreased affinity of the protein towards biotin.  
Samples: Protein sample, green; protein with estradiol, dark blue; protein with DHT, olive; protein 
with testosterone, black; protein with DHEAS, blue; protein with androstenedione, brown; protein 
with biotin, red 
 
Figure 6.  Analysis of sbAvd protein-testosterone interaction by MRFS method (A) A 
schematic representation of the experimental assembly used in the analyses. Testosterone was 
tethered to the AFM tip using a flexible PEG crosslinker. The steroid-binders sbAvd-1 and sbAvd-2 
were covalently bound to the mica surface via a short homobifunctional spacer. (B) The force-
distance cycle of the sbAvd-1 – testosterone interaction showing an unbinding event. The typical 
non-linear shape of the event results from the elastic properties of the PEG linker. (C) The force-
distance cycle showing a sbAvd-2 – testosterone bond dissociation. Insets in (B) and (C) represent 
force-distance cycles in which the protein-testosterone interaction is inhibited with free testosterone.
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Tables 
Table 1. Kinetic parameters and the determined thermostability of sbAvds  
The kinetic parameters determined by SPR analysis. The biotin binding affinity of avidin is too high 
to be determined by SPR. The transition midpoint of thermal unfolding (Tm) and the calorimetric 
heat of unfolding were determined by DSC. Delta Tm represents the increase of Tm in the presence 
of 50 µM ligand. 
 
Additional files 
Additional file 1  
Structural comparison of Avd-BTN and Avd-HABA complexes. 
3D-structures of Avd complexed with biotin (A) and HABA (B). These two ligands have different 
hydrogen bonding interactions with the amino acids at the binding site. (A) Hydrogen bonds formed 
between the ureido ring of biotin and Avd are shown here as dashed green lines. (X-ray 
crystallographic structure (PDB 2AVI)) [41]. (B) A significant difference between biotin and 
HABA binding to Avd is seen in the interaction of the ligand with asparagine 118. Although other 
Avd key residues interacting with the BTN ureido ring also interact with HABA, there is no 
hydrogen bonding partner for N118 in HABA. Again, hydrogen bonds formed between the 
carboxyl group of HABA and Avd are shown as dashed green lines. The loop between β-strands 3 
and 4 was not resolved in the avd-HABA –complex (coordinates kindly provided by Prof. Oded 
Livnah). The figure was made with the VMD program [42]. 
 
Additional file 2 
Sequencing results and input from the control selections. 
The percentage of wt Avd and Avd(N118M) mutant sequences after sequencing analysis from the 
different rounds of HABA selection. The amount of input phages is shown as colony forming units 
(cfu) per milliliter of culture. 
Protein Ligand SPR   DSC   
  ka (1/Ms) kd (1/s) KD (M) Tm (˚C) ∆Tm (˚C) ∆H ×104 (cal/mol) 
wtAvd - - - - 85.5 - 5.4 
wtAvd Btn n.d. n.d. n.d. 123.2 37.7 12.8 
wtAvd Tes - - no binding 86.2 0.7 5.6 
sbAvd-1 - - - - 80.6 - 5.2 
sbAvd-1 Btn 4.2 ×105 5.6 ×10-4 1.4 ×10-9 83.2 2.6 6.4 
sbAvd-1 Tes 1.0 ×103 9.5 ×10-3 9.0 ×10-6 81.5 0.9 5.7 
sbAvd-2 - - - - 82.5 - 4.6 
sbAvd-2 Btn 1.0 ×103 6.8 ×10-4 6.6 ×10-7 83.0 0.5 4.2 
sbAvd-2 Tes 813 8.5×10-3 1.1×10-5 83.1 0.6 4.8 
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Additional file 3 
Gel-filtration chromatograms of sbAvd-1 and sbAvd-2 proteins.  
The chromatograms of steroid-binding proteins determined at wavelength of 280 nm by gel-
filtration. Besides the main peak, there is also a small peak of oligomeric form of the protein in the 
chromatogram of sbAvd-1 protein (gray curve). It is a typically observation also in the case of 
wtAvd [26]. The chromatogram of sbAvd-2 protein is shown with black curve. The tetrameric form 
of the protein is dominant in both samples. 
 
Additional file 4 
The effect of ligand-binding to the stability of wtAvd, sbAvd-1 and sbAvd-2 proteins.  
DSC thermograms were obtained from the protein sample (0.225 mg/ml) by scanning temperature 
range of 20 °C to 130 °C with heating rate of 120 °C/min. The analysis was conducted in the 
absence and presence of ligands (50 µM). 
 
Additional file 5 
The cloning primers used in the study.  
The restriction enzyme cleavage sites are indicated in italics.    
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Additional file 6 
A schematic presentation of the construction strategy of the Avd L1,2 library.  
For 1-2 loop library a nucleic acid fragment of 105 base pairs was amplified (Step 1, A) with the 
primers Avd_NheI_5’ and Loop 1-2 _R1_3’ (schematically referred in the figure as 
Avd_mutant_3’) using wtAvd cDNA as a template. Parallel to this, a nucleic acid fragment with 
357 base pairs, was PCR-amplified (Step 1, B) with the primers Loop 1-2_R2_5’ (schematically 
referred in the figure as Avd_combine_5’) and Avd_NotI_3’, also using wtAvd as a template. 
Amplified fragments were combined in a second amplification step in the presence of PCR primers 
Avd_NheI_5’ and Avd_NotI_3’, wherein a DNA fragment of 462 base pairs was obtained.  
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